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A b s t r a c t  
 
Background: Attack-related cognitive symptoms in migraine are frequent yet scarcely 
characterized and undervalued as contributors of disability. Conflicting evidence arose 
about an increased risk of cognitive decline in older migraine patients.  
 
Objectives: (1) to study the occurrence of cognitive symptoms in migraine attacks; (2) 
to evaluate objective evidence of cognitive dysfunction in migraine attacks and its 
neuronal correlates and (3) to study the effect of persisting migraine in cognitive 
function or cognitive decline in older adults. 
 
Methods:  Occurrence of attack-related cognitive symptoms was detailed by systematic 
literature review and a cross-sectional clinical-based systematic survey; their relevance 
to disability was studied prospectively using headache diaries. An instrument (Mig-
SCog) was developed, validated and tested to identify and quantify attack-related 
subjective cognitive symptoms. Cognitive function during attacks was evaluated by a 
systematic literature review and a clinical-based prospective two-period randomized 
cross-over study using an extensive neuropsychological battery. A briefer battery was 
tested in repeated applications in interictal patients and controls. Brain perfusion during 
attacks was studied with arterial spin labeling magnetic resonance imaging (ASL-MRI) 
and cortical response to a working memory task with blood-oxygen level dependent 
functional magnetic resonance imaging (BOLD-fMRI).  A prospective controlled cross-
sectional population-based study of neuropsychological performance of older adults 
with persisting migraine and non-migraine headache was followed by a 5 years re-
evaluation of the same sample, to screen for cognitive decline. 
 
Results: Cognitive symptoms were the most frequent non-migraine defining symptoms 
reported in the prodromic(37%) and headache(38%) phases of migraine attacks in a 
systematic review of 28 series, with a total sample of 8392 patients. Cognitive symptoms 
are also present in the postdromic or resolution phase, although fatigue (71%) is 
reported more often.  Of 165 patients prospectively surveyed, 87% reported an average 
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of 2.5 attack-related symptoms, over two-thirds executive (attention, processing 
efficiency and speed). Cognitive symptoms were ranked prospectively by 34 migraine 
patients recording 229 attacks, being second only to pain in terms of intensity and 
attack-related disability. An instrument to quantify migraine attack-related symptoms 
was constructed from a set of 43 candidate items, using factor analysis. The reduced 9 
item Mig-SCog is fast to apply covering executive functions and language, having good 
internal consistency (Cronbachs’ alpha 0.82) and reliability (Cohen’s kappa 0.55) and 
high correlation with external validity measures such as the 43-candidate item list 
(rho=0.69) and the Cognitive Failures Questionnaires(rho=0.61). The Mig-SCog presents 
negligible recall bias (no difference in scores obtained during an attack or while 
headache free) and Migraine patients score it higher for migraine higher for migraine 
(7.9±4.6) than for non-headache pain (2.3±2.9, p<0.0006) or pain free (1.6±2.4, 
p<0.0006). Comparing Mig-SCog scores in migraine and tension-type headache patients, 
those were higher for migraine in all scale items (p<0.0001) except those related to 
naming (8 and 9). The AUC of Mig-SCog score for the diagnosis of Migraine was 0.835 
(95% CI of 0.763-0.906, p< 0.0001) reinforcing specificity for migraine. 
Ten studies of neuropsychological evaluation during migraine attacks are available in 
the literature, only half had data allowing comparison of cognitive performance within 
and outside attacks (encompassing 163 migraine patients). All these were able to 
demonstrate some type of impairment (most often executive) although some bias could 
not be excluded from their study design. In our sample of 24 patients which completed 
an extensive neuropsychological evaluation in these two conditions (attack and 
headache-free) controlling for the majority of relevant bias (in particular the practice 
effect), performance was worse during the attack in the majority of cognitive tests, in 
particular in word reading speed (p=0.013), verbal learning (p=0.01), short term verbal 
recall with (p=0.01) and without (p=0.013) semantic cueing and delayed recall with 
(p=0.003) and without (p=0.05) semantic cues. Another sample of 24 interictal migraine 
patients and 24 matched controls performed equally in a shorter battery focused on 
executive functions that was applied twice with a short interval (average 45 days) to test 
the practice effect of repeated evaluations that was demonstrated in all tests, being 
significant in Stroop Interference test (p=0.002, multiplicity corrected); a meaningful 
score change was determined for each raw test scores.  
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We were unable to find any relevant brain perfusion nor brain activation differences 
evoked by a working memory task during a spontaneous migraine without aura attack 
of an average intensity of 6.8 on a 0-10 VAS scale and an average duration of 16 hours in 
a sample of 13 women, compared to being headache-free. 
Persistent migraine or headache after the age of 50 related to worse performance in 
some neuropsychological tests (attention and processing speed in migraine patients, 
n=61; sematic memory and memory retrieval in non-migraine headache, n=50) in a 
population sample of 478 individuals tested extensively.  After 5 years, 275 (57.5%) of 
the same sample were screened for cognitive decline, that occurred in 14.9% of the 
sample. Neither migraine nor non-migraine headache influenced the odds of decline. 
 
Discussion: Attack-related cognitive symptoms are very frequent, mostly executive and 
contribute to disability, supporting that they should be addressed as endpoint in clinical 
trials of acute migraine treatments and included in disability assessments. An efficient 
way to assess attack-related subjective cognitive symptoms in clinical practice or 
research is now available – the Mig-SCog. Although migraine-related reversible cognitive 
dysfunction was demonstrated during attacks, no advances on potential brain 
mechanisms underlying these findings were made. Interest is focused to obtain more 
functional data, with studies of evoked activation paradigms, functional connectivity and 
combined imaging and neurophysiological studies. Although persisting headache in 
older adults seems to influence executive performance, these changes are most likely 











R e s u m o  
Introdução: Os sintomas cognitivos que ocorrem durante a fase álgica das crises de 
enxaqueca são muito frequentes, no entanto foram pouco estudados e sobretudo pouco 
valorizados como potenciais contributos para a incapacidade funcional verificada 
durante as crises. A relação entre sintomas referidos pelos doentes e a efetiva disfunção 
cognitiva nas crises é inconsistente; a mais, não existe uma explicação fisiopatológica 
evidente nas já conhecidas alterações do funcionamento cerebral associadas à crise de 
enxaqueca que sejam potencialmente relacionáveis com este tipo de disfunção. A 
potencial persistência de queixas cognitivas na fase intercrítica em doentes com 
enxaqueca é controversa mas, a existir, poderá contribuir para um potencial aumento de 
risco de declínio cognitivo nestes doentes.  
  
Objetivos: Este projeto de investigação apresenta 3 objetivos principais: (1) estudar a 
ocorrência de sintomas cognitivos durante as crises de enxaqueca; (2) avaliar a 
ocorrência de disfunção cognitiva objetivável e do seu substrato neuronal e (3) estudar 
o efeito da persistência da enxaqueca até idades tardias (acima dos 50 anos) na função 
cognitiva e no risco de declínio cognitivo. 
 
Métodos: A ocorrência de sintomas cognitivos durante a crise de enxaqueca foi estudada 
inicialmente através da realização de uma revisão sistemática da literatura que permitiu 
recolher e classificar os principais sintomas já descritos. Em seguida procedeu-se à 
aplicação de um inquérito sistematizado numa amostra de base clinica de doentes com 
enxaqueca episódica. A perceção da relevância destes sintomas para a incapacidade 
atribuível à crise de enxaqueca foi estudada prospectivamente com diários de enxaqueca 
numa outra amostra de base clínica de doentes com enxaqueca episódica. Foi 
desenvolvido e validado um novo instrumento (Mig-SCog) que permite identificar e 
quantificar de forma sistemática os sintomas cognitivos subjetivos associados às crises 
de enxaqueca. Este instrumento foi testado de forma a avaliar a sua especificidade para 




De forma a avaliar a efetiva ocorrência de disfunção cognitiva na fase álgica das crises de 
enxaqueca foi efetuada uma revisão sistemática da literatura avaliando todos os estudos 
que efetuaram avaliação neuropsicológica em doentes durante as suas crises de 
enxaqueca. Atendendo às limitações encontradas, foi realizado um estudo prospetivo 
cruzado e randomizado efetuando uma avaliação neuropsicológica extensa de um grupo 
de doentes durante uma crise de enxaqueca sem aura e no seu estado normal, livre de 
dor. Adicionalmente foi montada e testada num estudo transversal controlado uma 
bateria neuropsicológica breve e prática que permitisse aplicações repetidas, em 
doentes com enxaqueca. Os potenciais mecanismos cerebrais subjacentes à disfunção 
cognitiva associada às crises foram estudados inicialmente comparando a perfusão 
cerebral durante uma crise espontânea de enxaqueca sem aura com a fase intercrítica 
aplicando um método quantitativo de avaliação de perfusão baseado em Ressonância 
Magnética, denominado Arterial Spin Labeling Magnetic Resonance Imaging (ASL-MRI). 
Na mesma amostra de doentes foi adicionalmente estudado o padrão de resposta cortical 
a uma tarefa cognitiva executiva (memória de trabalho) utilizando outro método de 
Ressonância Magnética, denominado Blood-Oxygen Level Dependent functional Magnetic 
Resonance Imaging (BOLD-fMRI). 
Foi efetuado um estudo transversal populacional controlado avaliando o desempenho 
neuropsicológico em adultos com enxaqueca ou outras cefaleias que mantinham as suas 
crises após os 50 anos de idade sendo esta amostra posteriormente reavaliada 
longitudinalmente (após 5 anos) de forma a determinar o risco de declínio cognitivo 
nesta população.  
 
Resultados: Os sintomas cognitivos são dos sintomas mais consistentemente descritos 
nas fases prodrómica (37% casos) e na fase álgica (38% casos) das crises de enxaqueca, 
identificados numa revisão sistemática de 28 séries clinicas envolvendo uma amostra 
total de 8392 doentes. Este tipo de sintomas também está presente nas restantes fases 
da crise, embora na fase posdrómica ou de resolução o sintoma predominante seja a 
fadiga (71% dos casos). Em 165 doentes questionados prospectivamente, 87% 
descrevem em média 2.5 sintomas cognitivos distintos ocorrendo durante as suas crises, 
cerca de 2/3 destes relacionáveis com sintomas executivos – sobretudo de atenção, 
eficiência e velocidade de processamento. As queixas de domínio cognitivo foram 
classificadas por 34 doentes registando prospectivamente 229 crises como o segundo 
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sintoma mais importante (a seguir à dor, em si mesma) responsável pela intensidade e 
incapacidade atribuível à crise de enxaqueca. Foi desenvolvida e validada uma escala 
prática e específica para identificar e quantificar os sintomas cognitivos subjetivos que 
ocorrem durante as crises, a partir de um conjunto de 43 itens candidatos desenvolvidos 
após entrevistas a doentes e revisão bibliográfica, utilizando analise fatorial. A escala 
obtida, de 9 itens (Mig-SCog), é de rápida aplicação e foca-se nos domínios de funções 
executivas e de linguagem, apresentando uma boa consistência interna (alfa de 
Cronbachs’ 0.82), fiabilidade (kappa de Cohen 0.55) e uma elevada correlação com 
medidas de validade externa, tais como a lista candidata de 43-itens (rho=0.69) e o 
questionário de falhas cognitivas (rho=0.61). A Mig-SCog apresenta um viés de memória 
negligenciável (não se verificaram diferenças nos resultados obtidos durante as crises e 
os reportados fora de crise) e resultado final verificado para a enxaqueca é mais alto 
(7.9±4.6) do que para uma dor somática (2.3±2.9, p<0.0006) ou em relação a estar sem 
dor (1.6±2.4, p<0.0006). O resultado do Mig-SCog é superior em doentes com enxaqueca 
do que em doentes com cefaleia de tensão em todos os itens da escala  (p<0.0001) exceto 
nos itens de nomeação (8 e 9). A AUC do resultado total do Mig-SCog para o diagnóstico 
de enxaqueca foi 0.835 (95% CI de 0.763-0.906, p<0.0001) reforçando a sua 
especificidade para a enxaqueca.  
Uma revisão da literatura identificou 10 estudos em que foi efetuada uma avaliação 
neuropsicológica durante as crises de enxaqueca, no entanto apenas 5 (incluindo 163 
doentes) apresentavam dados comparáveis de avaliação fora de crise. Em todos estes 
estudos foi possível identificar disfunção cognitiva na crise através da utilização de testes 
neuropsicológicos, em particular testes computorizados de funções executivas e testes 
convencionais (em papel) de leitura e velocidade de processamento, memória verbal e 
aprendizagem, muito embora não se pudessem excluir vieses importantes devido ao 
desenho dos mesmos. Na nossa amostra de 24 doentes que completaram uma avaliação 
neuropsicológica extensa em duas condições (numa crise e fora de crise) controlando a 
maioria dos vieses relevantes (em particular, o do efeito de aprendizagem) foi possível 
documentar um declínio de desempenho na maioria dos testes efetuados, em particular 
na velocidade de leitura (p=0.013), aprendizagem verbal (p=0.01), memória verbal de 
curto termo com (p=0.01) e sem (p=0.013) ajuda semântica e memória verbal de longo 
termo com (p=0.003) e sem ajuda semantica(p=0.05). 
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Na fase intercrítica, 24 doentes com enxaqueca tem um desempenho idêntico a controles 
emparelhados numa bateria breve de avaliação neuropsicológica contendo sobretudo 
testes executivos. Os testes desta bateria foram avaliados em aplicações repetidas num 
intervalo curto (em média 45 dias) para testar o efeito de aprendizagem, que foi 
demonstrado em todos os testes, sendo significativo no Stroop Interferência (p=0.002, 
corrigido para a multiplicidade). Foi quantificada a variabilidade mínima com potencial 
significado clínico.  
Os estudos de perfusão cerebral não conseguiram identificar alterações significativas de 
perfusão global ou regional durante as crises de enxaqueca sem aura, quando 
comparadas com a fase intercrítica numa amostra de 13 mulheres avaliando uma crise 
com uma intensidade média de 6.8 (numa escala visual de 0-10) e uma duração média 
de 16 horas. Do mesmo modo, nem o desempenho nem a ativação cerebral obtida com 
uma prova de memória de trabalho foram diferentes nestas duas condições, na mesma 
amostra de doentes com enxaqueca sem aura.  
A persistência de crises de enxaqueca e de outras cefaleias após os 50 anos foi associada 
com um declínio de desempenho nalguns testes neuropsicológicos de atenção e 
velocidade de processamento (na enxaqueca, n=61) e de memória semântica e 
recuperação de informação mnésica (noutras cefaleias, N=50) quando comparados com 
controlos sem cefaleias numa amostra de base populacional de 478 indivíduos testados 
em todos os domínios cognitivos. A reavaliação de 275 (57.5%) indivíduos da mesma 
amostra após 5 anos permitiu estimar o risco de declínio cognitivo em cerca de 14.9% 
da amostra, no entanto este risco não foi influenciado pela presença de enxaqueca nem 
de outras cefaleias.  
 
Discussão: A ocorrência de sintomas cognitivos durante as crises de enxaqueca é muito 
frequente. Os sintomas mais consistentemente descritos são atribuíveis às funções 
executivas, o que pode ser devido a uma seletividade específica das alterações do 
funcionamento cerebral associadas à crise de enxaqueca para o sistema executivo ou à 
relevância deste tipo de funções no funcionamento do dia-a-dia, em particular com o 
desempenho laboral e nas interações sociais. De acordo com a perceção dos doentes, 
estes sintomas contribuem de forma relevante para a incapacidade associada à crise de 
enxaqueca, substanciando a necessidade de incluir medidas subjetivas ou objetivas de 
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disfunção cognitiva como parâmetros de avaliação de eficácia nos ensaios clínicos de 
fármacos para controle da crise, assim como em medidas ou escalas de avaliação da 
incapacidade. A documentação objetiva destes sintomas é possível através de testes 
neuropsicológicos no entanto não existe ainda uma medida prática ou universal que 
permita a sua quantificação de forma fiável. Foi desenvolvido e validade um instrumento 
fiável e específico que permite quantificar a existência de sintomas cognitivos subjetivos 
durante as crises (o Mig-SCog), sendo facilmente aplicável em contexto clínico ou em 
investigação. A determinação dos mecanismos cerebrais potencialmente implicados na 
fisiopatologia destes sintomas é difícil e os dados disponíveis não permitem ainda a 
construção de um modelo teórico consistente. Os estudos de perfusão cerebral permitem 
distinguir os processos cerebrais ocorrendo durante as crises de aura (que condicionam 
hipoperfusão cortical) dos processos que ocorrem nas crises sem aura (sem 
hipoperfusão), sugerindo mecanismos fisiopatológicos distintos para estas duas fases da 
crise. O interesse futuro está focado agora na obtenção de mais dados de estudos 
funcionais, quer estudos com paradigmas de ativação evocada, quer de conectividade 
funcional ou mesmo estudos combinados de imagem e neurofisiologia. Apesar de as 
cefaleias e/ou enxaqueca persistentes após os 50 anos terem influência no desempenho 
cognitivo executivo desta população (de forma idêntica à documentada noutras 
situações de dor crónica ou recorrente), estas alterações são mais provavelmente 
adaptativas e reversíveis e não parecem influenciar o processo normal de 
envelhecimento ou degeneração cerebral nem do declínio cognitivo associado à idade.  
 
Palavras Chave 
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The oldest record containing the description of an headache syndrome dates from 
around 4000 BC, identified in Babylonian cuneiform tablets (1), although it is believed 
that trepanation was performed for relieving evil spirits causing headache, madness and 
seizures from inside the head, much earlier, in the Neolithic period (9000 BC)(2).  More 
detailed clinical records were found in several Egyptian papyri, including the Ebers 
papyrus (1550 BC). Ebers papyrus includes a syndromic description of migraine(3) and 
even describes an episode in which Ra, the solar deity which was believed to have 
created all forms of life and to rule all parts of the world (the sky, the earth and the 
underworld)(4), was given an headache after using some lesser deities remedies 
intended to cure of all his ills. It was Isis, the goddess of motherhood, magic and fertility, 
that used a mixture of honey and plants including the “berry-of-the-poppy-plant” (an 
opium poppy) that drove out the pain in Ra’s head(5). 
 
The first description of a visual aura followed by a migraine headache was made 
by Hippocrates of Kos (400 BC)(6) and the first detailed description distinguishing 
migraine from other headaches and including in the migraine syndrome all symptoms 
that are currently mandatory criteria for migraine diagnosis(7) was made by the Greek 
Aretaeus of Cappadocia (30–90 A.D.)(8). In this text he already included details about 
attack related humor changes “…torpor, heaviness of the head, anxiety, and ennui…”, as 
well as co-morbid reactive depression “…are weary of life, and wish to die”. The Roman 
Galen of Pergamon (121-200) further described several headache entities, introducing 
the terms hemicrania, cephalalgia and cephalaea to distinguish between headache types. 
He also published observations that implicated the stomach, the meninges, the 
pericranium and cranial blood vessels in migraine etiology(8).  The treatise de Medicina 
wrote by another Roman, Aulus Cornelius Celsus (25–50 A.D.), includes the first clear 
description of attack-related cognitive symptoms in migraine: “In the head, then, there is 
at times an acute and dangerous disease, which the Greeks call cephalaia; the signs of which 
are hot shivering, paralysis of sinews, blurred vision, alienation of the mind, vomiting, so 
that the voice is suppressed, or bleeding from the nose, so that the body becomes cold, 
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vitality fails. In addition there is intolerable pain, especially in the region of the temples and 
back of the head.”(9).  
 
Byzantine physicians (330-1453) maintained the theory of Galen, on which the 
humors of the body and head explained migraine, relating the stomach and the head in 
the concept of “bilious headache” that also ensued in the medieval Persian medical 
books(8).  In the 12th century, the Benedictine abbess, philosopher and physiologist 
Hildegard of Bingen considered her own visual auras as spiritual visions, influencing a 
mythic interpretation of migraine by the Catholics in the following century(10). In the 
13th and 14th centuries, most of the medical treaties about headache focused on herbal-
based treatments(10). It was not until the 17th and 18th centuries that innovative 
discussion on headache pathogenesis and treatment erupted.  
 
European physicians such as the Dutch  Nicolaas Tulp (1593–1674 A.D.) 
described various types of headaches including Cluster headache(8) and the English 
Thomas Willis (1621–1675 A.D.) was the first to provide the description of premonitory 
symptoms of migraine, that included fatigue, bursts of energy and hunger (10). The first 
medical book focusing on headache was published by Edward Liveing(11) (1832–1919 
A.D.), in which he included various detailed clinical description of the syndrome, 
including observations on hereditability, epidemiology, natural history, and about the 
attack in itself – triggers, prodromes, visual, sensitive and aphasic auras (interpreted as 
epileptic phenomena), pain and accompanying symptoms. Cognitive symptoms were 
described as a disturbance of “ideational consciousness”; a clear reference to 
disturbance of higher cerebral faculties is described under the sub-title of “Psychical 
Phenomena”, in chapter III, “Phenomena of the Paroxysm”(11). He divided these 
phenomena in “intellectual” and “emotional”, describing the former as ”...impairment of 
memory and in confusion and incoordination of ideas..”, “.. confusion of thought..”, 
“…unable to collect his thoughts…”, “…feeling silly…”, “…loosing their senses…”, although 
it is often not clear if some of these descriptions are related to the aura or the headache 
phase of the attack. The “emotional” phenomena were clearly stated to start in 
premonition of the attack, complaints of “…irritability of temper…”, “ill-humor” and a 
“vague and unaccountable sense of fear…” could precede the attack by one or two days, 
and “great mental depression” could linger through the entire paroxysm(11). In his 
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treaty he also included chapters on migraine pathology, co-morbidities and treatment. 
By the end of the 19th Century the dominant view was that migraine resulted from a 
cerebral disturbance, an “excess of nervous system energy”, as defended by Willian 
Gowers (1845-1915) in is Manual of Diseases of the Nervous System(8).  
 
During the 20th century, migraine research derived from clinical aspects to 
exploring migraine pathogenesis, genetics and treatment; some of the relevant scientific 
advances in migraine research were about these areas – migraine pathogenesis was 
initially related to vascular changes, due to the  identification of intracranial vascular 
changes (1938) and of pain structures in the head (1940) and then the theory was shifted 
to a neuronal etiology, after the analysis of spreading scotoma of visual aura (1941), its 
relation to cortical spreading depression of Leão (1944), the documentation of the 
spreading oligemia of migraine with aura (1981) and the identification of the first gene 
for familial hemiplegic migraine (1996). Further evidence integrating these phenomena 
was added by the theory of neurogenic inflammation (1984), the identification of the 
“brainstem generator” (1995) and of the central sensitization mechanism and allodynia 
(1996)(12). Therapeutic weaponry was initiated with the clinical introduction of 
ergotamine (1918), the identification of serotonin (1959) and later with the advent of 
the triptans (1988). The discovery of Calcitonin Gene-Related Peptide (CGRP) (1990) 
probably heralds a range of therapeutic targets for next generation drugs(12). The 
clinical major breakthrough of the 20th Century was the establishment of a consensus 
basis for diagnosis of headache disorders, the international headache classification 
(1988, 2004, 2013)(7, 13, 14), that allowed better definition and higher quality research 
and therapeutic trials. With the widespread use of the classification the focus was set on 
diagnosis and diagnostic criteria and the study of other clinical aspects of migraine 
became less expressive. In particular, cognitive symptoms almost ceased to be 
mentioned in clinical series of migraine and only a handful of studies approach the 











The Migraine Attack 
Migraine is the third most frequent disease in the world, affecting 14.7% of the World 
population(15), but after puberty the female gender has thrice the prevalence of males. 
While the prevalence in prepubescent individuals is low, it increases particularly in the 
most productive working years, between the third and fourth decades of life (24% of 
women and 7% of man), then declines to around 6.5% in women and 5% in man after 
the sixth decade (16). Migraine characteristics also seem to change with age, attacks 
being less typical in young and older patients(17), and headache frequency seems to 
decline with age(18). 
 
Migraine is a chronic disorder with episodic manifestations of syndromic attacks, 
occurring on average 2.1 per month that can last from 4 to 72h, their average length 
being around 32h40 minutes(19, 20). The attacks can be divided in four phases: 
prodromes, aura, pain and resolution or postdromes(21). During an attack, most 
patients are not able to function normally – 33% report severe disability (completely 
impaired for any activity) 47% moderate disability (partial impairment), 18% mild 
disability and only 1% report being functional(16). Burden of Migraine is calculated 
estimating in 5.3% the proportion of time spent in the symptomatic (ictal) state and in 
43.3% the disability assigned to migraine episodes, resulting in migraine being ranked 
as the seventh highest among specific causes of disability globally (responsible for 2.9% 
of all Years Lived with Disability, YLDs)(15).  
 
The premonitory phase of the migraine attack includes symptoms attributed to 
migraine that start as far as 3 days before the actual headache or pain onset, but most 
often within the 24h preceding the painful phase(22); average prodrome duration is 
around 9 to 10  hours(21, 23). Interpreting these symptoms or premonitory signs, 
patients are able to predict the occurrence of the attack, with an increasing accuracy that 
ranges from 20% in the previous day to 90% 2 hours before pain onset(22). Not all 
patients experience prodromes, prevalence estimates range from 7 to 88% (22-24) yet 
prodromes can be distinguished from unspecific symptoms occurring in the interictal 
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phase(25) and some prodromes are noticed by patients family members or social 
interlocutors(26). Prodromes usually persist up to the point of pain onset(27) yet often 
do not resolve at this point nor with the end of the headache, persisting through the 
resolution phase, or the posdrome(22).   
 
The prodromes were initially distinguished from the other more exuberant 
phenomena preceding the onset of pain - the aura – for having insidious onset, lasting 
several hours and affecting mood, behaviour, wakefulness, gut motility and fluid balance 
suggesting potential hypothalamic dysfunction in this phase, supporting the view of 
migraine as a neurogenic disorder(21). It was not until recently, with functional 
neuroimaging, that hypothalamic involvement in the early stages of the migraine attack 
was documented (28, 29), supporting the potential role of this structure in the 
prodromal phase of the attack, although in one study it’s activation persisted thru the 
pain and pain relief(29). The role of the hypothalamus in migraine can be either as a 
generator or trigger sensor for the attack (supported by the association of attack 
triggering to sleep disturbances and hormonal fluctuations)(30, 31) or in nociceptive 
modulation(32). Its dysfunction can explain both autonomic symptoms(33) and mood 
changes, through its connections to the limbic system(34). 
 
The aura is a rare and complex neurological event occurring in around 15% of 
migraine patients. Most patients(81%) do not experience auras in every migraine 
attack(35). The most frequent clinical manifestation of aura is visual, being present in 65 
to 99% of patients with aura. Other symptoms that may be present are sensory (31%), 
aphasic (18%) and motor(6%), occurring in various combinations (36, 37), although the 
designation of “typical” aura includes visual, sensory and aphasic symptoms in 
succession, as defined in the International Classification of Headache Disorders (ICHD-
III) (7). 
 
The clinical hallmark of a migraine aura is the progression of symptoms over time 
(lasting around 15 to 30 minutes(35)), with progressive symptom resolution of one type 
or one location preceding the onset of the next symptom or site; also the simultaneous 
presence of positive and negative symptoms(7, 36). Not all auras are followed by a 
headache - as much as 10% have isolated auras(36). most patients (55%) have less than 
1 attack per month and it’s most frequent duration is 15 to 30 minutes(35), although 12 
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to 37% of patients can have episodes lasting longer than 1 hour(38).  The presence and 
type of aura and/or headache determines the subdivision of migraine diagnosis in the 
ICDH-III(7). 
 
Karl Spencer Lashley in 1941, describing his own visual auras, was able to map and 
rate the progression of visual symptoms across the visual field to a rate of propagated at 
a rate of 3 mm/minute or less, describing the typical excitatory expanding scintillating 
fortification figures followed by the inhibition scotoma and progressive recovery(12) 
now consistent with typical visual aura. This typical and consistent progression of 
symptoms had a neurophysiological correlate, the phenomenon of Cortical Spreading 
Depression (CSD), described by Aristides Leão in 1944, as a cortical wave of spreading 
electrical excitation followed by depression occurred and propagated at a rate of 3 mm 
per minute occurring in rabbits’ brains after mechanical or chemical stimulation(39). It 
was not until the advent of functional neuroimaging studies that it was possible to 
observe an similar phenomena translated into BOLD (Blood-Oxygen Level Dependent) 
signal changes in the living human brain cortex during a migraine aura (40). 
 
The pain of migraine starts within the aura phase in as often as 54% of attacks(41), 
while the remaining have an average free interval between the end of the visual aura and 
headache onset that is usually shorter than 30 minutes (35). During this free interval, 
some patients fell completely well while others describe mood changes, perception 
difficulties, cognitive changes and somatic symptoms(42) being unclear is these 
symptoms represent the lingering or onset of prodromes after the aura(22, 23, 25, 27). 
The headache is the most frequently occurring phenomena of migraine and its 
characteristics define the diagnosis of Migraine(7). The head pain is typically unilateral 
(bilateral in 25 to 40%) throbbing (47 to 91%) or pressing (90%) moderate to severe, 
mostly felt in the trigeminal sensory distribution (eyes 67%, temporal 58%, frontal 56%) 
or neck (40%). Headache onset is usually progressive with a median time to peak of 
around 90 minutes and pain is aggravated by activity in 53 to 90% of patients. Headache 
lasts in average 6 to 24 hours and its average intensity of the attack in episodic migraine 
is around 8/10 on a Visual Analogue Scale(20, 43, 44) although the classification only 




        Migraine pain is associated with several non-painful symptoms such as photophobia 
(increased sensitivity to light, in 55 to 97% of attacks), phonophobia (increased 
sensitivity to normal-volume auditory stimuli in 47 to 95%), osmophobia 
(hypersensitivity to odors in 25 to 75%) and kinesiophobia (intolerance to movement in 
53 to 98%) and nausea (80 to 87%) and vomiting (44 to 67%) (20, 44-47) but not all 
need to be present to allow diagnosis(7). 
 
Pain is thought to be a consequence of the activation of the trigeminovascular system 
by the cortical release of neurochemical mediators by the Cortical Spreading Depression 
(CSD).  The activated perivascular nociceptive trigeminal sensory afferents release CGRP 
and nitric oxide with consequent sterile neurogenic inflammation (vasodilatation, 
plasma protein extravasation and mast cell degranulation) that further activates 
meningeal nociceptive trigeminal sensory afferents, explaining the pain projection on 
the trigeminal territory. This information travels to the trigeminal ganglion, then the 
brainstem trigeminocervical complex and up to the thalamus, were it is integrated as a 
nociceptive input in the pain matrix of the brain(48). Dysfunction of structures involved 
in the modulation of neuronal excitability and pain, such as  the periaqueductal grey and 
the locus coeruleus in the brainstem, the thalamus and even reduced activation of 
descending cortico-trigeminal inhibitory pain pathways are thought to be responsible 
for symptoms accompanying the headache, such as allodynia, photophobia, and 
phonophobia(49). 
 
The headache will at some point decrease progressively, either imperceptibly or 
quickly until it disappears, even without any specific intervention to shorten the 
attack(50). Attacks can then be shortened or interrupted by several strategies, the most 
common being medication, sleep or vomiting(50). However, 60 to 94% of patients have 
up to seven(25, 50-52) different persisting migraine symptoms after headache 
resolution, that last  on average 25.2 hours (< 12h in 54% of patients; although most 
patients (39 to 60%) have postdromal symptoms consistently, only 26% have them in 
all attacks(25, 52).  The more complete or typical is the migraine attack, the higher the 
probability of having posdromal symptoms(52). 
 
Little is known about the mechanisms that underlie the attack resolution nor the 
posdrome; given the fact that many of the posdromal symptoms are also present in the 
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prodromal phase of the attack, it was proposed that this phase would represent a slow 
decline or resolution of the brain process activated since the beginning of the attack that 
had been overshadowed by headache, and could theoretically involve the same brain 
structures, such as the hypothalamus(51). This is supported by functional imaging 
studies that reveal persistence of dorsolateral pons, midbrain and hypothalamic 
activations after headache relief with sumatriptan(29, 53); nevertheless, the effects of 
medication used to treat the attack may also have an impact of symptoms arising after 
the painful phase has subsided (52, 54, 55).  
 
  Clinical and physiological data(56) supports that the migraine attack starts before 
pain onset and does not end with pain relief; although patients can distinguish attack 
phases, the transition between phases is arbitrary, or even variable. Even considering 
the time lapse in between migraine attacks - the interictal phase - there is evidence of 
differences of brain function in migraineurs, compared to controls. As an example, 
migraine patients are more likely to be light-sensitive and their cortical responses to 
light are triggered with a lower threshold than matched controls even in the absence of 
pain(57).  This increased responsiveness of the migraine brain to an external stimuli 
seems to be mediated by cortical information processing abnormalities that translate 
into reduced amplitude of early responses and lack of the normal decrease in mean 
amplitude of responses with repeated visual, auditory, somatosensory or cognitive 
stimuli (habituation) in the interictal phase, reverting to normal function just before and 
during an attack(58). 
 
        Description of cognitive difficulties occurs in all phases of the attack and some 
reports suggest their occurrence also in the interictal phase (59, 60). 


















Cognitive Function can be generally defined as the conscious and unconscious 
mental process by which one becomes aware of concepts or ideas; it involves a wide 
range of brain functions, such as perception, reasoning, memory, language, learning etc.; 
these functions have complex interactions that influence emotions and behaviors(61).  
The study of cortical cytoarchitecture by Broadmann (1909) generated the 
concept that the cerebral cortex differences in the organization were related to specific 
cortical functions; the cortex was then divided into sensory, motor, association (areas 
processing information from a sensory modality) and multimodal association cortex 
(areas integrating information from different modalities), reflecting the functional 
specialization of specific brain areas. Later, neurophysiological studies have identified 
patterns of neuronal responses organized in functional columns in the brains’ neocortex; 
these cortical columns have multiple cortical-cortical and cortico-subcortical reciprocal 
connections and are organized into functional subsets or nodes, each belonging to a 
number of connected functional systems(62).  Brain systems are collections of 
processing units that are spatially separate yet connected and communicating, being the 
basis of the brains’ functional integration ability. The organized action of these systems 
supports complex brain operations, such as the higher brain functions(62).  
To study higher brain functions cognitive neuropsychologists assume that there 
is a meaningful relationship between the organization of the brain and that of the mind 
and also that cognitive processes can be viewed as modules, being relatively 
independent from each other - a classical view coming from the study of brain 
lesions(63). The principal methods used to study mental capacities rely on direct 
observation, behavioral checklists, semi-structured interviews and formal 
neuropsychological tests or psychometric tools, in which an experimental standardized 
measurement of performance in a specific function or task is applied and compared with 
normalized populations of interest(64).  
Functional imaging has revolutionized the study of brain functions and its’ 
mapping in the last 20 years as it has allowed the identification of brain areas of higher 
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energy consumption (measured by local changes in blood flow, metabolism and tissue 
oxygenation) associated with the performance of specific tasks, changes assumed to be 
the reflexion of increased neuronal activity(65).  Studying evoked brain activity lead to 
astonishing advances in identifying functional specialization of cortical and subcortical 
areas but studying temporally related patterns of activations and deactivations allowed 
the identification of large-scale intrinsic brain activity patterns that were denominated 
as “resting state” networks, believed to be the basis for mind-wandering and related 
forms of spontaneous thought (66).  
 
Although the study of cognitive functions has greatly expanded it is still very 
complex not only due the limitations of each technique but especially to the 
determination of meaningful changes and to the definition of “normality”. Cognitive 
performance is able to be influenced by many variables, examples including sleep 
deprivation(67), hypo or hyperglycaemia(68, 69),  heat or cold exposure(70, 71), 
positive or negative mood changes(72, 73), effects of nicotine(74), caffeine(75) or 
alcohol(76) also of many drugs including stimulants or sedatives(77, 78), effects of 
literacy(79) or musical training(80) and particularly age, as cognitive performance 
progressively improves from childhood to adulthood and slowly declines with further 
aging (81, 82). 
 
Cognitive functions decline in normal aging is not homogeneous; perceptual 
speed and  numerical ability start to decline from early adulthood (mid-twenties) while 
verbal ability, inductive reasoning, verbal memory, episodic memory and verbal fluency 
decline starts from the fifties on (83, 84); the impact of the aging process is not uniform 
amongst healthy individuals conditioning important variability. In addition, several 
health problems accelerate age-related cognitive decline and are risk factors for 
dementia, such as lack of environmental stimulation physical inactivity, obesity, 
smoking, vascular comorbidities (diabetes, hypertension, hyperlipidemia), 




Pain is also able to influence cognitive functioning; acute pain has been shown to 
modify the cerebral activity pattern induced by a cognitive task(88); in chronic pain a 
correlation between the level of cognitive dysfunction and pain ratings has been 
documented, as was an improvement in cognitive performance with effective pain 
control(89). Although the mechanism underlying the pain-cognition interaction is not 
defined, it is well known that the several of cortical areas through which pain is 
generated from nociception (the ‘‘pain matrix’’)(90) can be activated in several cognitive 
settings. In theory, recurrent nociceptive inputs may compete with cognitive information 
processing; also neuroplastic and neurochemical changes resulting from chronic pain 































THE RESEARCH PROBLEM 
 
Migraine is the third most prevalent disease in the World, being the seventh highest 
specific cause of disability globally (responsible for 2.9% of all Years Lived with 
Disability, YLDs)(15). This Global Burden of Migraine assessment is exclusively based on 
attack related disability yet the identification and valorization of the specific attack 
symptoms producing migraine-related disability is not consensual(92-94).  
 
Headache is the hallmark of migraine and its most consistent disability-related 
symptom, yet headache relief does not always translate into functional recovery(54);  in 
particular, difficulties in performing cognitive tasks are pointed out as important 
contributors to attack-related disability(54, 93, 95). 
  
Attack-related cognitive symptoms in Migraine are described in medical texts at least 
since the first century(9) yet detailed knowledge about these symptoms occurrence, 
characterization or physiopathology is scarce in medical literature. Objective 
documentation of reversible cognitive dysfunction during migraine attacks seems to be 
consistent, although most of the studies supporting this findings are small and bear some 
methodological limitations (60, 96-100). No systematic way to identify or quantify these 
symptoms exists, that would allow better characterization of its frequency or impact.  
 
Migraine is currently perceived as a complex brain disorder in which several cortical and 
subcortical structures interplay in a given sequence or pattern, giving rise to different 
clinical expressions of the same phenomenon in an orchestrated plot. The frequency of 
repetition of these events is associated to structural brain changes, documented in 
synaptic density (grey matter) and  connectivity (white matter)(101). Imbalance of 
cortical or subcortical influences may underlie cognitive symptoms perceived by 




Although migraine is clinically more relevant and expressive at young-adult age, 
persisting attacks at late adult life or in the elderly could potentially influence the normal 
pattern of cognitive age-associated decline, as pain itself is known to influence 
cognition(89). Evidence from large population-based longitudinal studies does not seem 
to support an increased risk for cognitive decline in migraine patients although some 
studies are able to identify interictal differences in some cognitive functions of migraine 
patients, compared to healthy controls (104, 105).  
 
Improving the knowledge about cognitive function during migraine attacks can provide 
clues to the brain processes occurring within the attack and help determining the 
sequence of brain events producing the episodic brain dysfunction of migraine patients. 
It can also help to understand potential mechanisms contributing to cognitive changes 
or adaptations to these repetitive dysfunctional events occurring with normal aging in 
migraine patients. 
 
Potential applications include (1) Development of better disability measures for 
migraine, that include cognitive dysfunction; (2) Inclusion of cognitive outcomes in trials 
of acute attack medication (with potential impact in reducing migraine-attack related 
disability); (3) Developing new therapeutic targets related to the brain mechanisms 










Objective #1:  
To study the occurrence of cognitive symptoms in migraine attacks 
- Identify, collect and systematize information about subjective cognitive 
symptoms occurrence during migraine attacks, based on data available on 
published peer-reviewed medical literature  
- Describe and classify, in a clinical series of migraine patients, the subjective 
cognitive symptoms most often reported during the headache phase of migraine 
attacks 
- Determine the intensity and disability of attack-related cognitive symptoms in a 
clinical series of migraine patients and to relate it with intensity and symptom 
related disability of migraine attack defining symptoms. 
- Develop a quantitative and practical instrument to identify and quantify attack-
related subjective cognitive symptoms in migraine (Mig-SCog) 
- Document the specificity of  the Mig-SCog for migraine  
 
Objective #2:  
To evaluate objective evidence of cognitive dysfunction in migraine 
attacks  
- Identify, collect and systematize information about objective cognitive 
dysfunction documented by neuropsychological testing during migraine attacks, 
based on data available on published peer-reviewed medical literature  
- Compare cognitive performance of migraine without aura patients during and 
outside attacks using an extensive battery of neuropsychological tests and 
controlling for the most important potential  confounders in this context   
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- Assemble a brief neuropsychological battery to identify and quantify objective 
executive dysfunction in migraine  
- Document brain perfusion changes occurring during migraine without aura 
attacks using the Arterial Spin Labeling Magnetic Resonance Imaging (ASL-MRI) 
technique. 
- Document brain responses to a cognitive (executive) challenge during and 
outside a migraine without aura attack using Blood Oxygen Level Dependent  
functional Magnetic Resonance Imaging (BOLD-fMRI) 
 
Objective #3:  
To study the effect of persisting migraine in cognitive function or 
cognitive decline in older adults  
- Compare objective cognitive function evaluated with extensive 
neuropsychological testing in healthy older adults without headache, with 
migraine and non-migraine headache 






Research question #1 - Are cognitive symptoms included in clinical series of migraine 
patients describing the migraine attack phenomenology? 
 
A systematic review of medical databases (Medline and Cochrane Library) was performed to 
identify and collect available data about cognitive symptoms occurrence in any phase of the 
migraine attack. Due to the high variability of the retrieved studies’ methodologies, data analysis 
was qualitative; symptoms were grouped into domains and each phase of the attack was 
evaluated independently. Tables with symptom frequency were plotted for each phase of the 
attack (prodromes, aura, pain and posdromes). 
 
Research question #2 – What attack-related cognitive symptoms do migraine patients 
report? Is there a pattern? 
 
A cross-sectional systematic survey about the occurrence of cognitive symptoms during the 
headache phase of migraine attacks was performed in a clinical-based sample of 165 episodic 
migraine patients in two phases; data from the initial 93 patients of this sample was also used to 
in the study of the development of the Mig-SCog. In this study, however, the sample was increased 
to improve the quality and consistency of symptom reporting. Data collection started with a 
dichotomic (yes/no) question regarding the occurrence of such symptoms followed by an open-
ended question regarding spontaneous description of each symptom. Finally, a self-administered 
symptom checklist was used to confirm the preceding spontaneous symptom elicitations, which 
included subjective cognitive (executive, spatial perception and language) and non-cognitive 
(mood, anxiety and visual) symptoms. 
Symptoms prompt as answers to the open-ended question and of the symptom checklist were 
classified and grouped into cognitive and non-cognitive domains, and within each domain into 
different functions and plotted into frequency tables. The relation between having cognitive 
symptoms during attacks with demographic and disease-related variables was sought.  
 
Research question #3 - Are attack-related cognitive symptoms relevant to migraine-




The migraine attacks of an independent clinical-based sample of 100 episodic migraine patients 
were prospectively recorded using paper headache diaries. Information collected included items 
of timing of the recorded attack (pain onset and relief, timing of rescue medication use) and 
scoring on a 0-10 Visual Analogue Scale the intensity and disability related to each attack and to 
each migraine symptom, including also two cognition related symptoms - pain worsening with 
mental effort and difficulty in thinking. Relationships between intensity and disability scores of 
the attacks an of each migraine symptom were explored. 
 
Research question #4 – Can we identify and quantify attack-related cognitive symptoms 
in migraine? 
 
An extensive (43 items) cognitive symptoms checklist was assembled based on structured 
interviews of 37 migraine patients and with data from literature review in order to develop a 
questionnaire that allows identification and quantification of subjective cognitive symptoms in 
migraine attacks. The extensive checklist was applied prospectively to an independent sample of 
93 migraine patients and factor analysis was conducted for item reduction. The reduced checklist 
retained 9 items that composed a multiple choice self-administered questionnaire – the Mig-
SCog. Construct validity, internal consistency, temporal stability and external validity of the 
questionnaire were tested. 
 
Research question #5 – Are cognitive complaints identified with the Mig-SCog specific 
for migraine? How reliable is the Mig-SCog?  
  
The Mig-SCog was prospectively applied in a clinical-based sample of headache patients in three 
different prospective studies with independent patient samples –one cross-sectional comparing 
migraine (N=98) and tension-type headache patients (N=51); the remaining included migraine 
patients using Mig-SCog for three different status (migraine, non-headache pain and pain-free, 
N=63) and in the last study the Mig-SCog was fulfilled within and in-between attacks, to screen 
for the recall bias (N=38).  Scores obtained in each situation were calculated and compared with 
the appropriate statistic method. Validity analysis was used to determine the sensitivity and 




Research question #6 – What is the evidence of cognitive dysfunction occurrence during 
migraine attacks? 
  
A systematic review of medical databases (Medline and Cochrane Library) was performed to 
identify and collect available data about the existence and pattern of impaired 
neuropsychological performance during migraine attacks, compared to the headache-free status.  
Due to the high variability of the retrieved studies’ methodologies, data analysis was qualitative; 
Tables with summaries of relevant results were plotted. 
 
Research question #7 - Do migraine patients have reversible cognitive impairment 
during attacks?  
 
A prospective two-period randomized cross-over study of neuropsychological performance of 
clinic-based independent sample of 39 migraine patients within a spontaneously occurring 
migraine without aura attack and in the headache-free period was conducted. Patients’ 
performance in an extensive neuropsychological battery was compared between both situations, 
while controlling for the most relevant potential bias. 
 
Research question #8 – How can we measure attack-related cognitive impairment?   
 
A battery composed of brief and practical routine neuropsychological tests focused on executive 
functions was assembled in order to be possible to sequentially test migraine patients in their 
ictal or/and inter-ictal status. A prospective cross-sectional controlled study of the performance 
of inter-ictal migraine patients in repeated short-term (6 weeks) applications of this battery was 
conducted. Cases’ performance was compared to that of matched controls, using a convenience 
sample of 48 volunteers from the hospital staff. The practice or learning effect of each test was 
quantified in order to determine the clinically meaningful predictable score change of repeated 
applications. 
 





A prospective longitudinal study of brain perfusion using Arterial Spin Labeling magnetic 
resonance imaging (ASL-MRI) was conducted in 13 female episodic migraine patients recruited 
among the hospital staff and in the acute care outpatient clinic during an untreated 
spontaneously occurring migraine without aura attack and repeated in a headache-free period. 
Cerebral global and regional brain perfusion was averaged for the total group and subtracted 
between the two sessions in order to identify perfusion differences. 
 
Research question #10 – Are there neuronal network abnormalities underlying the 
attack-related executive symptoms in migraine? 
 
The previous study was complemented by the evaluation of cortical activation using Blood 
Oxygen Level Dependent functional magnetic resonance imaging (BOLD-fMRI) in response to an 
executive task (N-Back) and a brief neuropsychological evaluation focused on executive 
functions in the same conditions, during an untreated spontaneously occurring migraine without 
aura attack and repeated in a headache-free period. The cortical activation pattern in response 
to the N-Back task was averaged for the total group and subtracted between the two sessions in 
order to identify activation differences. The performance on the neuropsychological evaluation 
was compared between the sessions and differences found were paralleled to the predictable 
score change of repeated applications. 
 
Research question #11 - Is ongoing migraine related to worse cognitive performance 
late in life? 
 
A prospective cross-sectional population based study of older adults (aged 50 or over) 
neuropsychological performance in an extensive neuropsychological battery was undertaken. 
The headache status of the sample was sought and classified into migraine, non-migraine 
headache and headache-free individuals, whom were used as controls. Cognitive performance 
was compared between groups. 
 
Research question #12 - Is migraine associated with an increased risk of cognitive 




The same sample of the previous study was revaluated after five years, to screen for cognitive 
decline, defined as a significant decline in memory and/or executive functions. The influence of 

























3. Subjective Cognitive Complaints during 













The following chapter is devoted to the study of the subjective perception of cognitive 
difficulties by migraine patients during migraine attacks – their cognitive symptoms. 
Description of cognitive difficulties is frequent in the clinical setting and patients’ 
perceptions relate these symptoms to working and social interaction disability during 
attacks. 
 
The existence of attack-related cognitive symptoms in migraine seems to be consistent 
throw-out historical medical descriptions at least since the first century(9). A systematic 
review of the most recent medical literature seeking the identification and 
characterization of this symptomatology is first presented, supporting that these 
symptoms are frequently described in clinical series of migraine patients and are 
included in all phases of the migraine attack (prodromes, aura, headache and 
posdromes). The most frequent symptoms report to executive functions (concentration 
difficulties, impaired thinking and slow processing) and language.  
 
As the headache phase is the most relevant in clinical terms, a prospective survey ensued 
which had the aim to improve knowledge about the symptoms most often described in 
this phase of the attack. The majority of patients felt cognitive symptoms during the 
headache phase of the migraine attack and their descriptions were fairly consistent and 
characterized by complaints of attention difficulties, diminished cognitive efficiency and 
processing speed impairment. An exhaustive description of patients’ symptoms using 





The following step was trying to document, by using patients’ perceptions, if these 
symptoms had relevant impact on the migraine attack. Over two-hundred migraine 
attacks were evaluated prospectively with diaries scoring each migraine symptom 
intensity and disability on a 0-10 Visual Analogue Scale. Cognitive symptoms were 
scored second only to pain in terms of intensity and attack related disability, raising 
awareness about the need to treat this relevant and overlooked part of the attack. 
 
To improve awareness about these symptoms there is a need to go beyond their 
identification. Cognitive symptoms’ complex nature and heterogeneity hampers the 
perception of their impact, therefore the need for a standardized instrument with the 
ability to identify and quantify cognitive symptoms during migraine attacks. The Mig-
SCog was developed and validated to this purpose.  
 
The Mig-SCog is a 9-item self-fulfilled, easy to apply and very brief questionnaire 
reflecting subjective impairment in two cognitive domains (executive functions and 
language) that was developed for migraine. Its clinical applicability was further tested 
and it has shown to be consistent, highly specific for migraine (compared to tension-type 
headache) patients and had a negligible recall bias. This instrument can be of help both 
in clinical practice and in clinical trials to monitor treatment effects on attack-related 










Are cognitive symptoms included in clinical series of migraine patients 
describing the migraine attack phenomenology? 
Clinical description of attack-related cognitive symptoms in 
Migraine. A systematic review.  
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Introduction: Documentation dating back to the Roman Era in the first Century comprises 
cognitive symptoms in the clinical description of the migraine attack. This important part of the 
migraine syndrome has been neglected through the centuries despite being a potentially 
valuable contributor to migraine-related disability.   
Objective: To determine if cognitive symptoms are included in clinical series of migraine 
patients describing the migraine attack phenomenology and if specific cognitive symptoms are 
present in each phase of the migraine attack. 
Method: Systematic reviewed of existing data on clinical description of the migraine attack, 
focusing on accompanying cognitive symptomatology. Data was organized and analyzed 
qualitatively, due to methodological differences between studies. 
Results: Twenty-eight articles were reviewed, with a total sample of 8392 migraine patients, 
37.1% with aura, 82.7% females with an age average of 39.6 years. Twenty one (75%) studies 
focused only on one phase of the attack (8 prodromes, 5 aura, 1 between aura and pain, 3 
headache and 4 postdromes), the remaining studied more than one attack phase. Cognitive 
symptoms were the most frequent group of symptoms reported in the prodromic(37%) and 
headache(38%) phases, while fatigue(71%) dominated the postdromic or resolution phase. Not 
enough data is available to estimate the frequency of cognitive symptoms during the aura.  
Discussion: Cognitive symptoms are consistently described in all phases of the migraine attack 
phenomenology in published clinical series of migraine patients and its occurrence seems to be 
different in different phases of the attack. Important methodological limitations prevent accurate 




INTRODUCTION     
 
Migraine is the third most frequent disease in the world, affecting 14.7% of the World 
population(15), and its prevalence is particularly high in the most productive working 
years(16).  
Migraine is a chronic disorder with episodic manifestations of syndromic attacks; 
during an attack, most patients are not able to function normally – 33% report severe 
disability (completely impaired for any activity) and 47% moderate disability (partial 
impairment) (16). Burden of Migraine is calculated estimating in 5.3% the proportion of 
time spent in the symptomatic (ictal) state and in 43.3% the disability assigned to 
migraine episodes, resulting in migraine being ranked as the seventh highest among 
specific causes of disability globally (responsible for 2.9% of all Years Lived with 
Disability, YLDs)(15).  
 
Migraine attacks are complex phenomena that start before the onset of pain. The 
elaboration of the International Headache Classification(14) has boosted the study of 
migraine by providing a simple definition focusing on the most expressive symptoms of 
the syndrome; the downside was that many more ill-defined, less expressive symptoms 
have been overlooked in the most recent years of migraine research. Some of these 
symptoms might be as common or as disturbing as pain itself or may provide important 
clues to the pathology of the brain process underlying the migraine attack and to the 
identification of relevant therapeutic targets for minimizing attack-related disability. 
One of such examples is attack related allodynia(106, 107); another might be migraine 
attack-related cognitive dysfunction(108, 109), which has a potential clinically relevant 
impact on attack disability. 
This study objective is to perform a systematic literature review to provide detailed 
information about non-migraine defining symptoms occurring during the migraine 
attack, focusing on cognitive symptomatology. The specific search questions were: Are 
cognitive symptoms included in clinical series of migraine patients describing the 
migraine attack phenomenology? If so, in which phase of the migraine attack 
(prodromes, aura, pain and posdromes) are they noticed by patients? Are different 
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symptoms described in different phases of the attack? Can a frequency of their 




Potentially eligible studies were identified through electronic databases search of 
Medline (through PubMed) and the Cochrane Library from inception to November 2014, 
without any limitations or restrictions. The search used the free text terms “migraine” 
AND “prodromes” OR “premonitory”, “migraine” AND “aura”, “migraine” AND “pain” 
“migraine” AND “prostdrome” OR “resolution”, and combined with “cognition” OR 
“cognitive” OR “neuropsychological” and with “cognitive” OR “executive” OR “memory” 
OR “language”- We additionally searched “migraine” AND “cognition” and “migraine” 
AND “clinical characterization”. The thesaurus terms used in these searches were 
"Headache" OR "Headache Disorders" OR "Migraine Disorders" OR "Migraine with Aura" 
AND "Cognition" OR "Cognition Disorders” AND “clinical medicine”.  
 
Study Selection and Data Collection 
Titles and abstract screening identified studies that described any type of cognitive 
symptom occurring in any phase of the migraine attack, including reviews, clinical series 
and research studies. Studies were excluded in title or abstract screening if they reported 
(1) cognitive testing or test results in migraine patients (2) cognitive symptoms 
associated with treatments used in migraine patients; (3) cognitive symptoms of chronic 
migraine and/or medication overuse headache or genetic forms of migraine (CADASIL, 
Familial Hemiplegic Migraine); (4) clinical characterization of migraine patients that did 
not include cognitive symptoms; (5) psychological or psychiatric symptoms in migraine 
patients; (6) cognitive or cognitive behavioral therapy in migraine patients; (7) letters 
or comments; (8) small series (less than 10 patients) or case reports; (9) papers in which 
clinic characterization of attacks referred exclusively to ICHD defining symptoms. 
References of relevant papers and references of reviews were also screened with the 




Data extraction and analysis 
Tables were constructed to summarize the included studies and relevant results from 
the studies selected. The data was organized, classified and analyzed qualitatively; 
different symptoms were grouped according to its characteristics into mood/ 
behavioral, migraine-related (including sensorial and gastrointestinal symptoms), 
cognitive or neuropsychological and autonomic symptoms. Each phase of the attack 
(prodromes, aura, headache and postdromes)(21, 50) was evaluated independently. 
Study designs, objectives and outcome measurements were very discrepant, 
nevertheless a few basic quantitative analysis were made to allow data organization, 
including (1) Averaging the frequency of each symptom between studies (considered 
only if there were at least 3 different studies with frequency values for any given 
symptom);(2) Total number of different symptoms reported within each group. Ethics 




1. Study flow and Details 
The study flow is depicted in Fig. 1. A total of 28 papers met the eligibility criteria for 
review and their characteristics are depicted in Table 1; four of these papers are 
abstracts from a poster presentations (110-113). The majority(82%) of the studies had 
prospective data collection, data collection was mostly done by questionnaires (12 
studies), only one study was controlled(114) -  table 1.  
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Legend: (*) This study focused on the time lapse between the end of the aura and pain onset; (†) 
Convenience sample of medical practitioners; (‡) Controlled study ; (∫) Sub-study of a clinical trial 




Figure 1 – Study Flow 
      Sample sizes varied from as little as 20 (115) and up to 1675 patients(119) , total 
number of patients included was 8392, 6943 (82.7%) were females, with an age average 
of 39.6 years. One study included only children(117), one only female patients(119), 5 
studies (530 patients) only migraine with aura patients(35, 37, 42, 115, 120); in total, 
more than one third (3110, 37.1%) the patients studied had aura. Twenty-three (82%) 
studies recruited patients exclusively in headache clinics yet only 13(46%) contained 
information about headache impact (attack frequency, duration, disease duration or 
impact scales)(17, 23-27, 52, 111, 117-121) and 3 about current prophylactic and/or 
acute medication for headache(21, 27, 111). 
Selected for title review
N=2802







-Reviews, N = 6
- Description of precipitating factors= 5 
- Not including cognitive symptoms, N=4
- Editorial, N=1
- Unable to obtain the manuscript=1  
New titles resulting of 
search of relevant references 
in all screened articles
N = 4
Excluded total = 180
- Clinical studies not including cognitive symptoms 
descritpion = 101
-Duplicated references =  54
- Comments, Editorials= 6 
- Reviews = 15
- Case reports = 4




Twenty one (75%) studies focused exclusively on one attack phase (8 the prodromes, 
5 the aura(35, 37, 115, 116, 120), one the time lapse between the end of the aura and the 
beginning of pain, 3 the headache and 4 the posdromes – table 1) Further analysis will 
be presented within each phase of the attack. 
 
2. Clinical Description of the Migraine Attack 
 
2.1 Premonitory phase or prodrome 
The premonitory phase includes symptoms attributed to migraine that start before 
the actual headache or pain onset, definitions of prodrome duration vary from as far as 
3 days, but most often within the 24h preceding the painful phase(22-26). Self-reported 
impairment of cognitive  functioning  and positive  start at 25-36  hours  before and peak 
in the 12 hours preceding the attack(121); average prodrome duration was 9 to 10  
hours in some studies(21, 23). Interpreting these premonitory symptoms, patients are 
able to predict the attack with an accuracy that ranges from 20% 24h before the attack 
to 90% 2 hours before pain onset(22). Not all patients experience prodromes, 
prevalence estimates range from 7 to 88%(22-24). Around two-thirds of children have 
premonitory symptoms, on average 2 different symptoms(117) while adults described 
an average of 12 different symptoms(26). Prodromes can be distinguished from 
unspecific symptoms that also occur in the interictal phase(25) and patients’  family 
members or social interlocutors also notice changes before the attack, mostly pallor, 
dark rings around eyes, irritability and inactivity or excessive dynamism(26).  
Most premonitory symptoms persist without increasing their intensity up to the 
point of pain onset(27) and often do not resolve, persisting all the way up to the 
posdrome(22).  Patients with prodromes are more likely to have more attack trigger 
factors, longer duration of aura, longer time between aura and headache, longer time to 
peak of headache, longer attack duration(26), longer time for triptan effect, higher 
probability of having posdromes and longer posdrome duration(23, 26). Also they more 
often have attacks of aura without headache and nausea and accompanying cranial 
autonomic symptoms (CAS) during headaches (23). The frequency of prodrome 
occurrence does not seem to be influenced by age (even in children) (17, 26, 117),  
gender (although in one study females reported more prodromes(26)), headache 
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intensity or impact but seems to be lower in patients taking migraine preventives(25). 
The presence of aura was found to increase the risk of reporting premonitory symptoms 
in one study (25) but not in others(24, 26). 
Cognitive symptoms are frequent as early as the prodromic phase of the attack, and 
are among the best predictors for the attack – difficulties with speech and reading 
predicted 92% and 90% of the attacks, respectively(22). One controlled study concluded 
that concentration difficulties, unhappiness, anxiety and yawning were the most 
common and consistent prodromal symptoms and were not present in the interictal 
period.(25). 
 
Table 2 - Frequency of non-migraine defining symptoms in the prodromic phase of 







































































































































































Fatigue / Asthenia 41 12  10-
49 
  25.6 38 46.5 41.
7 
60.7 62.5 
Tiredness 32 12 6  46 72.5 25.6 31     
Adynamic / 
Inactive 
-   >50         
Emotional/mood 
changes 
39 24    24.3 23.4    61.4 62 
Irritability 30 8 10 >50  38.5  42 28.1 24.
3 
55.7  
Stress/ Anxiety 19 4      46 15.2 12.
6 
  
Claustrophobia -  4          
Depression 16 4  10-
49 
   39 17.6 1.9   
Hyperactivity / 
Excited/ Euphoric 











Nausea 23  8.
2 
  23.5  24 28.6 5.8  48.5 
Anorexia -       20     
Vomiting -       6     
Constipation 10 2    5.6  21     







   22     




   22 11     
Phonophobia 28  6.
1 
>50 36 38.4 1.1 44 36.4 10.
7 
 54.5 
Photophobia 27  8.
2 
>50  48.8 1.3 37  7.8  57 
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>50  5.7  1.6     
Smell distortion/ 
osmophobia 
16      0.7   3.9  45 
Taste distortion - 2     0.4      
Paresthesia -  6.
1 
   0.9      




33 49.7 3  35 2.9 55 58.5 
Muscle ache -  2 10-
49 
  0.2      






  0.5      




 28 3.3 26     




 22.9 1.1      
Ear Symptoms/ 
Tinnitus 
-  2    0.5      
Strained / swollen 
head 
-  25 10-
49 









37   >50  51.1  36 28.1 4.8 54.1 50.5 
Difficulty with 
thoughts 
-     34.6       
Difficult to 
read/write 
-   >50  20.2       













Pale face/ face 
changes 
21  2 >50  17.6    43.
7 
  
Dark rings around 
eyes 
-   10-
49 
        




 27.8 0.5 40 35.8 10.
7 
 34.5 
Somnolence 13 2 2     35     
Insomnia -       27     
Sleep 
disturbances 
-        13.9 1.9   
Thirst / Water 
craving 
24     26  17    30 




 18.2       
Food Craving 14 8    18.2 0.4 15 17.4 3.9  35.5 
Frequent 
urination 
10 2    16.2  12     





>50   1.1 1.9     
Sweating -  2 10-
49 
        
Dry Mouth/ Nose 
symptoms 
-  2    0.9      
Sighing/ Diff 
breathing 
-  2    0.2      
 
Legend : Values represent percentages reported in each series; †Average percentage was calculated 
for each symptom if the symptom was reported in at least 3 different studies 
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Thirteen (46%) of the included studies analyzed the prodromic phase of the attack, 
eleven studies included frequency data on non-migraine defining symptoms(table 2).  
Fifty different symptoms were described in the 11 studies which detailed the prodromal 
phase, mostly migraine-related (40%) or autonomic(30%), on average 4.1 different 
symptoms were reported in each study (6.8 migraine-related and 4.5 autonomic).  Of all 
the symptoms reported consistently, the most frequently were fatigue/ asthenia(41%), 
mood changes(39%) and concentration problems(37%). Evaluating grouped symptom 
frequency, cognitive symptoms(37%) were most frequent  than mood/ behavioral 
(26%) and others. 
2.2 The Aura 
The frequency of aura occurrence is around 15%, declining with age(17). Typical 
migraine aura age onset is around 10 to 20 years, most patients(55%) have less than 1 
attack per month and it’s duration is 15 to 30 minutes(35), although 12 to 37% of 
patients can have auras lasting longer than 1 hour(38). On a clinic based population, 
only 19% of patients with aura had auras in every migraine attack(35), most of the 
patients have the majority of their attacks without aura. Not all auras are followed by 
an headache, 42% of patients have some auras without headache and 10% never have 
headaches(36).  
The most frequent clinical manifestation of aura is visual, being present in 65 to 99% 
of patients with aura; sensory (31%), aphasic (18%) and motor(6%) symptoms occur 
in various combinations (36, 37). Most visual auras are unilateral(69%) and start in 
the central vision field(62%); visual phenomena are variable yet photopsias, flickering 
lines and the zig-zag lines are present in 40 to 87% of auras(35, 36); typical fortification 
spectra is less frequent(20%)(35).  Other visuo-perceptive changes are described 
during auras, such as macro/micropsia, cromatopia, acromatopsia, palianopsia, 
pelopsia, teleopsia, simultanagnosia or visual halucinations in 1 to 13% of aura 
patients(35, 115, 116, 120); some of these symptoms were also described by controls 
in one study(114). Less frequent symptoms are prosopoagnosia, visual agnosia(116, 
120) out-of-body experiences or parasomatic (“duplicated”) body phenomena(122). In 
a controlled study, only corona phenomenon and visual splitting were specific for 
migraine with aura, although many other visuo-perceptive symptoms seem to occur 
more frequently in aura patients(114).  
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Sensory symptoms are mostly unilateral (84%) and start in the hand(96%) moving 
up to the arm(78%), face (67%) and tongue(62%), less often to the lower limb(24%) 
and present as tingling or paresthesias, sometimes followed by numbness(36). Higher 
cortical sensory symptoms, such as hemiasomatognosia, are rare (0.5% of aura 
patients)(115). Aphasic symptoms may occur in up to 50% of auras (116, 120) and are 
most often expressive (paraphasias 76%, non-fluent aphasia 72%) although impaired 
comprehension (38%)(36) and/or alexia may ensue. Memory is rarely involved – 
anterograde or retrograde amnesia may occur in up to 18%, other phenomena being 
even rarer (ex. “dejá vu” and “jamais vu” phenomena, despersonalization) and some 
also occurred in healthy controls(116). 
Calculus  may also be disturbed in up to 13%(120) or auras, as well as other “mental 
or personality” changes, with a frequency of around 3 to 7%(37, 115, 116). Other 
hallucinations (gustatory, 0.5%, olfactory up to 1%(115, 123) or auditory 0.17%(124)) 
are described in auras. 
 
Motor symptoms are rare, occur almost exclusively after the other clinical 
manifestation of the aura, are almost strictly unilateral and their progression is similar 
to the sensory progression– hand and arm (89%), tongue and face (44%) and foot and 
leg (56%), often lasting more than one hour (36, 125).  
 
Eight(29%) studies analyzed the aura, including 39 different symptoms(table 3), 
mostly migraine-related (49%) or cognitive(28%), on average 2.6 different symptoms 
were reported in each study (4.0 migraine-related and 3.8 cognitive).  Five studies had 
symptom frequency data available, two of which contained details about sensorial 
migraine related symptoms, autonomic or mood changes(27, 116). The remaining 
focused on neuropsychological symptoms (other than ICDH-III aura defining 
symptoms), only three being consistently described–language difficulties(32.8% 







Table 3 – Frequency of non-migraine defining symptoms occurring during the aura and 
headache phases of Migraine Attacks, as described in the literature 
 









































































































































































































     16.
0 

















  4.2  24.
0 







Depression      4.0  4.1 10
-
49 
     
Hyperactivity 
/ Euphory 
     12.
0 
























Eructation 6.1       41       
Abd. 
Distension 




     
Abdominal 
Pain 
6.1       2.0       
Diarrhea       19   9.5     
Constipation           6.6    



































  8.8  
Taste 
distortion 
         10.
8 
    





















    
Body 
weakness  
8.2       6.1     2.9  





         18     













Tinnitus 2.0       2.0       
Dizziness 20.
4 










Light  head 8.2     12         
Swelling head 24     4.0         
Tight head/ 
pressure 
6.1        > 
50 





       10
-
49 












   7.7  28.
0 









    8.3 12.
0 
6.8        
Impaired 
thinking 
     16.
0 









































      12.
9 
  
Hallucinations  7.5 1.0            
Sensorial 
perception 
 2.5    4.0         
Automatisms  5.0             




















   
Dark rings 
around eyes 
       2.0       
Yawning 12.
2 
  1.4       25.
4 
   
Thirst / Water 
craving 
          32.
2 









Fluid retention              56 
Frequent 
urination 
      29.
0 
   24.
3 
   
Lipothymia 2.0      12 2.0       
Feels 
cold/Shivers 
4.1       2.0       
Sweating 2.0              
Dry Mouth 2.0              
Legend : Values represent percentages reported in each series; migraine-defining symptoms are 





2.3 The Headache 
The painful phase of migraine starts within the aura in as often as 54% of the 
attacks(41); other have an average free interval between the end of the aura and 
headache often shorter than 30 minutes(35), although it can last 10 to 60 minutes(42). 
In the free interval some patients are well yet others have mood changes(60%), 
perception difficulties (40%), cognitive (36%) and somatic symptoms (72%)(42). It is 
unclear if these symptoms represent the onset of prodromes after the aura or its’ 
persistence through the total length of the attack(22, 23, 25, 27).  
The headache is the most frequent occurring phenomena of migraine, being an unilateral 
(bilateral in 25-40%) throbbing (47-91%) moderate to severe pain, mostly felt in the 
trigeminal sensory distribution (56- 67%) with progressive onset and median time to 
peak around 90 min., being aggravated by activity in 53 to 90% of patients. Headache 
lasts an average 6 to 24 hours, with an average VAS intensity of 8/10(20, 43, 44).  
Migraine pain is accompanied by photophobia (55-97%), phonophobia (47-95%), 
osmophobia (25-75%), kinesiophobia (53-98%), nausea (80-87%), vomiting (44- 
67%)(20, 44-47) and cutaneous allodynia(63%)(126, 127). Cognitive symptoms can 
persisting from the premonitory phase(22) or start during headache(17, 20, 27, 54, 118, 
119). Patients describe not being able to think or concentrate(up to 71%) nor to carry 
out activities such as shopping (up to 83%), work or taking care of children (60%). These 
symptoms are more frequent when attacks are severe and contribute to migraine 
associated disability(95).  
One of the included studies analyzed the time between the aura and the pain and 9 
(32%) the headache phase of the attack, detailing 41 different symptoms (table 3), 
mostly migraine-related (44%) or autonomic(22%), on average 2.7 different symptoms 
were reported in each study (4.6 migraine-related and 2.4 mood/ behavior).  The most 
frequently occurring consistent symptoms were impaired thinking (51.8% patients), 
blurred vision (36%) and stiff neck (34.7%). Evaluating symptom frequency within each 
group, the most frequent were cognitive(38%), followed by mood/ behavioral (32%) 
and migraine related (32%). Also during pain, family or friends notice facial changes and 




2.4 Postdromes or Resolution Symptoms 
The migraine headache will at some point decrease progressively, either 
imperceptibly or in a faster way until it disappears, even without any specific 
intervention to shorten the attack(50). Attacks can also be shortened or interrupted by 
medication, sleep or vomiting(50). However, 60 to 94% of patients have several (on 
average 7 (25, 50-52)) persisting symptoms after headache resolution, that last on 
average 25.2 hours (<12h in 54%). The definition of the postdromal period varies in 
different studies, some authors even allowing the existence of mild headache in this 
phase(51, 52, 54, 112). The frequency of postdromes occurrence does not seem to be 
influenced by age(17) but it relates to having greater number of family members with 
migraine, having prodromes and/or aura and having higher functional impact of the 
attacks and having lower attack frequency(52). Some postdromes occur more frequently 
in certain clinical situations, for instance photophobia, phonophobia and GI upset are 
more frequent after migraine with aura, while somnolence and concentration difficulties 
occur more often in patients on preventive treatments. Most patients (39-60%) have 
postdromes consistently, although only 26% have them in all attacks(25, 52).  
 
Table 4 – Frequency of non-migraine defining symptoms in the postdromic phase of 

































































































Fatigue/ Tiredness 71 52.0 67.5 88.2 55.0 71.8 88.2 72.0 
Emotional/ mood changes -   23.5  6.8   
Stress/ Anxiety -    15.0    
Irritability 22  12.5 28.5 20.0  26.5  
Depression/ lower mood 32 56.0 42.5  26.0   4.0 
Happy/ Euphoric 15 16.0 15.0  10.0  29.4 2.0 
Introverted/ isolation -  7.5    14.7  












 Nausea/ anorexia 18   14.8 10.0  38.2 7.0 
Constipation/ Diarrhea 12  22.5 6.8 13.0 8.4   
Abdominal pain -    6.0    
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Photophobia 16  12.5 36.0 26.0 2.1 5.9  
Phonophobia 15  0.5 31.8 27.0 0.4 14.7  
Osmophobia -  2.5    2.9  
Taste distortion -  7.5      
Sensitive skin/ hypersensitivity -   5.2 10.0    
Paresthesia -     1.8   
Cranial Autonomic -  2.5   0.5   
Stiff / aching neck 26  35.0 41.9  3.2 23.5  
Reduced physical energy 34  72.5   5.2 23.5  
Muscular Weakness 21 54.0 5.0   6.2 35.3 6.0 
Clumsy/ hungover 25  15.0   11.7 17.6 55.0 
Blurred vision 13  17.5 17.4 16.0 2.0 11.8  
Dizziness 20   19.3  5.7 35.3  
Head tenderness -  57.5      








Concentration problems 35  65.0 55.5 28.0 11.7 38.2 12.0 
Diff. thoughts -   33.4   8.8  
Lower Intellect/ “fog” - 56.0     14.7  
Reduced attention span -  55.0      
Diff. reading/Writing -   16.8     









Yawning 20 8.0 32.5 13.9 24.0    
Thirst/ drinking more 18 8.0 35.0 32.2 15.0 0.5   
Frequent/ lower urination 17 14.0 22.5 21.2 10.0    
Fluid retention -    5.0    
Feeling cold -    17.0    
Less apetite 21 32.0     23.5 7.0 
Food Craving 8 16.0  15.1 9.0 0.2  0.2 
Pale face -   21.4  0.2   
Somnolence -    29.0    
Insomnia -  0.5  12.0    
Legend : Values represent percentages reported in each series; †Average percentage was calculated 
for each symptom if the symptom was reported in at least 3 different studies 
 
Seven(25%) of the included studies analyzed the posdromes, including 42 different 
symptoms (table 4), the most frequent being migraine-related(43%) or 
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autonomic(24%), on average 4.5 different symptoms were reported in each study (8.0 
migraine-related and 4.0 autonomic).  Of the symptoms reported consistently, the most 
frequent were fatigue/tiredness(71%), concentration problems(35%) and reduced 
physical energy(34%).  Evaluating symptom frequency within each group, 35% had 
mood/ behavioral, 27% cognitive, 22% migraine-related and 17% autonomic 
symptoms. The most common postdromal symptoms reported in a study that used focus 
groups to detail this phase of the migraine attack were tiredness, nausea, head pain, 
difficulty concentrating and physical weakness(54); these patients reported that 
postdromal symptoms were clinically relevant, as they felt decreased physical activity, 
difficulty at work, difficulty performing general cognitive tasks and true impact on family 
and social life(54). Tiredness, asthenia and somnolence were consistent postdromes and 
were not felt in the interictal phase in one controlled study(25). 
 
DISCUSSION 
This review retrieved clinical information about non-migraine defining 
symptomatology occurring during the attack from clinical series of migraine, with a 
special focus on cognitive symptoms. Answering our first research question, we found 
28 studies including 8392 patients, in which cognitive symptoms were described 
spontaneously in clinical interviews or actively sought using questionnaires, electronic 
diaries and even in a concept elicitation focus group. These observations support that 
cognitive symptoms are a part of the subjective experience of the migraine attack, 
consistently with early historical descriptions of migraine and with everyday clinical 
experience. 
The oldest description of migraine (mentioning all ICHD-III(7)symptoms) made 
by the Greek Aretaeus of Cappadocia (30–90 A.D.)(8) already included details about 
attack-related mood changes “…torpor, heaviness of the head, anxiety, and ennui…”; the 
treatise de Medicina wrote by the Roman Aulus Cornelius Celsus (25–50 A.D.) includes 
the first allusion to attack-related cognitive symptoms- “In the head, then, there is at times 
an acute and dangerous disease (…) the signs of which are hot shivering, paralysis of sinews, 
blurred vision, alienation of the mind, vomiting….”(9). Fifteen hundred years later, the 
English Thomas Willis (1621–1675 A.D.) described premonitory symptoms such as 
fatigue, bursts of energy and hunger(10) and Edward Liveing(11) (1832–1919 A.D.) 
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published the first medical book about headache, were cognitive symptoms are included 
as disturbance of “ideational consciousness” found under “Phenomena of the 
Paroxysm”(11). He divided these in “intellectual” and “emotional”, describing the former 
as ”...impairment of memory and in confusion and incoordination of ideas...”, “… confusion 
of thought...”, “…unable to collect his thoughts…”, “…feeling silly…”, “…loosing their 
senses…”; the “emotional” phenomena included “…irritability of temper…”, “ill-humor” 
and a “vague and unaccountable sense of fear…” and could precede the attack by one or 
two days, while a “great mental depression” would linger through the entire 
paroxysm(11).  
Even by then, the migraine attack was described in different phases; in this review, 
cognitive symptoms are documented in all phases of the attack, although the pattern 
described in each phase could differ. The prodromes are the best studied– 46% of the 
studies (2991 patients) contained information about 50 different prodromal symptoms. 
Most were migraine-related or autonomic, supporting the view that the hypothalamus 
may play a role in the development of migraine attacks(28). In our pooled data, the most 
frequent prodromal symptoms were cognitive (due to the high frequency of 
“concentration problems”), and mood/ behavioral (“fatigue, asthenia and mood 
changes”).  
Studies about the aura were scarcer, only 5 (1416 patients) that described 39 
different symptoms, mostly migraine-related or cognitive.  These observations may be 
biased as it is difficult to disentangle some complex neuropsychological phenomena 
from more vague cognitive symptoms – an example being “speech difficulties”, that may 
reflect true aphasia or mild everyday word finding hesitations. Also, we know that pain 
does not always start after the aura(41) so some symptoms relate to pain phase. The 
frequency of such symptoms could not be determined due to the scarce information 
available (only 2 studies).  
Seven(25%) studies including 3810 patients described 41 non-migraine defining 
symptoms occurring in the headache phase of migraine attacks, most were migraine-
related(blurred vision, dizziness, stiff neck or osmophobia).  The most frequent 
occurring symptoms were cognitive, such as “impaired thinking”, “feeling distracted or 
slow”, and “speech difficulties”, in line with previous studies suggesting the existence of 
attack-related cognitive dysfunction(108, 109). 
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Seven studies dwelt with the postdromes, including 1633 patients and describing 42 
different symptoms, the majority migraine-related (including persistent mild pain in 
36%). The most frequently reported symptoms were mood/behavioral changes, 
specially fatigue and/or tiredness, reported in all studies with frequencies varying from 
52 to 88% (average 71%), depressive feelings (32%) and reduced physical 
energy(34%).  
The present data supports that cognitive symptoms occur in all phases of the 
migraine attack, mostly affecting executive function (concentration difficulties, impaired 
thinking and slow processing) and language, a pattern consistent with evidence of attack 
related neuropsychological dysfunction(108, 109). Having migraine predicts limitations 
in cognitively demanding work(128); specifically, the migraine-attack associated 
concentration problems contribute to a perceived difficulty in handling the mental 
aspect of work during attacks, such as making decisions or performing out-of-the 
ordinary or complex work tasks. Patients also report more errors in tasks involving 
reading, writing, communication and arithmetic and the need to work in a slower pace. 
Mood changes, such as irritability, additionally  limit patients’ working abilities and 
interfere with interpersonal issues at work(93). Patients spontaneously discussing their 
experiences of migraine attacks in twitter report impact on productivity at work (3.5%) 
and school (2. 8%), but also in social life (3.5%) and specially in mood (43.9%)(129), 
maybe a reflection of persisting mood changes in the resolution phase. 
There are a number of important limitations of this study findings, the first being that 
almost all studies were not controlled and data collection was not standard – most 
studies used clinical interviews and several different questionnaires, which induces an 
insurmountable bias on item selection and valorization. The statistical analysis 
performed in this review has low accuracy, it merely aimed to set and indicative 
proportion of symptoms to improve the qualitative analysis and should not be assumed 
at face value. The samples were mostly clinic-based but little information was available 
about migraine impact, recruiting was not homogeneous, as some studies included only 
aura patients, one studied only children and one only females. Another methodological 
limitations included the definition of each attack phase, that was not uniform between 
studies nor is there a consensus about their definition, some overlap being possible 
between phases. Also, the majority studies did not include information about the use of 
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preventives or acute attack treatments that could have concurrent symptoms by 
themselves. Adding to the potential reporting bias, not all the patients experience all 
phases of the attack and, in this review, symptoms described in different phases of the 
attack are also described by different patients, in different studies. One can even argue if 
patients noticing or not noticing prodromes and postdromes could represent a different 
subset of migraine patients- in Kelman series(23) they seem to be more sensitive to 
triggers, having longer duration of every phase of the migraine attack and have higher 
frequency of accompanying symptoms.  
 
Conclusions 
Due to the large number of included patients in this review, it is possible to 
assume that cognitive symptoms are consistently included in the description of the 
migraine attack phenomenology in published clinical series of migraine patients. 
Existing data also seems to support that cognitive symptoms are described in all phases 
of the attack, being the most frequent non-migraine defining symptoms reported in the 
prodromal phase and during headache. The cognitive symptoms most frequently 
described by patients are “concentration problems” in the premonitory phase and 
“impaired thinking” during headache. Concentration is also the most relevant cognitive 
complaint on the resolution phase of headache, but the most frequent non-migraine 
defining symptom of this phase is fatigue. Nevertheless, interpretation of this data is 







What attack-related cognitive symptoms do migraine patients report?  
Is there a pattern?  
 
Subjective Cognitive Symptoms during the Migraine attack. 
A prospective study of a clinic based sample. 
 
Gil-Gouveia R, Oliveira AG, Martins IP.  
Subjective Cognitive Symptoms during the Migraine attack.  A prospective study of a clinic based 
sample.  Pain Physician 2016 [in press]; Impact Factor: 4.77 
 
ABSTRACT  
The migraine attack is much more that a severe headache; it aggregates a range of different 
symptoms that contribute to attack-related disability. Cognitive dysfunction is an 
unacknowledged part of the migraine attack.   
Our objective is to provide a profile of the frequency and character of migraine attack-related 
cognitive symptoms occurring specifically during the headache phase of the attack, by 
performing a cross-sectional systematic survey about cognitive symptoms in a clinical-based 
sample of episodic migraine patients, using an open-ended question followed by a self-fulfilled 
symptom checklist. 
We studied 165 migraine patients (15 males, age average 37.3 ± 10.7 years), 87.3% of which 
spontaneously described cognitive symptoms occurring during the headache phase of the 
migraine attacks. On average 2.5 ± 1.6 symptoms were reported per patient, uninfluenced by 
demographic or disease-related variables. The most common spontaneous symptoms were 
within the executive domain, such as poor ability to concentrate (37%), difficulty in reasoning 
(25%) and thinking (23%). The pattern of responses on the symptoms checklist corroborated 
those reported spontaneously and quantitative scores of the checklist were higher in patients 
with spontaneous symptoms. 
This study detailed the frequency and character of migraine attack-related subjective cognitive 
symptoms and found its frequency to be similar to reports of other migraine defining symptoms 
(ex. nausea, photophobia) in recent clinical series. Patients’ reports were consistent and 
characterized by complaints of attention difficulties, diminished cognitive efficiency and 
processing speed impairment. 
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INTRODUCTION     
 
The 2010 Global Burden of Disease study rates Migraine as the neurological 
disorder with the highest disability-adjusted life years (DALYs), being the seventh 
disabler worldwide(15, 130). In this study, the estimated disability of one day with a 
migraine attack was 43.3%(130); loss of effectiveness while at work reported by 
migraine patients varies amongst studies and countries, most commonly within the 
range of 40 to 50%(92).   
Disability assessments on migraine rely on patients’ self-report of ability to 
function during an attack. Some instruments also measure interictal burden, including 
limitations of work responsibilities and career progression, disruption of social and 
family interactions and ultimately health-related quality of life and comorbidities related 
to Migraine(131).  
Ictal disability is assumed to be due to the pain and its impact has been measured 
using pain frequency, duration and intensity(131-136). During a migraine attack, pain is 
only a part of a constellation of symptoms and quite often patients report that their major 
cause of disability is not the pain itself, but other symptoms such as nausea and 
vomiting(133, 136-138), photophobia(137) or cognitive impairment(118).  
Cognitive symptoms occurring during migraine attacks have been described 
since the first century(9); in more recent clinical series of migraine, cognitive symptoms 
described include not being able to think or concentrate (up to 71% of patients), being 
unable to carry out activities such as shopping(up to 83%), work or taking care of 
children(60%) contributing to migraine associated disability(95). However, cognitive 
dysfunction is far more often characterized in the premonitory(22-25, 27, 117)  and 
posdromal phases(22, 25, 51, 52) of migraine. 
In a previous study we conducted structured interviews about the occurrence of 
cognitive symptoms during migraine attacks, aiming to generate items for the 
development of an instrument to quantify subjective cognitive symptoms during attacks, 
the Mig-SCog(118).  In the present study, using a similar methodology in a qualitative 
research study, we aim to detail the character and frequency of migraine attack-related 
subjective cognitive symptoms occurring in the headache phase of the attack in a clinic-
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based sample of migraine patients. In addition, we want to determine if any demographic 
or disease related variable influenced the expression of such symptoms. 
 
 
SUBJECTS and METHODS 
 
Population  
Volunteers were recruited from Headache Outpatient Clinics of two general 
hospitals in Lisbon, Portugal.  Inclusion criteria were: a)  age over 16 years old; b) at least 
two years of education (able to read and write); c) history of episodic migraine with or 
without typical aura, as defined by the ICDH-III(7);d) written informed consent of adult 
patients or of their legal guardians, in the case of patients aged 16 and 17. Because our 
focus was on cognitive symptomatology we excluded patients with chronic migraine, 
medication overuse and co-morbid mood disorders, factors potentially able to negatively 
influence cognition (89, 139). Non-typical auras and chronic tension-type headache were 
also exclusion criteria; episodic tension type-headache was allowed if the patient was 
able to distinguish between headache types. Previous history of alcohol or drug 
dependence or abuse or the presence of concomitant medical, neurologic or psychiatric 
disorders with influence on cognition were also exclusion criteria, as was pregnancy. The 
study protocol was approved by each Hospital’s Institutional Review Board. 
 
Study design 
Recruitment and inclusion were carried out in a regular headache clinic visit 
along with standard clinical evaluation (detailed medical history, headache history, 
physical and neurological observation). After informed consent, a standardized data 
collection was performed, that included checking ICDH-III criteria and registering 
demographic and clinical details, such as gender, age, literacy, disease duration, current 
attack frequency, duration and intensity, attack and aura characterization, and detailed 




Data collection started with a closed question - “Do you feel any change of your 
mental abilities during the headache phase of your migraine attacks?” having a 
dichotomic (yes/no) answer. If the answer was affirmative, the researcher prompted the 
open-ended research question “please describe the main changes you usually feel” in 
order to elicit the spontaneous phrases or expressions that patients use to describe their 
experiences. Patients with aura were instructed to report only symptoms that occurred 
in attacks without aura or, if they had exclusively migraine with aura attacks, they were 
instructed to exclude symptoms that also started during the aura and persisted into the 
headache. All answers were recorded, irrespective of their content. All subjects had then 
to complete a self-administered symptom checklist of 43 items, including subjective 
cognitive (executive, spatial perception and language) and non-cognitive (mood, anxiety 
and visual) symptoms (118) which was used to confirm the preceding spontaneous 
symptom elicitations. Each item/symptom was rated qualitatively (yes/no) and on a 3-
point scale - occurring often(2 points), rarely(1 point) or not occurring(0 points) during 
the attacks. A “don’t know, don’t want to answer” option was also available in order to 
avoid blank answers; if a blank answer was spotted upon checklist return the patients 
was prompted to complete it.  
 
Data and Statistical Analyses 
            Answers to the open-ended question about cognitive symptoms were analyzed, 
classified and grouped into domains and functions by two authors (RGG, IPM) 
independently; discrepancies were resolved by consensus. Spontaneous symptoms 
were classified into non-cognitive and cognitive and then further classified into their 
specific domain (ex. executive, memory, language and others) and grouped into different 
functions within each domain (ex. initiative, processing speed etc.).  The same process 
was applied to non-cognitive complaints, that were classified as mood-related, sensorial 
or migraine related, and groups into different symptoms (ex. mood, vision, phonophobia 
etc.). The number of different spontaneous symptoms was calculated for each domain, 
as was as the number of patients reporting each symptom, in order to obtain an average 
frequency of each symptom, in each domain. A frequency table was built including all 
cognitive and non-cognitive symptoms reported; the average number of symptoms per 
patient was calculated. Demographic and disease-related variables were compared 
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between patients with and without spontaneous cognitive symptoms with the chi-
square test for proportions and Student’s t-test for means.  
Analysis of the symptom checklist excluded missing answers analysis-by-analysis 
(“don’t know, don’t want to answer”). Items were scored qualitatively (having/not 
having the symptom) and quantitatively (0 to 3) to analyze relative impact of each 
symptom. Checklist symptoms frequency derived from qualitative item scores. 
Quantitative items scores were used to calculate scores for each domain and for the total 
checklist. Linear regression analysis, using the total symptom checklist score as a 
dependent variable was performed to study the influence of demographic and disease-
related variables.  




Total population had of 172 volunteers; seven were excluded due to medication 
overuse(n=5) or chronic tension-type headache(n=2). The study population consisted of 
165 volunteers(15 males), nine left-handed, with an age average of 37.3 ± 10.7 
years(range 16 to 63 years). Average disease duration was 20.5±12.2 years (range 6 
months to 57 years), 25 patients had Migraine with aura(15.2%) and average HIT-6 
Score was 61.2±7.3 (range 43 to 76).  
Forty-one patients(29.7%) were on migraine prophylactics, most commonly on 
topiramate(11), propanolol(9), amitriptyline(7) and valproic acid(5) and flunarizine(2) 
or combinations. Attack treatment was based on triptans(33.4%), followed by 
analgesics(28.6%) and NSAIDs(28.5%) and ergots(9,0%).  Twelve(7%) patients were 
taking low-dose anxiolytics or serotonin-specific reuptake inhibitors, 41(25%) were 
taking the combined oral contraceptive pill and 6(4%) were on hormone replacement 
therapy.  
 
2.1 – Spontaneous cognitive symptoms 
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Seventeen patients(10.3%) did not feel any change of their mental abilities during 
the headache phase of their migraine attacks; the remaining 148(89.7%) patients 
reported on average 3.6±2.0 (range 1 to 9) different spontaneous subjective symptoms. 
These were classified as cognitive in 144(87.3%) patients, the average number of 
symptoms reported by patient being 2.5±1.6 (range 1 to 9, median of 2). 
 
Table 1 – Spontaneous symptoms - Descriptive analysis 
 
















Cognitive 54 416 7.7 144 (87%) 2. 5± 1.6 (0-9) 
Executive 31 297 9.6 132 (80%) 1. 7± 1.2 (0-5) 
Language 9 52 5.8 42   (25%) 0. 3± 0.6 (0-3) 
Memory 5 22 4.4 18   (11%) 0. 1± 0.4 (0-2) 
Spatial perception 2 2 1 2   (1%) 0. 01± 0.1 (0-1) 
Multi-domain 7 43 6.1 39 (24%) 0. 3± 0.5 (0-2) 
      
Non-Cognitive 32 188 5.9 97 (59%) 1. 1± 1.2 (0-5) 
Mood 9 69 7.7 54 (33%) 0. 4± 0.7 (0-3) 
Sensorial 5 24 4.8 22 (13%) 0. 1± 0.4 (0-2) 
Migraine 18 95 5.3 60 (36%) 0. 6± 0.9 (0-3) 
 
The 148 patients reported the occurrence of 86 different symptoms during their 
headaches, using 604 different expressions to describe their symptoms. Fifty-
four(62.7%) symptoms were cognitive– table 1.  
 
The most frequent cognitive symptoms described related to executive 
dysfunction(71.4%), followed by language complains(12.5%). Non-cognitive symptoms 
were also frequent, mostly migraine related(50.5%) or mood changes(36.7%). Detailed 
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description of spontaneous symptoms is presented in tables 2 (cognitive) and 3 (non-
cognitive). 
      None of the demographic variables (gender, age, literacy, disease duration, aura, 
previous diseases or current treatments, headache prophylaxis, attack treatment, attack 
frequency, intensity or duration and disease impact, measured by the HIT-6 score) 
influence the likelihood of reporting cognitive difficulties during migraine attacks.  
 
Table 2 - Cognitive difficulties spontaneously reported in the headache phase of 
migraine attacks 
 

















Low inhibitory control 7 1.7% 
Lower tolerance / intolerant / grumpy 5  
Can’t stand the pain / unable to stop thinking about the pain 2  
Avoidance 11 2.6% 
I want to be alone/ must be alone/ I want to isolate myself/ have to be in 
isolation 8  
Difficulty in interaction with others / difficulty in social interaction / lower social 
abilities (friendliness and empathy) 3  
Difficulty in maintaining attention 72 17.2% 
Difficulty or lack of attention / disperse / unable to focus or concentrate/ lower 
ability to concentrate/ worse concentration/ higher effort to achieve a minimum 
concentration level 61  
Less attention/ distracted/ difficulty in paying attention/ difficulty in maintaining 
attention 8  
Lose the notion of things / I feel the need to abstract from reality or not pay 
attention / I get abstracted / I feel lost in my thoughs 3  
Cognitive Processing Efficiency/  Reasoning 99 23.8% 
Difficulty in reasoning / higher effort to reason / lower reasoning/ unable to 
reason / ineffective reasoning 41  
Difficulty  in thinking /I can’t think/ lower ability to think/ thinking is effortful / I 
don’t feel like thinking/ I’m not able to think straight / I have a hard time thinking 
/thinking is bothersome/ I can’t think a long period of time/ I’m not able to think 
the same way as usual 38  
Difficulty in making mental or intellectual effort/ intellectual laziness / mental 
fatigue/ I do not feel like thinking 4  
I’m not able to have complex thoughts/ lower performance/lower work 
efficiency/ fear of failing more complex reasoning / less efficient flow of ideas / 
lower ability to process information 6  
I get witless or rattle-brained / lower brain reflexes / rattle-headed/ brain 
blocked/ confused / incapable 10  
Stamina 27 6.5% 
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Tiredness/ more tired / exhausted 8  
Less strength in all my body/ difficulty in standing up / less strength 3  
Fell washed-out / I fell sluggish / without action / without energy / asthenia / 
globally indisposed 8  
Lose all my abilities/ just exist / do not react, like a vegetable / get diminished / 
it feels like being anesthetized/ less reaction / I seem to be sedated/ get 
alienated of what is around me  8  
Initiative 10 2.4% 
I don’t feel like doing anything / unwilling / reluctant to do anything 3  
Without initiative/ less predisposed to do things / lower motivation 3  
Everything is done with effort /I have a hard time doing anything 4  
Motor initiative and speed 8 1.9% 
Physical movement is difficult/ I cannot move/ unwilling to move 4  
I walk slower and my movements are slower / moving is harder, slower and my 
body fells heavier/ slower movements, even when walking/ physically slower 4  
Processing Speed 38 9.1% 
Slower thoughts/ need to think longer / slower reasoning / sluggish thinking 11  
I fell slower or slowed/ slowness/ slowing/ lower speed/ idle/ slower reactions/ 
slower on chores 27  
Planning 8 1.9% 
I have to write down everything I’ll need to do/ have to plan with notes  2  
Unable to organize daily chores/ I have a hard time organizing/ not able to 
program anything/ difficulty in planning ahead 6  
Decision Making 9 2.2% 
Difficulty in decision taking/ difficulty in settling things/ less able to make a 
decision 4  
Difficulty in getting things done / cannot execute things / not able to perform 
any chore / lower ability to act 5  
Cognitive Flexibility 4 1.0% 
Difficulty in multitasking/ less able to pay attention to several simultaneous 
simple stimuli 2  
Difficulty in solving practical problems/ difficulty in responding to stimuli or 
requests 2  
Monitoring 1 0.2% 
Fear of making errors at work 1  
Calculus 3 0.7% 
Difficulty in calculation or simple math’s/ difficulty in sums, measurements, 
calculus 3  
 TOTAL EXECUTIVE 297 71.4% 










Learning 7 1.7% 
Difficulty in memorizing/ difficulty in learning new information / difficulty in 
retaining information in a short period of time 3  
I need more time to learn new things 1  
Studying is difficult / the study is less productive 3  
Retrieval 15 3.6% 
Memory lapses/ I forget thinks/ forgetful/ I fail to remember  9  
My memory gets affected/ I get problems with my memory/ lack of memory/ 
damaged memory 6  
 TOTAL MEMORY 22 5.3% 










Naming 2 0.5% 
Difficulty in speaking out people’s names 1  
I ‘m not able to remember simples objects names 1  
Speech Fluency 27 6.5% 
Difficulty in keeping a simple conversation/ difficult to chat/ cannot organize the 
sentences to speak properly/ I have a hard time programming what I  want to 
say/ I’m not able to communicate/ I find it hard to explain what I mean, while 
talking 8  
Difficulty talking/ not able to talk/ my speech gets stunted/ I have a hard time 
talking/ I feel the need to abbreviate all conversations  18  
Difficulty in articulating the speech 1  
Comprehension 7 1.7% 
Difficulty in understanding when being spoke to / It’s hard to understand verbal 
information 5  
Unable to pay attention to what’s being asked / I’m not able to talk back when 
being spoke to  2  
Reading and Writing 16 3.8% 
I cannot write, I forget how to write properly / I find it difficult to write/ writing 
takes longer than usual / I misspell more often when writing 5  
Difficulty in reading/ difficulty in understanding what’s written 11  
 TOTAL LANGUAGE 52 12.5% 








Spatial perception/ Topographic disorientation 2 0.5% 
Pay less attention to normal paths or routes 1  
Difficult to calculate distances 1  
Difficulty in complex tasks (Multiple domains) 43 10.3% 
I’m not able to do anything/ completely disabled/ I get disabled/ I find it hard to 





Table 3- Other differences (non-cognitive) of mental capacities spontaneously reported 
during the headache phase of migraine attacks 













Depressed Mood 7 3.7% 
Lowering of mood / changes in mood / sadness / tearfulness / will cry 6  
Emotional fragility 1  
Lower interest  31 16.5% 
Can’t find patience to do anything / less patience /Lack of patience / impatience 30  
Everything is bothersome 1  
Anxiety 28 14.9% 
Irritable/ irritability 21  
Anxious/ panic/ despair/ nervous / very nervous 5  
Out of control/ upset 2  
Nervous tension 3 1.6% 
Uptight/ tense 2  
Need to relax 1  
 TOTAL MOOD 69 36.7% 















Balance 5 2,7% 
Disturbed by traveling 1  
Stunned / Dizzy 2  
Unbalanced and dizziness / I lose my balance while walking 2  
Visual disturbances 17 9.0% 
Vision impairment / foggy vision /lack of sight /different or difficult vision/ I’m 
unable to see properly / difficulty in seeing / out-of-focus vision/ difficulty in far 
seeing 17  
Sensitive disturbances 2 1.1% 
Slight hand numbness/ numb hand 2  
 TOTAL SENSORIAL CHANGES 24 12.8% 
    
I avoid to do any chore/ I avoid chores that have higher reasoning demands 2  
Difficulty in household chores/ difficulty in everyday chores and routine 
activities/ I’m not able to do household chores 8  
I can’t work/ I’m not able to work properly 4  
Difficulty in cooking 2  
Difficulty in driving/ unable to drive 16  
I do everything wrong/ I no longer know how to do anything 2  

















Photophobia 34 18.1% 
I need to get my eyes closed / difficulty in keeping the eyes open/I’m not able to 
open my eyes/ I cannot look at anything 8  
Difficulty in watching television/ difficulty in staring at a computer screen/ 
Difficulty in making visual effort / I’m bothered by visual effort 11  
I need to be in the dark / I cannot stand the light/ light worsens the pain/  I get 
photosensitive 15  
Phonophobia 27 14.4% 
I need to be in a quiet room/ It’s hard for me to hear any noise/ noise disrupts my 
concentration 10  
I lack the patience to listen to anything/ I can’t hear anything or anybody/ lower 
tolerance to noise/ I’m bothered by noises/ the sound of my own speech is 
distressful 11  
Difficulty listening/ Cannot listen/ I have a hard time listening to what people say/ 
the sounds seem far away 6  
Kinesiophobia 19 10.1% 
Difficulty walking/ I have a hard time walking 5  
My wish is to be still / I need to stay still 2  
I feel like lying down/ I urge to lie down/ I need to rest still/ I cannot wait to go to 
bed 7  
Difficulty in climbing stairs/ Physical effort is difficult/ I’m not able to make any 
effort/ Cannot pick up any weight 4  
Difficulty in turning my head 1  
Osmophobia 2 1.1% 
Can’t stand any smell or odor 2  
Gastrointestinal upset 3 1.6% 
I get nauseated / Bothersome nausea 2  
I can’t eat/ I get stuffed without eating 1  
Sleep disturbances 7 3.7% 
Not able to sleep 2  
Sleepiness / too sleepy 5  
Others 3 1.6% 
I get haggard / I get pale with dark circles around the eyes 2  
I need to squeeze my head 1  
 TOTAL MIGRAINE RELATED 95 50.5% 
 
 
2.2 – Symptom checklist 
 
Most of the items of the symptom checklist had less than 10% missing values (“do 
not know, don’t want to answer”), exceptions were: difficulty in drawing(59% missing), 
in naming famous people(19%), in mental calculus(13%), in writing(11%) and about 
right/left orientation(10%).  All the items of the symptom checklist had at least one 
positive answer. Positive answers were extremely frequent (> 90%) in only 3 items: 
attention (…do you have trouble concentrating?, 93%), stamina (… do you feel tired?, 91%) 
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and anxiety (…do you feel irritable?, 90%). Answers were very frequent (>80%) in items 
of motor initiative and processing speed (88%), attention, cognitive flexibility, cognitive 
processing efficiency and motor processing speed(85%); non-cognitive very frequent 
answers included anxiety(84%) and visual symptoms (82%). Complete description of 
the symptom checklist answers is available (table 4).  
          None of the demographic variables (gender, age, literacy, disease duration, aura, 
previous diseases or current treatments, headache prophylaxis, attack treatment, attack 
frequency, intensity or duration and disease impact using HIT-6) had influence on the 
total score of the symptoms checklist that was used as the dependent variable in a linear 
regression analysis.  
 
Table 4 –Scores of the symptom checklist, per item 
During your headache... 

















Attention 132  80%  
…do you have trouble concentrating? 154 0 93% 1.5 ± 0.6 
…do you find it difficult to follow or maintain attention 
when being spoken to? 
140 0 85% 1.2 ± 0.7 
… are you easily distracted? 103 7 62 (65)% 1.0 ± 0.8 
Stamina 150  91%  
… do you feel tired? 150 1 91 (91)% 1.5 ± 0.6 
Initiative 94  57%  
… do you have trouble starting an activity ? 128 8 78 (81)% 1.2 ± 0.7 
… do you have trouble in taking initiative? 118 6 72 (74)% 1.0 ± 0.7 
… do you forget to take your pain-killers? 36 3 22 (22)% 0.3 ± 0.6 
Motor initiative and speed 146  88%  
… do you have trouble performing tasks at your normal 
speed?  
146 1 88 (89)% 1.4 ± 0.7 
Planning 112  68%  
… do you have trouble in remembering about things you 
need to do (e.g. paying bills, making phone calls etc.)? 
105 6 64 (66)% 1.0 ± 0.8 
… do you find it hard to plan your routine chores (e.g. 
cooking, shopping etc.) and compromises? 
120 11 73 (78)% 1.1 ± 0.7 
Cognitive Flexibility 118  72%  
… are you able to deal with several stimuli at the same time 
(ex to be able to drive)? 
141 5 85 (88)% 1.0 ± 0.8 
… do you find it difficult to change your activity? 95 12 58 (62)% 0.8 ± 0.8 
Monitoring 53  32%  
… do you lose the correct notion of time? 53 7 32 (34)% 0.4 ± 0.6 
Cognitive processing efficiency / Reasoning 124  75%  
… do you have trouble thinking? 125 1 76 (76)% 1.1 ± 0.8 
… do you have trouble maintaining the tread of your 
thoughts? 
141 2 85 (86)% 1.3 ± 0.7 
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...do you feel confused? 107 2 65 (66)% 0.8 ± 0.7 
Processing speed 143  87%  
… do you find it difficult to think at your normal speed? 146 1 88 (89)% 1.4 ± 0.7 
… do you find it difficult to react at your normal speed? 140 5 85 (88)% 1.4 ± 0.7 
Calculus 118  72%  
… do you find it difficult to do mental calculation? 118 21 72 (82)% 1.2 ± 0.7 










Naming 57  35%  
…  do you have trouble speaking out other people’s 
names? 
78 1 47 (48)% 0.6 ± 0.8 
… do you have trouble in remembering objects names? 65 2 39 (40)% 0.5 ± 0.7 
… do you have trouble in memorizing people’s names? 68 9 41 (44)% 0.6 ± 0.8 
… do you have trouble recognizing famous people? 16 32 10 (12)% 0.2 ± 0.4 
Comprehension 87  53%  
… do you have trouble in understanding when being spoke 
to? 
87 2 53 (53)% 0.8 ± 0.8 
Speech Fluency 83  50%  
… do you have trouble in organizing your ideas in order to 
speak correctly? 
97 5 59 (61)% 0.8 ± 0.8 
… do you speak with a lot of interruptions or brakes? 108 4 65 (67)% 1.0 ± 0.8 
… do you switch the words you want to speak by others? 71 7 43 (45)% 0.6 ± 0.7 
… do you switch the sounds or syllables within words ? 50 10 30 (32)% 0.4 ± 0.7 
… is your voice slurred when speaking? 71 9 43 (46)% 0.6 ± 0.8 
… do you have difficulty in organizing a sentence or a 
conversation? 
99 1 60 (60)% 0.9 ± 0.8 
Reading and Writing 102  62%  
… do you have trouble writing? 82 18 50 (56)% 0.8 ± 0.8 
… do you find it difficult to read? 121 11 73 (79)% 1.3 ± 0.8 







Spatial Perception 47  28%  
… do you fell disoriented in a familiar place? 48 1 29 (29)% 0.4 ± 0.6 
… do you find it difficult to draw? 29 98 18 (43)% 0.6 ± 0.7 
… do you confuse left with right? 26 16 16 (17)% 0.2 ± 0.6 
… do you have trouble following a route (by driving or 
walking)? 
85 3 52 (52)% 0.7 ± 0.7 











 Mood Changes 82  50%  
… do you feel like crying? 104 2 63 (64)% 1.0 ± 0.8 
… do you feel sad? 130 4 79 (81)% 1.2 ± 0.8 
… do you feel euphoric or pleased? 11 9 7 (7)% 0.1 ± 0.3 
Anxiety  143  87%  
… do you feel irritable? 148 0 90% 1.4 ± 0.7 
… do you feel nervous or anxious ? 138 2 84 (85)% 1.3 ± 0.7 
Visual Symptoms 111  67%  
… do you have staring? 136 3 82 (84)% 1.4 ± 0.8 




The most frequent cognitive symptoms identified in the symptoms checklist were 
executive, followed by language and spatial perception, having a distribution per domain 
that was comparable to that of the spontaneous symptoms (table 5).  
 














      
Total 148 (90%) 165(100%)  3. 6± 2.0 35.9 ± 15.6 
      
Cognitive 144 (87%) 83 (50%)  2. 5± 1.6  30.4 ± 13.6 
Executive 132 (80%) 119 (72%)  1. 7± 1.2  20. 2± 7.7 
Language 42   (25%) 82 (50%)  0. 3± 0.6  8.8 ± 6.0 
Spatial 
percep. 2   (1%) 47 (28%) 
 0. 01± 0.1  1. 5 ± 1.5 
      
Non-
Cognitive 
97 (59%) 112 (68%) 
 
1. 1± 1.2  7. 1± 3.0 
Mood 54 (33%) 112 (68%)  0. 4± 0.7  5.0± 2.3 
Sensorial 22 (13%) 111 (68%)  0. 1± 0.4  2. 1± 1.3 
 
Non-cognitive symptoms, classified in mood-related or sensorial, showed identical 
frequency when classified by the symptom checklist, but mood-related complaints were 
proportionally more frequent than sensorial symptoms when answering to the open-
ended research question (table 5).  
 
Table 6 – Checklist scores in patients with and without spontaneous symptoms 
 Spontaneous 
Symptoms (all) P 
Spontaneous 
Symptoms (cognitive) p 
No Yes No Yes 
SYMPTOM 
CHECKLIST 17 148 -- 21 144 -- 
Total 22.7 ± 15.0 39.2 ± 14.8 <0.0001 24.1 ± 14.3 39.5 ± 14.8 <0.0001 
       
Cognitive 18.0 ± 12.8 31.9 ± 13.1 <0.0001 19.0 ± 12.4 32.1 ± 13.1 <0.0001 
Executive 12.4 ± 7.4 21.1 ± 7.2 <0.0001 13.0 ± 7.1 21.2 ± 7.2 <0.0001 
Language 4.7 ± 4.6 9.2 ± 6.0 0.001 4.8 ± 4.7 9.3 ± 6.0 0.001 
Spatial perception 0.9 ± 1.3 1.5 ± 1.5 0.119 1.1 ± 1.2 1.5 ± 1.6 0.206 
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Non-Cognitive 4.6 ± 3.3 7.3 ± 2.9 <0.0001 5.1 ± 3.4 7.3 ± 2.9 0.002 
Mood 3.5 ± 2.2 5.2 ± 2.2 0.004 3.8 ± 2.3 5.2 ± 2.2 0.011 
Sensorial 1.2 ± 1.2 2.2 ± 1.2 0.002 1.3 ± 1.3 2.2 ± 1.2 0.004 
 
Quantitative scores on the symptoms checklist were higher in patients 
spontaneously reporting symptoms in the open-ended question (table 6). 
 
DISCUSSION 
In this study we screened for the frequency subjective cognitive symptoms 
occurring during the headache phase of migraine attacks. Cognitive complaints were 
found to be very common in this setting; we were able to provide an extensive 
description of symptoms using patients’ phraseologies in order to help clinicians to 
recognize their usual pattern. The consistency of our findings supports patients’ 
spontaneous claims of cognitive impairment during attacks, These symptoms probably 
contribute to the self-perceived decrease of 64% in work efficiency during attacks(92) 
and to migraine related disability and burden; their identification allows to improve 
the perception of patients’ impairment and the adequacy of treatment strategies.  
 The majority (87.3%) of episodic migraine patients report cognitive symptoms 
during attacks, a percentage comparable to reports of nausea(52-86%), 
photophobia(55-80%), phonophobia(47 to 100%) and pain aggravation by physical 
effort (53-70%) in large clinical series of migraine(17, 18, 44, 141), supporting that 
cognitive symptoms are an intrinsic part of the attack(118). Analysis of prodromal and 
postdromal cognitive symptoms’ incidence is around 20 and 30% respectively, 
comparable to reports of photophobia (21 and 18%), phonophobia (21 and 15 %) and 
nausea (23 and 11%) in the same attack phases(22-25, 52, 54).  
 
Non-cognitive symptoms included in the answers to our study question were 
either attack-related (such as photophobia, phonophobia, gastrointestinal upset, etc), 
accompanying mood changes (anxiety, depressed mood, etc) or sensorial complaints 
(balance, visual and sensitive disturbances), all described in clinical series of migraine 
patients(20, 43, 44). These were unanticipated answers, as often occurs with open-
ended questions. To our purpose of surveying the maximum variety of spontaneous 
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cognitive symptoms without influencing or leading the answers, an open-ended question 
was more likely to provide in-depth information, while assuming the risk of over-
interpretation of the term “mental abilities”. The fact that all non-cognitive symptoms 
reported were migraine-related can be valued as a concurrent validity measure, 
implying that patients’ answers were strictly referring to phenomena occurring during 
migraine attacks. 
On average, 2.5 cognitive symptoms were reported spontaneously by each 
patient, which can be explained either by the high frequency of different symptoms but 
most likely by the difficulty in describing the symptomatology; 92% of patients reported 
1 to 4 symptoms. Cognitive difficulties are often vague and difficult to define either 
because its experience may not be universal or they may be influenced by performance 
of complex tasks involving several cognitive domains. To support this view, 24% of 
patients reported difficulties in complex tasks, such as cooking, driving or everyday 
tasks, being unable to define what the specific difficulties of task execution were.  
We were unable to find a relation between the presence of cognitive symptoms 
during attacks and any of the demographic or migraine related variables, nor to migraine 
impact.  
Variables that were expected to influence the report of subjective cognitive 
complaints include psychological disturbances (depression, chronic stress/exhaustion 
and sleeping problems(142)), the female gender (especially during pregnancy(143) or 
menopause(144)), medication (including migraine prophylactics, antidepressants and 
hormones)(145-147) and age(81).   
Our study design limited the influence of some of these variables, as we excluded co-
morbid mood disorders and pregnancy. We were unable to find any effect of age in the 
frequency of spontaneous symptoms or in the score of the symptoms checklist, probably 
reflecting the young age average of our population, typical of migraine patients. Our 
sample had a low percentage of patients on prophylactic treatment (under one third), 
42% of which were using topiramate, a drug that influences cognitive functioning(145). 
We were unable to find any relation of topiramate use to the number of spontaneous 
cognitive symptoms nor to the score of the symptoms checklist. Around 7% of our 
subjects were taking low-dose anxiolytics or serotonin-specific reuptake inhibitors and 
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4% were post-menopausal women on hormone replacement therapy, however our data 
did not allow us to determine any effect of these variables.  
The lack of association of cognitive symptoms to migraine disease duration or impact 
suggests that cognitive dysfunction in episodic migraine is mainly an attack-related 
phenomena and perception of cognitive decline is not a consequence of migraine, by 
itself(104). This assumption requires confirmation in further studies powered to answer 
this question. 
There were three symptoms very consistently described by patients using a very 
similar phraseology, the first being a lower ability to concentrate (14.7% of symptoms, 
reported by 37% of patients), followed by difficulty in reasoning (9.8% of symptoms, 
25% patients) and being “less able” to think (9.1% of symptoms, 23% patients), 
reflecting attention and cognitive processing efficiency problems. Symptoms that could 
be attributed to executive domains comprised about 2/3 of spontaneous complaints, 
probably relating to their relevance in daily functioning compared to other domains (E.g. 
impaired drawing ability). The symptom checklist also screened infrequent cognitive 
activities; difficulties in determining some symptoms’ occurrence were reflected in high 
percentages of missing answers of some items – 59% patients were unable to say if they 
had drawing difficulties, 19% did not know if it was hard to recognize famous 
personalities and 13% if their mental calculus was appropriate, during attacks. Average 
scores on the symptom checklist were lower in patients without spontaneous symptoms. 
The differences between spontaneous or cued reporting can be due to lower impact of 
these symptoms or to differences in metacognition abilities of some individuals. 
The pattern of spontaneous cognitive symptoms identified is consistent to 
previous descriptions of difficulties during attacks(9, 11, 95), with descriptions of 
prodromal and postdromal symptoms(22-25, 52, 54) and to objective impairment, as 
identified by neuropsychological testing during attacks(108, 109) most consistently in 
domains of attention, processing speed, working memory and learning. Language related 
symptoms were also frequent, while memory complaints were not as usual. 
It remains speculative why this specific pattern emerges during attacks and even 
putting aside the discussion if these subjective symptoms relate to clinically relevant 
brain dysfunction, their consistency supports that these brain functions are modified 
during migraine attacks. Attention, processing speed and working memory have some 
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common characteristics, namely (1) being basic executive functions, related to pre-
frontal activity; (2) representing brain processes that subserve other higher-order 
cognitive domains and (3) depending on subcortical circuitry.  
Attention may be viewed as brain network function involving three subsystems – 
alertness or arousal (thalamic function), orienting or selection (parietal function) and 
executive or conflict resolution (anterior cingulated function) that might interact or 
function independently(148). Processing speed is influenced by subcortical white 
matter(149) and/or cortical structures(150). Working memory is a prefrontal cortex 
function that involves different areas according to the specific task required; recent 
evidence suggests that dorsal prefrontal cortex plays a more prominent role in encoding 
information while retrieval may be mediated either by the ventral or the dorsal 
prefrontal cortex(151).  
The participation of cortical brain areas in migraine attacks has been documented 
for in the insula, temporal lobe(152) and cingulated and pre-frontal cortex(153). 
Subcortical structures, such as the raphe nuclei with its cortical serotoninergic 
projections (ex. orbitofrontal cortex, precentral gyrus, temporal pole, insula and 
somatosensory area)(154) and the thalamus are also activated during attacks in 
humans(153) and may represent the anatomical substrate explaining this 
symptomatology. Improving the knowledge about cognitive dysfunction during 
migraine attacks can provide clues to the brain processes occurring within the attack and 
help in determining the sequence of brain events resulting in the episodic dysfunction of 
migraine patients. 
We acknowledge that the frequency of cognitive symptoms occurrence is 
probably overestimated in our study, as the research question was open-ended and 
interview based, which may incite the patient to respond affirmatively. We could have 
chosen to use a standard research method in issue exploration, such as the modified 
Delphi technique, that would have had the advantage of improving the consensus over 
which symptoms would be relevant in this context and increase accuracy of results. 
However, it has several potential disadvantages such as higher work load, the potential 
of low response rates and for molding opinions by investigators and the risk of reducing 
variability(155). Our priority was to be as inclusive as possible, to identify the maximum 
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variety of spontaneous cognitive symptoms without influencing or leading the answers 
and we wished to provide clinicians the expressions most often used by patients. 
We chose a clinic-based population with episodic migraine, excluding severe co-
morbid mood disorders, chronic migraine and medication overuse because we wanted 
to focus on the attack and avoid potential confounding factors on cognition (89, 139). As 
a consequence, our results cannot be extrapolated for the general population, but are 
probably useful in neurology and headache clinics. Medication use is an important 
potential confounder not controlled for and acknowledged as a limitation of this study.   
We conclude that reversible subjective cognitive symptoms are consistently 
described in the headache phase of the migraine attack. The pattern most often reported 
(either by its frequency or by its relevance on functional ability) is of attention, cognitive 
efficiency and speed impairment, probably relating to pre-frontal or, most likely, 
subcortical brain networking dysfunction. Migraine attacks are the hallmark of Migraine 
as a disease; further knowledge about brain function during these events may help to 
identify new therapeutic targets or developing therapeutic agents in which efficiency 
would not be restricted to the control of pain, but also to attack-related reversible 
cognitive symptoms. 
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ABSTRACT  
Background: The socio-economic impact of Migraine is mostly related to work loss either by 
absenteeism or decreased work performance. Migraine associated cognitive dysfunction during 
an attack may contribute to these difficulties. 
Objective: To analyze the presence and relevance of cognitive symptoms during migraine 
attacks and to relate their intensity and symptom related disability with other migraine defining 
symptoms. 
Methods: Consecutive migraine patients of headache clinic completed diaries scoring each 
migraine symptom (including cognitive symptoms) intensity and symptom related disability. 
Results: Of 100 consecutive patients included in this study, 34 (all females, age average 31.8±8.8 
years) returned information on 229 attacks, on average 6.7 per participant. Every symptom’s 
intensity was always rated slightly higher than the disability it caused. Pain was the symptom 
scored with the highest intensity and disability, followed by cognitive symptoms (difficulty in 
thinking and worsening with mental effort) and photo and phonophobia. Scoring was 
independent of any of the clinical variable. Attack intensity and disability scores correlated with 
intensity and disability from pain and from worsening with mental effort. 
Conclusions: Attack-related cognitive symptoms are intense and disabling. Intensity and 
disability subjectively attributed to some attack-related cognitive symptoms correlate to 
intensity and disability subjectively attributed to the migraine attack. New acute migraine drugs 
trials should include cognitive evaluation as a secondary end-point, in order to be able to 








              Cognitive symptoms, although reported frequently by patients during migraine 
attacks (22, 54, 95, 118, 133, 136, 156) are not considered as core symptoms of the 
migraine diagnosis(7). Patients self-report being only 46% effective when working 
during migraine(92), but which part of this disability is related to cognitive dysfunction 
is undetermined.  
Cognitive symptoms often precede migraine attacks, being very frequent in the 
premonitory phase of migraine(23, 25, 157) and having a high predictability for an 
attack (22). Disturbances of speech or thought are also described in the time gap 
between the end of the aura and the onset of pain (42). Cognitive difficulties can persist 
after the headache phase as postdromes (22, 25, 51, 54, 157) and may not be relieved by 
acute migraine medication (95, 158). Cognitive symptoms are not a usual endpoint of 
acute treatment trials in migraine. 
Cognitive dysfunction during migraine has been documented in some studies(98, 
100, 102, 109, 159), with involvement of the domains of processing speed(109), working 
memory, visual-spatial processing(98, 102, 159), immediate and sustained attention and 
verbal learning(100, 109). This is suggestive of preferential dysfunction of the pre-
frontal and temporal cortices during migraine attacks. 
These migraine-related clinical manifestations on cognition are important 
evidence of functional brain changes underling migraine pathophysiology and should be 
appointed as a therapeutic targets to be dealt with when evaluating acute treatment 
drugs. 
Our objective was to analyze the presence and subjective relevance of cognitive 
symptoms during migraine attacks, by collecting data prospectively on paper diaries 
regarding the intensity and disability of cognitive and migraine-defining symptoms(7) 
in each attack of migraine patients. 
 
SUBJECTS and METHODS 
1.  Population  
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 Participants were recruited consecutively on a Headache Outpatient Clinic, either 
first or follow up visits during the first semester of 2013 and invited to participate.  
Inclusion criteria were: a) age between 18 and 55 years; b) minimum education of nine 
years; c) minimum headache frequency of one monthly attack in the 3 months preceding 
inclusion; d) written informed consent; e) diagnosis of definite episodic migraine with 
or without aura according to ICDH-II(13) 
 Exclusion criteria were simultaneous presence of migraine (either with or without 
aura) and other headache types that could present with attack-related or nonattack-
related cognitive symptoms, including tension-type headache, chronic migraine with or 
without medication overuse and migraine aura without headache. A history of past or 
current alcohol or drug dependence or abuse and the presence of severe or uncontrolled 
medical or psychiatric disorder were also exclusion factors. The study protocol was 
approved by the Institution’s Review Board. 
 
2. Study design   
Recruitment and inclusion were carried out by a headache specialist at a regular 
clinic visit who verified the patient eligibility criteria and carried out a standard clinical 
evaluation. After informed consent had been obtained, data was collected including 
verification of ICDH-II criteria for diagnosis, gender, age, literacy, disease duration, 
current attack frequency, duration and intensity , attack and aura characterization, use 
of prophylactic treatment and detailed medical and pharmacological history. At the end 
of the routine appointment, the patient was asked to complete the Mig-SCog(118) and 
HIT-6(140) scales. The Mig-SCog(118) is a 9-item questionnaire that quantifies self-
reported subjective cognitive symptoms during migraine attacks and its score can run 
from 0 to 18, the higher scores representing higher frequency of cognitive symptoms; 
the HIT-6 (140) is a 6-item standardized questionnaire that measures the impact of 
migraine on functional status and well-being. Patients were also given 10 headache 
diaries, one for each migraine attack, including information about timing of the attack 
(start and end of pain, timing of medication and of completion of the diary), medication 
use (acute and rescue medication) and about intensity and disability related to each 
attack. Attack treatments were grouped into 5 categories: Triptans, NSAIDs, Analgesics 
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(including combination analgesics with codeine, caffeine or ergots) and Anti-emetic 
drugs in combination (either with triptan, NSAID or analgesic). On one side of the sheet, 
patients were asked to rate each migraine symptom’s intensity on 0-10 visual analog 
scale (VAS), for that specific migraine attack (intensity of pain, nausea, photophobia, 
phonophobia, kinesiophobia(45), worsening with physical effort, worsening with 
mental effort, difficulty in thinking and global attack intensity). On the reverse side of the 
sheet, patients were asked to rate each migraine symptom related disability on 0-10 VAS 
scale, for that specific migraine attack (disability attributed to pain, nausea, photophobia, 
phonophobia, kinesiophobia(45), worsening with physical effort, worsening with 
mental effort, difficulty in thinking and global attack disability).  
Diaries were returned on follow up appointments occurring before the 31st December 
2013. 
 
3. Statistical Analyses 
          Statistical analysis used Stata release 12 (Stata Corp., College Station, TX).  
Generalized Estimating Equation (GEE) with gamma family and a log link, with an AR(1) 
correlation structure and robust standard errors based on the Huber-White-sandwich 
variance estimator was used to analyze the relationships between scores of the different 
migraine symptoms adjusted by all other symptoms. A correlation coefficient between 
scores of any two symptoms was obtained with Spearman’s rank correlation after 
averaging each patient’s symptom scores over all the episodes. GEE analyses using global 
attack intensity and global attack related disability as the dependent variables were 
performed. Significance was set at the 5% level (p <0.05). The Holm-Bonferroni 




One hundred patients were included in this study, eight males, with an age average 
of 31.2 ± 7.5 years, of whom 13 had migraine with aura and 87 without aura. There were 
9 (14%) dropouts for several reasons (losing their diaries, forgetting to bring the diary 
in the scheduled follow-up, not having had time to fulfill the diaries or returning very 
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incomplete diaries that were not included; one patient emigrated); 57 patients failed to 
attend the scheduled follow-up.  
Thirty-four patients returned 229 impact diaries, an average of 6.7 ± 3.0 (range 1 to 
10) per participant. Patients not returning their diaries were similar in their 
demography and headache characteristics to participants (table 1) but were excluded 
from further analysis.  
 
Table 1 - Clinical Characteristics of participants and non-participants 




Total Number   66 34 -- 
Gender (Female : Male) 58 : 8 34 : 0 n.s. 
Age (years, average ± sd) 30.9 ± 6.8 31.9 ± 8.8 n.s. 
Literacy (years, average ± sd) 14.8 ± 1.5 15.4 ± 1.3 n.s. 
Associated Diseases (yes : no) 19 : 47 11 : 23 n.s. 
Migraine (with : without aura) 8 : 58  7 : 27 n.s. 
Disease Duration (years, average ± sd) 15.1 ± 9.2 15.4 ± 9.7 n.s. 
Attack frequency (monthly, average ± sd) 5.1 ± 4.8 5.8 ± 5.2 n.s. 
Preventive Medication (yes : no) 25 :  41 13 : 21 n.s. 
HIT- 6 (score, average ± sd) 62.9 ± 4.2 63.4 ± 4.4 n.s. 
Mig-SCog (score, average ± sd) 7.6 ± 4.1 8.6 ± 4.1 n.s. 
Legend: sd – standard deviation; n.s. non-significant, p> 0.010 
 
The study sample consisted of 34 females, one left-handed, of whom 6 had migraine 
with aura and 28 without aura, with an age average of 31.8 ± 8.8 years. Average HIT-6 
Score was 63.4 ± 4.4 (range 50 to 70), reflecting a moderate to severe impact of migraine 
although 68% of the sample had 5 or less headache days in the month preceding 
inclusion. Mig-SCog Score average was 8.6 ± 4.1 (range 2 to 18), a medium score of 
subjective cognitive complaints.  
Medical co-morbidities were present in 11 (32%) patients, mostly vascular risk 
factors (high cholesterol and obesity, 2 patients each), followed by thyroid dysfunction 
(2), asthma or allergies (2), mild anxiety or depression (2) and others (congenital 
glaucoma and esophageal reflux or gastritis). Twenty (67%) of these patients were on 
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birth control methods (19 oral contraception, 1 local hormonal devices) and 13 (43%) 
on prophylactic headache treatment (amitriptyline 2, topiramate 6, propranolol 3, 
valproid acid 2). Five (15%) patients were on other medical treatments (lower dose SSRI 
antidepressants 2, asthma treatment, thyroid hormone, statin and topic glaucoma 
treatment, 1 patient each). 
Headache diaries were completed on average 14.2 ± 7.5 hours (range 4.1 to 26.4) 
after the end of each attack. The average time interval from inclusion to handing back of 
the diaries was 96.1 ± 64.2 days (range 19 to 270 days, 8.8 months).   
 
1.2 Migraine attack characteristics 
Average duration of the studied attacks was 20.0 ± 14.3 hours (range 4.2 to 67.2 
hours). Analyzing attack clinical features, 207 (90.4%) fulfilled the ICDH-II criteria for 
migraine, 19 (8.3%) for probable migraine and only 2 (0.9%) could be classified as 
probable tension-type headache. On average, patients waited 3.0 ± 4.5 hours (range 5 
minutes to 20 hours and 45 minutes) before taking their acute medication.  
 
All the patients took acute medication in at least one of their attacks; most of the 
patients (18, 52.9%) took it in all reported attacks and twelve (25%) took it in more 
than 2/3 of attacks. 
 
Of the 229 attacks studied, 221 (96.5%) were treated. The first choice of abortive 
treatment in this sample were triptans (48.4% of treated attacks), either alone (38.5%) 
or in combination with an anti-emetic drug (5.9%) or with an NSAID (4.1%). NSAIDs 
were the second choice in 40.7% of patients (alone 29.9% or with an anti-emetic 6.8%). 
Analgesics, combination analgesics with codeine, caffeine or ergots were used in 9% of 
attacks, in 1.8% adding an anti-emetic. 
Rescue medication was used in 45.7% (101) of initially treated attacks and taken 
on average 4.5 ± 5.2 hours (range 15 minutes to 20.5 hours) after the initial therapy. 
The first choice of rescue treatment were NSAIDs (43.6%, with 5% adding an anti-
emetic  and 5.9% a triptan).  Triptans were chosen secondly as rescue therapy by 
35.6%, adding an anti-emetic in 3.0%.Thirteen percent of attacks required repeated 
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rescue medication. Analgesics, combination analgesics with codeine, caffeine or ergots 
represented the choice in 10.9% of attacks, in 1% adding an anti-emetic. 
1.3 Symptom Intensity and Disability 
Results of scoring symptom intensity and symptom-related disability on a 0-10 VAS 
scale are depicted in table 2. Intensity was rated slightly higher than disability, in all 
symptoms. Pain was the symptom with higher intensity and disability, followed by 
cognitive symptoms (difficulty in thinking and worsening with mental effort) and photo 
and phonophobia. 
 
Table 2 - Average Scores of Symptom Intensity and Symptom related Disability  
 Intensity (0-10 VAS) Disability (0-10 VAS) 
 Average ± SD Range Average ± SD Range 
Global – of the Attack 5.5 ± 2.1 0.9 - 10 4.2 ± 2.0 0 – 9.3 
Pain 6.0 ± 1.8 1.7 -10 5.2 ± 2.2 0.7 -9.9 
Nausea 3.2 ± 2.1 0 – 8.6 2.5 ± 2.1 0 – 8.6 
Photophobia 4.4 ± 2.3 0.4 – 9.6 3.5 ± 2.6 0 – 9.6 
Phonophobia 4.3 ± 2.3  0.3 – 10 3.5 ± 2.6  0 – 9.4 
Kinesiophobia 4.0 ± 2.0 0 – 8.6 3.2 ± 2.2 0 – 8.7 
Worsening with Physical Effort 4.2 ± 2.1 0 – 9 3.6 ± 2.2 0 – 8.6 
Worsening with Mental Effort 4.9 ± 2.0 0.4 – 9 4.1 ± 2.2 0 – 8.8 
Difficulty in thinking 4.8 ± 2.1 0.3 – 9 4.1 ± 2.2 0 – 8.8 
 
 
1.4 Correlations and Regression Analysis 
Age was found to correlate with disease duration (Spearman’s rho 0.659, p<0.0001) 
and inversely with attack frequency (Spearman’s Rho -0.475, p=0.005). Reported attack 
duration correlated with time to take rescue medication (Spearman Rho 0.645, 
p<0.0001) after initial acute treatment, but not with time to take initial acute treatment. 
There were no other significant correlations between disease related variables (age, 
literacy, disease duration, attack frequency, reported attack duration and number of 
attacks reported, HIT-6 and Mig-SCog scores). 
Correlation coefficients between using each type of acute medication and intensity 
and disability of cognitive symptoms (worsening with mental effort and difficulty in 
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thinking) are depicted in table 3; Intensity of cognitive symptoms was correlated with 
the use of triptans or analgesics as first choice in rescue treatment; disability of cognitive 
symptoms related to all drug groups except anti-emetics in combination with any other 
drug. . Intensity and disability of cognitive symptoms had no correlation to the need of 
rescue treatment.  
 












Triptans 0,396 0,163 0,630 0,001* 
NSAIDs 0,138 -0,018 0,294 0,083 
Analgesics 0,539 0,228 0,851 0,001* 




Triptans 0,653 0,293 1,012 <0,0001* 
NSAIDs 0,427 0,201 0,652 <0,0001* 
Analgesics 0,847 0,536 1,157 <0,0001* 




Triptans 0,433 0,112 0,754 0,008* 
NSAIDs 0,198 -0,024 0,420 0,081 
Analgesics 0,661 0,178 1,144 0,007* 




Triptans 0,627 0,261 0,992 0,001* 
NSAIDs 0,359 0,116 0,602 0,004* 
Analgesics 0,775 0,429 1,120 <0,0001* 
Anti-emetic drugs plus 0,227 -0,117 0,570 0,196 
Legend: significant correlation, p< 0.010 
 
Correlations found between intensities of each migraine symptom were scarce – 
intensity of pain only correlated with intensity of worsening with mental effort (p=0.02), 
intensity of nausea with intensity of kinesiophobia (p<0.001), intensity of photophobia 
with that of phonophobia (p<0.001), intensity of kinesiophobia with worsening with 
physical effort (p<0.001), the degree of worsening with physical effort related to 
worsening with mental effort (p<0,001) and with intensity of difficulties in thinking 
(p=0.002); finally the degree of difficulty in thinking correlated with worsening with 
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mental effort (p<0.001).  Global attack intensity was correlated with pain intensity and 
worsening with mental effort (graphic 1).  
 
 
Graphic 1 – Correlation of each symptom’s intensity with Global Attack Intensity 
 
Legend: Values within balls represent Correlation Coefficients; (*) Significant correlations p< 0.001 
 
       Correlations between disability scoring for each migraine symptom were also 
analyzed; disability of pain had no significant correlation with any other symptoms. 
Disability due to nausea correlated with disability of kinesiophobia (p <0.0001), 
disability of photophobia correlated with that of phonophobia (p 0.002),  phonophobia 
also correlated with the disability attributed to difficulty in thinking (p 0.003), disability 
of kinesiophobia with that of phonophobia (p <0.001). Disability of worsening with 
physical effort correlated with disability due to kinesiophobia (p 0.03) and disabilities of 
difficulty in thinking and worsening with mental effort were also correlated (p<0.001). 










Legend: Values within balls represent Correlation Coefficients; (*) Significant correlations p< 0.001 
 
The correlation of each symptom-related disability with symptom intensity 
revealed that disability of nausea correlated with intensity of nausea (p<0.001), intensity 
of worsening with mental effort (p 0.01) and intensity of difficulty in thinking (p 0.006). 
Disability of some symptoms correlated only with disability of the same symptom, such 
as with photophobia (p<0.001), phonophobia (p<0.001), kinesiophobia (p 0.004) and 
worsening with physical effort (p 0.004). Global attack disability also correlated with 
global attack intensity (p 0.008). Disability due to pain, worsening with mental effort and 
difficulty in thinking had no correlations with any of migraine symptoms’ intensity.  
GEE analysis using global attack disability as the dependent variable failed to 
show association with any of the studied variables (age, literacy, comorbidities, current 
medication, current migraine prophylactics, migraine diagnosis, disease duration, attack 
frequency and duration, HIT6 and Mig-SCog scores) with the exception of global attack 






This prospective study of 229 migraine attacks revealed that patients are able to 
score intensity and disability of specific migraine attack-related symptoms 
independently. Patients’ scores of each symptom’s intensity were higher than the 
corresponding symptom-related disability scores, possibly reflecting self-perceived 
individual coping mechanisms during attacks although we cannot exclude a chance 
association. Amongst all proposed migraine symptoms, pain by itself was rated as having 
the highest intensity, had the highest disability during attacks and was correlated with 
global attack intensity and attack-related disability, which supports the current view that 
pain control measures (pain freedom, pain relief and sustained pain freedom) are 
adequate primary endpoint of drug trials for the treatment of acute migraine 
attacks(160).   
Cognitive symptoms sought (worsening with mental effort and difficulty in 
thinking during attacks) were scored after pain both in intensity and attack related 
disability, followed by photophobia, phonophobia, worsening with physical effort, and 
kinesiophobia. Unexpected findings were the low scores attributed to nauseas’ intensity 
and associated disability that we speculate to be related to the early use of an anti-emetic 
drug (in around 13% of treated attacks), associated with a pain-killer, although our study 
design did not allow us to test this hypothesis.  
Attack-related disability was highly correlated to both pain and worsening with 
mental effort, suggesting that some aspects of cognitive dysfunction have a role in 
migraine disability, independently of other symptoms. However, with our study design, 
we were unable to estimate the proportion of the variability of the attack-related 
disability that is explained by cognitive symptoms. 
Current guidelines include some other migraine associated symptoms, such as 
nausea, photophobia and phonophobia and a measure of total migraine freedom 
(instead of simple pain freedom) as secondary endpoints in acute migraine treatment 
trials(160). These guidelines do not include cognitive endpoints nor to other migraine 
related symptoms. This fact reflects not only the lack of therapeutic agents that are able 
to treat all migraine symptoms but also influences the perceived lack of control on 
symptoms other than pain – if we are not measuring, we will never know. The inclusion 
of impact and quality of life measures, medication needs and other unconventional 
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endpoints in prophylactic drug trials has allowed the evaluation of subtle benefits in 
difficult populations(161). The inclusion of measurements of cognitive impact or 
disability could help establish differences between acute medication profiles. To our 
knowledge, only two studies evaluated cognitive performance during an attack and after 
treatment (97, 162) as outcome measures. 
In our study, none of the clinical variables analyzed had influence on symptom 
intensity or disability scoring. For most symptoms, their related disability correlated 
with its intensity reflecting that intensity is related to the disability or symptom impact. 
Disability due to pain and to cognitive symptoms (worsening with mental effort and 
difficulty in thinking) failed to demonstrate a relationship to each symptoms’ intensity, 
suggesting that the symptoms themselves are not the major factor determining their 
related disability. Intensity of some symptoms was, however, related. Examples include 
kinesiophobia and worsening with physical effort, which is understandable if we 
acknowledge that kinesiophobia is a part of the avoidance behavior observed during 
migraine attacks, due to the aggravation of pain or enhancement of its throbbing 
character by head movement and/or  psychical effort(45); nausea and kinesiophobia 
intensity were also correlated, which can be related to increased prevalence of motion 
sickness in migraine patients(163), as is supported by the fact that disability of 
kinesophobia and disability of nausea and worsening with physical effort were also 
correlated. The degree of worsening with physical effort was associated with the degree 
of worsening with mental effort and of difficulty in thinking, probably reflecting the 
patients’ perception of the need to stop all activity. 
Intensity of photo and phonophobia being related reflects the fact that sensitivity 
to light and sound are believed to be the clinical expression of impairment of sensory 
processing during attacks(164), which is supported by the fact that their associated 
disabilities are also correlated; using the same line of thought difficulty in thinking and 
worsening with mental effort intensities and disabilities are also related as  both can be 
interpreted as cognitive dysfunction related phenomena(109, 118).  
Interesting enough, pain intensity was associated with the degree of worsening 
with mental effort, which may reflect higher impact of the attack, as pain intensity has 
been shown to have some influence in attack related cognitive changes(109).The fact 
that we analyzed treated attacks is an obvious limitation of this study, as treatment 
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influences symptom intensity and symptom-related perceived disability. Treatments 
can also act as confounders, for cognitive symptoms and nausea can be side-effects of 
migraine acute medications(158, 165), although in some reports enhancement of 
cognitive function was reported after treatment (60, 166). We were able to identify some 
associations between some of the initial acute treatments used and cognitive symptoms, 
although the interpretation of this data is conflicting. The association of the use of 
triptans and combination analgesics to a higher intensity of cognitive symptoms might 
be either a consequence drug effects or of the choice of such more effective drugs in face 
of a higher intensity attack. Taking anti-emetics doesn’t seem to correlate with cognitive 
symptoms impact yet this group was heterogeneous (included patients taking triptans, 
NSAIDs and analgesics). Our study design does not allow an accurate determination of 
the effect of each treatment in cognitive functioning, although this is an important topic 
for future research.  
Our patient sample was clinic-based, reflecting episodic migraine patients with 
some comorbidities and a moderate to high impact disease (high HIT-6 score), some 
(38%) requiring migraine prophylactic medication. Migraine prophylactics and other 
chronic medications can influence cognitive performance and subjective symptom 
reporting(145). The co-morbidities and concomitant treatments of our study population 
were scarce and mild and we assumed they had little influence on cognitive or other 
migraine related symptoms, as reflected in GEE analysis. Although the sample was clinic-
based, it does not represent the usual population of tertiary headache centers (high 
frequency attacks, high need for prophylactics, medication overuse and frequent co-
morbidities) nor does it apply to the population-based low impact migraineur, which are 
limitations to the generalization of our findings. On the other hand, it was useful to select 
the migraine patients in whom disability is almost exclusively related to the attacks, (i.e., 
having low interictal impact) and having a high probability of being active and employed, 
strengthening the view that episodic attack-related cognitive dysfunction contributes to 
disability. The possibility of a recall bias is also a limitation that we minimized by having 
the patients to report as soon as possible (on average 14 hours) after each migraine. 
The most important limitation of this study is the high attrition, as only 35% of 
the patients returned their diaries. Participating patients were similar to non-
participating patients in all clinical variables, including disease impact and Mig-SCog 
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scores. There were 14% of dropouts and other potential reasons for the high attrition 
include the lack of financial compensation for the participants and the demography of 
the sample that consisted of young working adults with a moderate impact long standing 
disease, which failed to return to the follow-up appointment within the estimated time 
frame.   
The benefits of treating the attacks early (first 2 hours, when the pain is 
mild(167)) are common knowledge for sufferers and have been documented in clinical 
trials and cost-effectiveness studies(168), leading to better medical counseling specially  
in headache clinics such as ours. An interesting observation of this study was that our 
population, despite having a high impact migraine and being treated and coached in a 
headache clinic, still waited on average 3 hours before taking their acute medication after 
the onset of the attack. There may be many reasons explaining this delay such as fear of 
side-effects, availability of medication or cost(167), yet another speculative contributing 
factor could relate to cognitive dysfunction, such as lack of initiative or mental slowing,  
to explain this delay.  
There is some evidence that reversible cognitive dysfunction occurs during 
migraine attacks(108, 169) corroborating patients’ spontaneous and subjective 
complaints(22, 118). Migraine subtypes and disease severity may influence the 
expression of such symptoms(169). The mechanisms explaining these symptoms are 
still elusive yet functional imaging has contributed to document changes in the human 
cingulated and pre-frontal cortex(153) during migraine attacks, as well as in the insula 
and temporal lobe(152). Interictal functional connectivity changes on executive resting 
state and salience networks have been documented(170, 171), as well as cortical grey 
matter differences of migrainous brains (172-174) . One aspect of cognitive dysfunction 
during attacks (worsening with mental effort) was found to correlate with attack-related 
disability, supplanting disability caused by nausea, photo and phonophobia, which is a 
reflex of its importance to migraine sufferers.     
In conclusion, cognitive symptoms are important contributors to migraine attack-
related disability. The cutting edge of new acute migraine drugs should evaluate the 
return to normal function as a primary end-point, including cognitive-related measures 
to evaluate the efficacy of such drugs in the return to normal cognitive performance, 
instead of simple freedom of pain.   
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Can we identify and quantify attack-related cognitive symptoms in migraine? 
 
A subjective cognitive impairment scale for migraine attacks - the 
MIG-SCOG: development and validation.  
 
Gil-Gouveia R, Oliveira AG, Martins IP.  
A subjective cognitive impairment scale for migraine attacks – the MIG-SCOG: development and 




Background: The burden of migraine is determined by impairment during attacks, due to pain 
or non-painful symptoms, such as cognitive symptoms.  
Objective: Development of a questionnaire to measure self-reported subjective cognitive 
symptoms during migraine attacks.  
Methods: Item generation was accomplished through structured patient interviews analyzed by 
a panel of experts. A set of 43 candidate items was applied to consecutive migraine patients. Test 
construction with factor analysis retained 9 items. Internal consistency was assessed with 
Cronbach’s alpha and Spearman’s rho, and convergent and construct validity by correlation to 
spontaneous cognitive complaints, the 43-item and the Cognitive Failures Questionnaires. 
Results: The 9-item Mig-SCog covers two domains, executive functions and language. Cronbachs’ 
alpha was 0.82. It correlates with spontaneous cognitive complaints(p<0.001), the 43-
item(rho=0.69) and the Cognitive Failures Questionnaires(rho=0.61). Test-retest 
reliability(Cohen’s kappa) was 0.55. 
Conclusions: Mig-SCog is a valid, reliable, consistent working instrument of fast self-








      Migraine is a highly prevalent disorder (16, 175, 176) and causes disability affecting 
millions of patents daily. Its overwhelming impact in world health was recognized by the 
World Health Organization in its 2001 World Health Report (177), as migraine was listed 
in the top 20 causes of Years of Life Lived with Disability (YLDs) worldwide, in both 
genders and all ages, being be responsible for 1.4% of the total of YLDs (177-179).  
      The disability imposed by migraine affects mostly young and active individuals, 
producing a significant public health and economic impact (135). Direct costs include 
health services and medication (135, 180)  yet indirect costs represent 70% of the 
economic burden and result from reduced productivity at work/ school or to 
absenteeism (135, 137, 181, 182). The family and leisure time is also affected, with 
impact on both to the patient and their personal relations (135). Adding to a documented 
decrease in quality of life both during and between attacks, additional unaccounted 
indirect costs also exist, due either to inability to participate or to phobic avoidance of 
leisure and social activities(131, 135).  
      Migraines’ degree of disability during attacks is determined by the frequency, 
duration and intensity of pain (131-136), but also from associated symptoms such as 
nausea and vomiting (133, 136-138). In addition, many patients report disabling 
cognitive symptoms (95, 133, 136, 156) and patient testing during attacks has revealed 
impairment in several cognitive domains such as processing speed, sustained 
attention/concentration, working memory, visual-spatial processing, 
alertness/fatigue(96, 102, 159), immediate and sustained attention and verbal 
learning(100). 
      Some authors also documented interictal mild executive dysfunction in a subgroup of 
migraine patients which was interpreted as a possible cumulative effect of repeated 
attacks(59). Further literature revealed conflicting results, showing no differences 
between migraineurs and controls in interictal cognitive function (183-185). 
     Patients often report that effective medication can relieve their pain and/or nausea 
but cognitive symptoms tends to persist (158), often through to the following day. 
Persisting symptoms are described by 80% of migraineurs and include mental tiredness, 
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asthenia, somnolence, depressed mood and concentration difficulties (25, 51). Acute 
migraine treatment with sumatriptan has been able to revert both pain and cognitive 
impairment in small uncontrolled trials(96, 102). 
      The cause of cognitive symptoms and impairment during attacks remains elusive, yet 
patients often complain that this type of symptoms can be as disabling as migraine pain 
itself. No measurement of this kind of subjective complaints exists(131-133). 
      Our aim was to develop a specific instrument to quantify subjective cognitive 
symptoms during migraine attacks. Such an instrument could contribute to the 
assessment of attack related disability and to monitor the effect of acute medication.  
 
SUBJECTS and METHODS 
      Patients were recruited from Headache and Neurology Outpatient Clinics of two 
general hospitals in Lisbon, Portugal. Consecutive patients, either first or follow-up visits, 
who fulfilled the inclusion criteria, were invited to participate. The study protocol was 
approved by the Hospitals’ Institutional Review Boards. 
     Inclusion criteria were: a) age over 16 years; b) at least second grade education (able 
to read and write); c) history of episodic migraine with or without aura, as defined by 
the ICDH-II(186); d) migraine that had be present for at least one year with a minimum 
of two attacks in the 3 months preceding inclusion; e) written informed consent. 
Exclusion criteria were chronic migraine, chronic daily headache with or without 
medication overuse, other headache diagnosis besides migraine, history of past or 
current alcohol or drug dependence or abuse, and severe or uncontrolled medical or 
psychiatric disorder.  
Generation of scale items 
      Structured interviews with consecutive migraine patients (n=37) from the outpatient 
headache clinic were conducted in order to identify cognitive symptoms during migraine 
attacks. From this patient-centered data, an expert panel of three neurologists with 
experience in headache and cognition selected relevant items and generated new items 
based both on cognitive complaints commonly described by patients during migraine 
attacks and on a relevant medical literature review. The panel also evaluated wording 
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for complexity and ambiguousness and supported item relevance and validity(187). This 
process resulted in a draft questionnaire that included an initial open-ended question – 
“Do you feel your mental capacities are different during your headache attacks? Please 
describe your main difficulties.” - followed by 43 multiple choice questions, asking about 
several domains of cognitive function during the attacks. Applicability and 
understandability of questions was evaluated by a focus group of 10 migraine patients.  
Patients had to self-rate each item-symptom in a 3 option scale - occurring often (scoring 
2 points), rarely (scoring 1 point) or not at all (scoring 0) during the attacks; it was also 
possible to answer “don’t know, don’t want to answer”, to access item 
comprehensiveness and adequacy. Some questions with reversed or clearly unrelated 
responses were included in order to access the no/ yes-saying bias(187). 
        The draft 44-item self-administered questionnaire was applied to 93 consecutive 
migraine patients interictally, immediately after their routine clinical appointment. 
Demographic and clinical data was collected and analyzed (age, gender, literacy, 
migraine diagnosis and characterization, disease duration, prophylactic medication use 
(yes/no)). One of the authors checked the forms for completeness. 
       For item reduction, items that performed poorly because of a high level (>10%) of 
“don’t know, don’t want to answer” responses were eliminated from the start. Factor 
analysis with varimax rotation of the remaining items was used to identify likely 
domains of cognitive function. Items with an eigen value of 0.400 or higher were retained 
unless they had an eigen value difference inferior to 0.300 between any two factors. The 
result was a simplified 9-item multiple choice self-administered questionnaire – the Mig-
SCog – with a total score varying from 0 to 18, the highest scores representing more 
expressive cognitive symptomatology during attacks. 
  
Statistical Analyses 
      Construct validity of the Mig-SCog was assessed by analyzing the spontaneous 
symptoms evoked by the first open question in number and content, and by using this as 
an empirical measure to infer the meaning of the total questionnaire score. The average 
number of spontaneous cognitive symptoms reported during the attacks was correlated 
with demographic and clinical variables (age, gender, literacy, disease duration, type of 
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migraine, average intensity, frequency and duration of attacks, current use of 
prophylactic medication) and with total score of the 43-multiple choice questionnaire. 
Qualitative analysis was performed by an expert panel of neurologists with experience 
in cognitive testing, who categorized the symptoms reported in non-cognitive and 
cognitive domains in both the spontaneous cognitive complaints and the questionnaires. 
      Internal consistency was assessed with Cronbach’s alpha and the lower bound of the 
one-sided 95% confidence interval. Inter-item, item-test and item-rest correlations were 
tested with Spearman’s rank correla
included in the total score for item-test correlations, but the item was excluded in the 
item-rest correlations and Cronbach’s alpha. The same methods were used to analyze 
dimensions within the final instrument: interdimension, dimension-total and 
dimension-to-own correlations and Cronbach’s alpha.   
      In order to provide evidence of external validity, convergent validity was assessed by 
correlating the reduced Mig-SCog scores to scores of the Cognitive Failures 
Questionnaire(188) – applied to 31 patients selected at random. This is a self-rated 
questionnaire that measures frequency of memory and cognitive failure behaviors in 
daily life, spanning the most frequent cognitive symptoms and domains(188). To assess 
test-retest reliability, the simplified 9-item self-administered questionnaire was applied 
within a 3 month interval to a random sample of 33 patients. The agreement for each 
item was tested by Cohen’s kappa and the correlation between total scores was tested 
with Spearman’s correlation coefficient. The simplified 9-item Mig-SCog was applied to 
a subsample of patients (n=33) who also rated themselves interictally, that is, referring 
to when they are not having an attack. Average scores were compared using the paired 
t-test.  
      Associations between patient variables and Mig-SCog socres were investigated with 
the Pearson’s correlation coefficient (continuous variables) or t-tests (binary variables). 
Using Ronald Fisher's classic z-transformation to normalize the distribution of Pearson's 
correlation coefficient (189), the sample size of this study has at least 80% power, with 
a 5% type-I error, to indentify an association between Mig-SCog scores and patient 
variables having a true correlation coefficient of 0.30 or more. 
      Statistical analysis was done with SPSS v16.5 (Statistical Product and Service 




      The preliminary study group consisted of 37 patients (28 females), of whom 12 had 
migraine with aura. The group had an age average of 36.4 years, mean disease duration 
of 16 years and an average MIDAS score of 16.4 on the previous 3 months. The majority 
of patients had 1-4 attacks monthly (67.6%), the attacks lasted less than 24h in 51.4% 
and were of moderate to severe intensity in 64.9%.On average, each patient described 
four frequent and 3.5 infrequent cognitive symptoms during migraine attacks.  These 
data were used to select the initial candidate items for the self-administered 
questionnaire.  
      The main study group consisted of 93 patients (86 females), 18 having migraine with 
aura. Age average was 39.2± 11.6 years (range 18 to 83 years), average years in school 
were 11.7 ± 5 years (range 2 to 22 years) and mean disease duration was 18.4± 11.2 
years (range 1 to 57 years). The majority of patients (53.8%) had 1-4 attacks monthly, 
most attacks lasting 4 to 24h (53.8%) and usually of moderate to severe intensity 
(98.9%). Sixty seven patients (72%) were currently doing migraine prophylactics. 
      Answers to the first open question generated on average 3.3 ± 1.6 cognitive 
symptoms by patient, ranging from 0 to 9. The number of cognitive symptoms reported 
was not shown to be associated with any of the patient variables studied.  
      Qualitative analysis of cognitive symptoms allowed its grouping in 21 items. These 
items were then analyzed and classified into cognitive and non cognitive symptoms. We 
observed that 37% of spontaneous complaints were not purely cognitive yet all were 
related to known attack-related symptoms that are recognized as able to interfere with 
global function during attacks. Non cognitive symptoms included humor/ anxiety 
changes (feelings of impatience, irritability, intolerance, sadness, despair, panic, lack of 
self-control, n= 47), specific symptoms related to avoidance behaviors during the attacks 
(visual, noise, movement and physical effort intolerance, n= 44) and eviction itself (need 
for isolation and to stay still, eviction of social contact, n=10) and global feelings of 
tiredness, exhaustion, dizziness, lack of balance or even  changes in appearance (n=13). 
      The most common reported symptoms were specific of cognitive domains (63%) and 
included attention (difficulty in thinking, decreased attention or concentration, mental 
confusion, trouble in studying, difficulty in performing mental calculation (n=84), 
planning (difficulties in routine chores such as cooking, domestic chores, working, 
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driving, in doing two tasks at a time, in resolving or organizing the day, n=29), lack of 
initiative (feeling impaired, “anesthetized”, diminished or blocked, “dumb”, decreased 
initiative, unable to take action, react or to decide, having trouble doing everything, 
n=25), language (difficulty in speaking, talking, understanding when being spoken to, 
writing, forgetting peoples and objects names, n=24), processing velocity (slowness of 
thinking, slowness when moving, needs more effort to do basic things, everything takes 
more time, more time to learn new information, n=20) and memory (lack of memory, 
empty mind, forgetfulness, forgetting to take pain killers, n=12). None of the patient 
variables was related neither to the number of spontaneous cognitive symptoms nor to 
the score of the 43-item questionnaire (p ns). Factor analysis with varimax rotation 
retained 4 factors explaining 70.6% of the observed variance and allowed item reduction 
to a 9-item questionnaire (tables 1&2). 
 
Table 1 - The Mig-SCog questionnaire (English Translation) 
During your Headaches, do you… 
…feel confused?  Often     Sometimes     No 
…have trouble performing tasks at your normal speed?              Often     Sometimes     No 
…have trouble following a route (driving or walking)?           Often     Sometimes     No 
…have trouble thinking?                                                                             Often     Sometimes     No 
…have trouble maintaining the tread of your thoughts?                 Often     Sometimes     No 
…have trouble in understanding when being spoke to?                 Often     Sometimes     No 
…have difficulty in organizing a sentence or a 
conversation?       
 Often     Sometimes     No 
…have trouble speaking out other people’s names?                         Often     Sometimes     No 
…have trouble in remembering the correct objects 
names?          
 Often     Sometimes     No 
 
      The reduced 9-item Mig-SCog had a completion time of around 1 minute. The average 
score was 8.63 ± 4.04, ranging from 0 to 18 (graphic 1). The score of the reduced 9-item 
the Mig-SCog was not influenced by gender (p=0.16), presence of aura symptoms 
(p=0.54), current migraine prophylaxis (p=0.43), age (p=0.63), disease duration 
(p=0.78), attack frequency (p=0.10), duration (p=0.44) and intensity (p=0.98), but was 
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associated with the total number of spontaneous cognitive complaints (p < 0.0001) and 
to lower literacy (p= 0.009). 
 





Factor 1 – Attention/ processing speed/ orientation 
… do you feel confused? 
… do you have trouble performing tasks at your normal speed? 
… do you have trouble following a route (by driving or walking)? 
22,2% 0.74 
Factor 2 – Language 
… do you have trouble in understanding when being spoke to? 
… do you have difficulties in organizing a sentence or a conversation? 
17,4% 0.70 
Factor 3 – Language – Naming 
… do you have trouble speaking out other people’s names? 
… do you have trouble in remembering the correct objects names? 
15,7% 0.79 
Factor 4 – Planning/ attention 
… do you have trouble maintaining the tread of your thoughts? 
… do you have trouble thinking? 
15,4% 0.74 
 
      The reduced 9-item Mig-SCog had a completion time of around 1 minute. The average 
score was 8.63 ± 4.04, ranging from 0 to 18 (graphic 1). The score of the reduced 9-item 
the Mig-SCog was not influenced by gender (p=0.16), presence of aura symptoms 
(p=0.54), current migraine prophylaxis (p=0.43), age (p=0.63), disease duration 
(p=0.78), attack frequency (p=0.10), duration (p=0.44) and intensity (p=0.98), but was 
associated with the total number of spontaneous cognitive complaints (p < 0.0001) and 
to lower literacy (p= 0.009). 
      Cronbach’s alpha of the reduced Mig-SCog was 0.82 (lower bound of the one-sided 
95% confidence interval ≥ 0.77). The median inter-item correlation coefficient was 0.34 
(range 0.05 to 0.56), the median item-test  was 0.68 (range 0.46 to 0.73) and the median 
item- -rest Cronbach’s alpha was 







Graphic 1 - Total score of the reduced 9-item Mig-SCog questionnaire 
 
      The median interdimension  was 0.49 (range 0.36 to 0.60). Dimension-total 
Cronbach’s alpha was 0.79 and correlation coefficients ranged from 0.71 to 0.84. The 
dimension-to-own alpha ranged from 0.70 to 0.79, and the correlation coefficients 
ranged from 0.50 to 0.70.   
      Construct validity of the reduced Mig-SCog scores was confirmed by the high 
correlations to the 43-item draft questionnaire scoring (Spearman’s  0.69, p<0.001) and 
to the total score of the Cognitive Failures Questionnaire (188) (Spearman’s  0.61, 
p<0.01).  
     Test-retest reliability of the 9-item the Mig-SCog revealed a highly significant (p 
<0.0001) Cohen’s kappa for each item, ranging from 0.58 to 0.76 (respectively 0.58 for 
items 1, 2 and 5, 0.62 for item 9, 0.66 for item 8, 0.71 for item 7, 0.74 for items 4 and 6 
and 0.76 for item 3). Cohen’s kappa for the 9-item Mig-SCog was 0.55 (p= 0.001) and 
Cronbach’s alpha ranged from 0.84 to 0.88, from first to second application of the 
questionnaire. Correlation of total scores in both applications was high (Spearman’s  
0.91, p <0.01) 
     A significant difference was shown between ictal versus interictal scores in the 




       Cognitive symptoms occur during migraine attacks and are often not reversed by 
effective pain treatment(158) nor contemplated as a valid end-point in acute treatment 
migraine trials (190). Cognitive symptoms during attacks contribute substantially to 
reduced ability to carry out activities(95) and therefore to migraine burden, yet no 
instrument exists to identify and quantify this type of symptoms. 
      The use of detailed neuropsychological testing during migraine attacks is not 
practical and currently available generalist testing instruments (191) are long, 
unspecific and unpractical for everyday clinical practice. Available subjective scales for 
cognitive symptoms are very often related to progressive neurological disorders and are 
developed to predict cognitive decline(192-196).   
      We aimed to develop an instrument that would be patient-centered and disease-
related. It also should be self-administered, of fast application, easily understandable, 
requiring a minimal literacy and cross-cultural. Although subjective, it should allow 
quantification and be versatile, being used either in relation to the usual headache 
pattern or to a specific migraine attack. 
      As no instrument as such existed previously, the main methodological difficulty of this 
study was item generation and selection. Item generation was clinical-based, relying on 
patients’ self-report of cognitive symptoms during migraine attacks, identified by open-
ended questions in a structured interview. Items generated were complemented by a 
panel of headache experts after relevant literature review (197). An extensive item list 
was then produced, to ensure that infrequent yet possibly relevant symptoms were 
contemplated. After analysis for language adequacy and item comprehension by a focus 
group, the extensive questionnaire was applied, yet still including an initial open-ended 
question, to ensure no relevant cognitive domain had been missed and to access 
construct validity. This effort to be as comprehensive as possible had the objective of not 
missing potentially relevant items to migraine. No effort was made to include cognitive 
symptoms that were infrequent in migraine nor to have the same representativity of 
each domain by defining the number of items allowed in each domain. It was expected 
that only a few cognitive domains would prevail, if the questionnaire was to be 
universally accepted by migraine patients. As it is a patient-based questionnaire, the 
domains identified were expected to most probably represent the main practical 
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cognitive difficulties present in everyday life chores and not necessarily the cognitive 
functions that were demonstrated to be impaired in cognitive testing during attacks (96, 
100, 102, 159).  
      Item reduction was first accessed by the ability of items to generate responses: Items 
with non-response rates of 10% or higher were eliminated. Exploratory factor analysis 
was used to identify conflicting or confounding items that could be attributed to several 
cognitive domains - these were systematically eliminated. The purpose was to obtain a 
clear and short questionnaire that would perform adequately on internal consistency, 
concurrent validity and test-retest reliability.  As the process went along, qualitative 
analysis of the spontaneous cognitive symptoms reinforced its construct validity. 
      The final 9-item Mig-SCog questionnaire is simple, reliable, and internally consistent 
and it has good temporal stability. Its performance is in line with an existing cognitive 
functions questionnaire(188), a good measure of everyday cognitive difficulties for 
young adulthood that has good correlation with laboratory evaluation (198).  Mig-SCog 
reflects only two cognitive domains – Executive functions (attention/ processing speed/ 
orientation / planning) and Language (naming and language), that are the most frequent 
spontaneous complaints of patients in everyday life and some the range of executive 
defects identified in objective testing of Migraine patients during attacks(96, 100, 102, 
159).  This is not the same as stating that these are the only symptoms expected to occur 
during migraine attacks, but that these are the most probable to be consistently reported 
by patients and, therefore, to be representative of their most troublesome cognitive 
symptoms. The Mig-SCog rating is significantly higher when patients refer to attacks 
compared to the interictal period, suggesting that cognitive symptoms during attacks are 
beyond everyday cognitive difficulties.   As an example, low processing speed and 
difficulties in planning may explain a common clinical observation that patients within a 
migraine attack are often unable to get around to take their acute medication, a fact that 
has important implications in efficacy of pain relief and attack impact (199, 200).  
      Our results show that the Mig-SCog questionnaire is a new working instrument that 
is versatile and may be applicable, in the future, both in clinical practice and in research 
settings, without significantly increasing patient evaluation time. Its scoring was only 
influenced by literacy, despite literacy had no influence on the number of spontaneous 
cognitive symptoms reported. This suggests that less literate individuals tend to overrate 
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the frequency of cognitive symptoms during attacks, probably because of a baseline 
lower cognitive performance(201, 202). 
      The Mig-SCog score was independent of any other clinical variable, leading to 
speculation that the expression of cognitive symptoms is attack-related and not disease-
related, much like the clinical expression of all other symptoms of a migraine attack. 
      It is recognized by the authors that more work needs to be done on validation of this 
instrument to other languages, such as English, and also to study its performance in 
cohorts of patients in different clinical settings and in other headache types. Limitations 
of this study are acknowledged, namely the possible effect of the recall bias, as the date 
of the last attack was not sought out. However, since neither the frequency nor the 
intensity of attacks was related to higher scoring on the Mig-SCog we think this bias is 
unlikely to be present. Another limitation is the absence of data regarding the type of 
migraine preventives used in this sample, as well as other relevant psychoactive drugs 
that could influence the occurrence of cognitive symptoms. The use of preventives was 
not related to any specific complaint nor scale item or total score of the Mig-SCog.    
       Sometimes the obvious needs to be stated (1) migraine acute therapy is not only 
about pain control. The ideal migraine drug must also contemplate non-pain related 
symptoms that contribute significantly to disability, so instruments that identify and 
quantify these symptoms are essential to improve migraine treatment strategies; (2) 
migraine related cognitive symptoms during attacks are real and disabling. Researchers 
need an instrument to evaluate the contribution of cognitive symptoms to impairment 
during attacks and physicians need a fast quantifiable report of cognitive symptoms by 
their patients, to redefine treatment strategies. Mig-SCog also offers patients an easy and 
quantifiable way of measuring ill-characterized, difficult to express, disabling symptoms 
to their attending physicians.  
      The Mig-SCog could be the first practical contribution to allow the valorization of 
cognitive symptoms of migraine patients during attacks. Hopefully, the importance and 
impact of these symptoms will be recognized in future guidelines of migraine trials, 
either as a valid endpoint of acute treatment efficacy (190) or as a part of the assessment 




Are cognitive complaints identified with the Mig-SCog specific for migraine?  
How reliable is the Mig-SCog? 
 
Clinical Utility of the Mig-SCog  
 
Gil-Gouveia R, Oliveira AG, Martins IP. Clinical Utility of the Mig-SCog.   
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ABSTRACT 
Background: Mig-SCog is a tool developed to quantify subjective cognitive complaints during 
migraine attacks. Yet, cognitive symptoms are frequent in everyday life, in non-headache pain 
and in non-migraine headache. 
Objective: To evaluate the Mig-SCog specificity for migraine-related cognitive impairment and 
the reliability of Mig-SCog scores obtained outside attacks.  
Methods: Mig-SCog scores were compared a) between migraine and tension-type headache 
(TTH) patients; b) in migraine patients between migraine attacks, non-headache pain and pain-
free status; c) in migraine patients during and outside a migraine attack.   
Results: Two-hundred and forty eight patients (51 TTH) were included; Migraine patients 
scored their attacks higher than TTH in the total Mig-SCog (8.0±4.1 versus 3.4±3.2, p<0.0001), 
with differences found in all scale items (p<0.0001) except those related to naming (8 and 9). 
The AUC of Mig-SCog score for the diagnosis of Migraine was 0.835 (95% CI of 0.763-0.906, p< 
0.0001). Migraine patients rated the Mig-SCog higher for migraine (7.9±4.6) than for non-
headache pain (2.3±2.9, p<0.0006) or pain free (1.6±2.4, p<0.0006). Scores regarding migraine 
attacks obtained during and outside an attack were similar (7.4±4.4 versus 6.9±4.0). 
Conclusions: Attack-related subjective cognitive symptoms, evaluated with the Mig-SCog, differ 
between migraine and TTH patients, particularly in items related to executive functions 
(processing speed and attention) and language (sentence production and understanding). The 
Mig-SCog applied to migraine patients produces higher scores related to migraine than to non-
headache pain or being pain free; patient scoring by memory for usual attacks is equivalent to 





The Mig-SCog(118) is a brief subjective assessment tool developed to identify and 
quantify subjective cognitive symptoms of migraine attacks. Attack-related cognitive 
dysfunction has been documented in executive, memory and language functions in most 
of the studies addressing reversible neuropsychological impairment during attacks (60, 
96, 98, 100, 102, 109, 159, 203).  These symptoms contribute to attack-related disability 
and may not be relieved by acute migraine medication (95, 158). In addition, cognitive 
dysfunction occurs as a side effect of some prophylactic migraine drugs(204), which  
may increase attack-related difficulties.  
 
The Mig-SCog was developed based on subjective cognitive complaints of 
migraine patients, and is a self-administered nine-item questionnaire (118). The 
instrument is directed to the main difficulties reported by patients during migraine 
attacks and has good psychometric properties (internal consistency reliability and test-
retest reliability) as demonstrated in a previous study(118). As it is fast and easy to 
apply, requiring only paper and pen, it is therefore a simple and inexpensive clinical 
instrument.  
The use of this instrument in daily clinical practice may help patient-doctor 
communication in the assessment of these symptoms. Particularly interesting aspects 
relate to treatment effectiveness or to restoring of normal function after an attack(95). 
Work productivity is perceived to be around 54% impaired during a migraine attack(92) 
and part of this self-perceived impairment could be related to cognitive dysfunction. 
However, cognitive symptoms are quite common, even in the younger population, and 
are generally associated with stress or sleeping disorders (142, 205). Therefore, an 
important property of this tool would be its ability to distinguish common cognitive 
symptoms that had been aggravated by a superimposed migraine attack, from migraine-
related subjective cognitive symptoms. 
The aim of this study was to further evaluate the Mig-SCog regarding aspects that 
relate directly to the usefulness of its clinical application. Specifically, we wanted to get 
answers to three questions: 1) does the Mig-SCog score cognitive symptoms differently 
in migraine patients and in tension-type headache patients?; 2) do migraine patients 
 
 102 
score the Mig-SCog differently between migraine attacks, pain-free periods and non-
headache pain situations? 3) does the Mig-SCog measure migraine-related cognitive 
difficulties only when administered during an attack, or is it reliable to score it during 
pain-free periods? 
In order to answer these questions, we designed a study comprising the following 
evaluations: 1) comparison of Mig-SCog scores between patients with migraine and with 
tension-type headache; 2) comparison of Mig-SCog scores when migraine patients 
referred to three different situations - a typical migraine attack, a non-headache painful 
situation (e.g. menstrual or low back pain) and a pain-free period.); 3) comparison of 
Mig-SCog scores, in a different sample of migraine patients, when scoring occurred 
during an actual migraine attack and when scoring was done outside an attack. 
 
SUBJECTS and METHODS 
 Population  
 Participants were recruited consecutively on a Headache Outpatient Clinic, both 
from first or from follow-up visits, and invited to participate.  Inclusion criteria were: a) 
age between 16 and 65 years; b) minimum of  four years of education ; c) minimum 
headache frequency of one monthly attack in the 3 months preceding inclusion; d) 
written informed consent of adult patients or their legal guardians in the case of patients 
aged 16 and 17; e) having a single headache diagnosis, either definite episodic migraine 
with or without aura or episodic or chronic tension-type headache, according to ICDH-
III(186); f) for the part of the study comparing Mig-SCog’ scores during with in-between 
migraine attacks, living or working within or nearby the study center was required (to 
improve accessibility). 
 Exclusion criteria were the simultaneous presence of migraine (either with or 
without aura) and tension-type headache, or the additional presence of any other 
headache type, including chronic migraine with or without medication overuse as well 
as the presence of systemic or psychiatric diseases with potential influence of cognition. 
History of substance abuse and current medications with potential influence on 
cognition other than migraine prophylactics was also an exclusion criteria. The study 
protocol was approved by the Hospital’s Institutional Review Board. 
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 Study design  
Recruitment and inclusion were carried out by a headache specialist (R.G.G.) at a 
regular clinic visit, who verified the study eligibility criteria and carried out a standard 
clinical evaluation. Patients were asked to complete the Mig-SCog(118) at the end of the 
appointment and to return it immediately to the doctor or the secretary. Data collected 
from the Mig-SCog included answers to nine items, presented as graded scores (0: 
absence of the symptom; 1: the symptom occurring sometimes during headache attacks; 
2: the symptom occurring often during headache attacks. The items relate to two 
cognitive domains: executive function (items 1, 2 and 3 directed to symptoms of 
decreased attention, processing speed and orientation, and items 4 and 5 relating to 
planning and attention) and language (items 6 and 7 relating to comprehension and 
speech production, and items 8 and 9 to naming abilities). Total Mig-SCog score is 
computed by adding up the scores of the nine scale items.   
According to the diagnosis and headache status, patients were asked to 
participate in one of three evaluations: 
1 - Discrimination of cognitive difficulty between migraine and tension-type headache: 
This part of the study included patients with a history of migraine and patients with a 
history of tension-type headache, using the ICDH-III(13) diagnosis as the gold standard.  
2. Discrimination of cognitive difficulties during migraine attacks from non-headache 
pain and from pain-free periods: This part of the study included migraine patients, who 
were asked to complete three Mig-SCog scales, each one with a different header: “During 
your headaches…”, “During a non-headache pain (such as low-back pain or menstrual 
pain)….” and “When you are pain free…“. . Therefore, patients would score the 
instrument by referring to their baseline pain-free status, to their usual migraine attacks 
and to a non-headache pain.   
3. Comparing the Mig-SCog scored during and outside an attack: This part of the study 
included migraine patients that were asked to score the Mig-SCog twice, once during a 
migraine attack and other in a headache free period. The Mig-SCog headers differed in 
the two situations: when applied during the attack it read “In this moment…” and when 
applied in the headache-free status it read instead of “During your headaches…” 
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Additional attack information was also collected, such as current pain intensity and 
duration of headache since its onset. Some patients were recruited on a headache day, in 
an emergency visit at the clinic, while others were recruited on a headache free day, and 
these were asked to return specifically on a headache day. In both groups, if acute 
treatment had been used in the 8 hours previous to the evaluation, the patient was 
excluded. Interval between evaluations could not be less than one month in order to 




Descriptive statistics are presented as absolute and frequencies or mean ± standard 
deviation. Patient characteristics were compared between groups with Student’s t-tests 
and chi-square tests as appropriate.  
In the study comparing migraine and TTH patients a ROC curve was plotted and the area 
under the curve (AUC), or c-statistic, determined. Each item of the Mig-SCog was recoded 
as binary variable (0 indicating absence of the symptom and 1 indicating presence of the 
symptom, whatever its frequency during the attacks) so that the sensitivity, specificity, 
positive and negative predictive values and likelihood ratio of each questionnaire item 
could be computed.  
In study comparing migraine patients’ Mig-SCog scores referred to three different 
situations, the normality of the Mig-SCog scores was tested using the Shapiro-Wilk test. 
As normality could not be assumed, the non-parametric Friedman test was used to 
compare total Mig-SCog scores and individual item scores between the three different 
situations within each subject. Differences between migraine and the two other 
situations were tested with the sign test, adjusting  p-values for multiplicity using the 
Bonferroni correction(206).  
In the study where migraine patients were asked to score the Mig-SCog outside and 
within an attack, scores were compared using the sign test. To evaluate test reliability 
the Intraclass Correlation Coefficient was calculated for the total score and for each item. 
Statistical analyses used SPSS v20. All statistical tests are two-sided and significance level 




1– Discrimination of Migraine and Tension-type headache  
One patient was excluded for not completing all of the Mig-SCog. The total study 
population of this part of the study consisted of 149 subjects: 98 with migraine (13 with 
aura) and 51 with tension-type headache (23 frequent episodic, 28 chronic). There were 
126 females (84.6%), eight left-handed, the average age was 32.6 ± 8.7 years (range 18 
to 65 years) and the number of years of education was 14.7± 1.7 (range 9 to 20 years). 
Forty patients (27%) were on prophylactic headache treatment with amitriptyline (8), 
topiramate (18), propranolol (9), valproic acid (4) and lamotrigine (1).  
The characteristics of migraine and tension-type headache patients are shown on 
table 1.  
 







Sample Size (N) 98 51 --- 
Females 90(91.8%) 36 (70.6%) 0.001 
Education (years) 15.0 ± 1.5 14.1 ± 2.0 0.005 
Age at inclusion (years) 31.4 ± 7.5 34.9 ± 10.2 0.070 
Disease duration (years) 15.4 ± 9.3 8.2 ± 10.0 <0.0001 
Medical Comorbidities 30 (30.6%) 24 (47.1%) 0.052 
Prophylactic treatments 37 (37.8%) 3 (5.9%) <0.0001 
Diagnosis  
-  Migraine (with/without aura) 






28 (45.1/54.9%)  
--- 
 
Migraine patients were more often females and their literacy was slightly higher 
literacy (one year, on average) than tension type headache patients; migraine patients 
also had longer disease duration and higher rates of prophylactic treatment.  Headache 










Type H. p*-value 
Frequency (episodes/ month) 5.3 ± 5.0 16.7 ± 11.4 <0.0001 
Attack duration (average in hours) 47.4 ± 32.2 15.6 ± 24.5 <0.0001 
Intensity (Severe) 52 (53.1%) 2(3.9%) <0.0001 
Unilateral pain 54 (55.1%) 8 (15.7%) <0.0001 
Maximum pain location  
- Trigeminal 
- Posterior 
- Hemi/ holocrania 
 
80 (81.6%) 
7 (7.1%)  
11 (11.2%) 
 
27 (52.9%)  





Quality  (Throbbing) 79 (80.6%) 1 (2.0%) <0.0001 
Associated symptoms 
     - Nausea  
    - Vomiting  
    - Photophobia  
    - Phonophobia    
    - Kinesophobia  
   - Worsening with physical effort  


























Average Mig-SCog total score in this population was 6.4 ± 4.4, ranging from 0 to 18; 
migraine patients had a significant higher average score (8.0 ± 4.1) than tension-type 
headache patients (3.4 ± 3.2, p<0.0001). Comparative analysis of mean scores in each 
item of the Mig-SCog is depicted in Figure 1.  
 
Figure 1 – Comparative analysis of Mig-SCog in each diagnosis, per item (sub-study 1) 
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Legend: Gray bars: Migraine, White bars: Tension-type headache ; Values within bars represent Mean Item 
Scores; 
                  ** Difference between Tension-Type Headache and Migraine is significant p<0.0001 
 
      Differences between migraine and tension-type headache are significant 
(p<0.0001) in items 1 to 7 but not in items 8 and 9 (having trouble in speaking other 
people’s names and having trouble recalling the correct name of objects). The 
difference in Mig-SCOg scores between migraine and TTH patients was maintained at 
the p<0.0001 level after adjustment with multiple regression by gender, age, literacy, 
disease duration, presence of other medical conditions, current medication and current 
prophylactic medication. 
The ROC Curve for the total Mig-SCog score is depicted in Figure 2; the area under 
the ROC curve (AUC) is 0.835 (95% confidence interval 0.763 to 0.906, p< 0.0001). The 
sensitivity, specificity, positive and negative predictive values and the likelihood ratio 
of each of the items of the Mig-SCog is shown in table 3. 
 




















Mig-SCog Items     
















































Item 5  




























































Legend: PPV – Positive Predictive Value; NPV – Negative Predictive Value;   
 
2. Comparison of Migraine with Non-Headache pain and Pain-Free  
Sixty-seven patients were included in this part of the study, 4 (6 %) were excluded 
(1 with chronic migraine, 3 with concomitant tension-type headache). The final 
population of 63 migraine patients included two left-handed individuals, 8 males 
(12.7%) and 6 (9.5%) patients with aura. The average age was 36.9 ± 10.5 years (range 
16 to 60 years) with 15.4± 4.0 years of literacy (range 6 to 23 years).  
The average attack frequency was 5.5±5.4 attacks monthly, lasting on average 29.8 ± 
25.8 hours, the vast majority being of moderate (73%) to severe(23.8%) intensity. 
Twenty-one participants (33.3%) were receiving migraine prophylactics, either 
propranolol (7), valproic acid (5), amitriptyline (2), topiramate (2) and 5 were taking 
combined prophylaxis (valproic acid with amitriptyline 2, topiramate with propranolol 
2 and topiramate with amitriptyline 1). This population had an average HIT-6 score of 
60.8 ± 7.2 (range 43 to 76).   
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The average Mig-SCog total score for migraine pain was 7.9 ± 4.6 (range 0 to 18), 
for non-headache pain was 2.3 ± 2.9 (range 0 to 16) and for the pain free status was 1.6 
± 2.4 (range 0 to 10).  
 
Figure 3 – Mig-SCog total score for Migraine, Non-headache pain and Pain-free 
 
Legend: vertical line within boxes represents the median; boxes represent the 25th and 75th percentile and 
T-lines the minimum and maximum values; * Difference between Migraine and Non-Headache pain is 
significant   (p<0.0003);  ** Difference between Migraine and Pain Free is significant (p<0.0003) 
 
 
Average scores of Mig-SCog differed between situations (p< 0.0001 by the 
Friedman test). The Friedman test for each of the Mig-SCog items showed similar 
results, documenting that median scores in each item differed between migraine, non-
migraine pain and pain free (p<0.0001).  
Post-hoc comparison of means with multiplicity-adjusted p-values showed that the 
average Mig-SCog score was higher for migraine, compared to the pain-free status 
(p<0.0006) and to the non-headache pain (p<0.0006). (Figure 3).  
All items presented had higher scores for migraine compared to the pain free status 




Table 4 – Pairwise comparison of Mig-SCog scores in Migraine, Non-headache pain and 
Pain free 
 Migraine 
(Av ± sd) 
Non-Headache 
Pain (Av ± sd) 
Headache 
Free (Av ± sd) 
Item 1 (confused) 0.78*;** ± 0.755 0.13 ± 0.423 0.15 ± 0.359 
Item 2  (speed) 1.43*;**  ± 0.633 0.81† ± 0.500 0.15 ± 0.399 
Item 3  (route) 0.85*;** ± 0.723 0.39† ± 0.576 0.12 ± 0.370 
Item4  (thinking) 1.25*;** ± 0.659 0.24 ± 0.495 0.24 ± 0.464 
Item 5 (thread of thoughts) 1.21*;** ± 0.708 0.22 ± 0.487 0.27 ± 0.510 
Item 6 (understand) 0.58*;** ± 0.762 0.10 ± 0.354 0.07 ± 0.265 
Item 7(organizing sentences) 0.76*;**± 0.761 0.16 ± 0.447 0.18 ± 0.386 
Item 8 (naming people) 0.36*;** ± 0.569 0.15 ± 0.359 0.21 ± 0.478 
Item 9 (naming objects) 0.43*;** ± 0.609 0.18 ±0.386 0.22 ±0.487 
Mig-SCog Total Score 7.66*;** ± 4.574 2.39 ± 2.954 1.61 ± 2.316 
Legend:  *Scores were higher for Migraine compared to Non-headache pain (p<0.0003); **Scores were 
higher for Migraine compared to Headache free (p<0.0003); 
 
3. Comparison of Migraine during and in-between attacks  
Fifty four patients were included in this part of the study. Sixteen patients (29.6%) 
were excluded because they completed only one of the evaluations, two patients failed 
to complete the baseline evaluation, while the other 14 failed to return for evaluation 
during an attack. The total study population consisted of 38 patients (1 male, 2.6%), all 
right-handed, 4 having migraine with aura (10.5%). The average age was 37.1 ± 10.1 
years (range 21 to 63 years) with 13.8± 4.8 years of education (range 4 to 22 years).  
Nineteen patients (50%) had 1-4 attacks monthly, most lasting 4 to 24h (47.4%) and 
of moderate to severe intensity (100%). Seven participants(18.4%) were receiving 
migraine prophylactics (amitriptyline 2, topiramate 2, propranolol 2 and 1 on 
propranolol and amitriptyline). The average HIT-6 score was 62.9 ± 6.2 (range 45 to 76).  
The index attack had an average duration of 11.4 ± 14.0 hours (range 30 minutes to 67.8 
hours) at the time of the evaluation and mean attack intensity was 6.2 ± 1.7 (range 3 to 
10) on a visual analogue scale (VAS). Average elapsed time between baseline and attack 
evaluation was 126.9 ± 104.1 days (range 26 to 418 days) – an average of about 4 
months.  
Average Mig-SCog total score in the baseline evaluation was 7.4 ± 4.3, range 1 to 18, 
and in the attack evaluation was 6.8 ± 4.1, range 0 to 17 (p= 0.26 by the sign test). 
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Comparison of median scores of each of the Mig-SCog items between attack and 
baseline also failed to reveal statistical differences. 
The intraclass correlation coefficient (ICC) for the average Mig-SCog score was 
0.805 (p<0.0001). The ICCs for each item were 0.631 (item 1, p=0.002), 0.627 (item 2, 
p=0.002), 0.657 (item 3, p=0.001), 0.769 (item 4, p<0.0001), 0.518 (item 5, p=0.015), 
0.735 (item 6, p<0.0001), 0.664 (item 7, p=0.001), 0.623 (item 8, p=0.002) and 0.659 
(item 9, p=0.001).  
 
DISCUSSION 
The Mig-SCog is a questionnaire developed to evaluate subjective cognitive 
dysfunction related to migraine that is self-rated and extremely short, which makes it 
usable in routine clinical practice. This study has demonstrated that the impact of 
subjective cognitive symptoms occurring in migraine and tension-type headache is not 
the same - migraine patients have higher total scores using this instrument than do 
tension-type headache patients. Not all of the 9 items of the Mig-SCog showed differences 
between the two diagnosis– items related to naming (items 8 and 9) were similar, 
suggesting that naming difficulties happen nearly as often in migraine as in tension-type 
headache patients. These items also had the lowest average scores of all items (below 
0.5 in both diagnosis) implying a small impact of this symptoms, irrespective of headache 
diagnosis. This is in accordance with the fact that language abilities are relatively 
resistant to brain dysfunction. The two other language items (6 and 7) of the Mig-SCog 
also presented lower scores both in migraine and tension-type headache patients than 
did items related to executive functioning (1 to 5) yet with an identifiable difference 
between diagnosis.  
Migraine patients evaluating their difficulties during non-headache pain or in 
their pain-free status using the Mig-SCog also scored items 8 and 9 (naming) lower than 
all other items but still higher than when with non-headache pain or being pain free, 
reinforcing that these complaints occur more often during migraine but its expression is 
not as strong as that of the remaining items of the Mig-SCog. Subjective language 
complaints are less frequent than memory complaints in the general population, and less 
often related to age; within language complaints, word finding difficulties seem to be 
much more frequent than proper name retrieval(207), which can explain why naming 
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were the items with lowest scores. Nevertheless, subjective language complaints bear 
some correlation to mild impairment in objective testing not only of language, but also 
of learning and attention (207).   
The executive items had the highest differences between patients with the 
diagnosis of migraine and tension-type headache, especially items 2 (performing tasks 
at the normal speed), 3 (difficulty following a route), 4 (difficulty thinking) and 5 (trouble 
maintaining the tread of your thoughts). All these items also had presented higher scores 
when comparing the migraine status to non-headache pain or being pain free. An 
interesting observation of this study was that in migraine patients, items 2 and 3 scores 
were different between non-headache pain and pain free status- Based on this 
observation we can speculate that speed and attention difficulties may relate to pain by 
itself(208), therefore possibly unspecific for migraine, although our study design does 
not allow the verification of this hypothesis. Conversely, item 2 had the highest scores in 
migraine, tension-type headache and non-headache pain but not in pain free status, 
which can lead to the speculation of being related to pain.  
Bearing in mind that subjective cognitive complaints are found to correlate with 
objective deficits in neuropsychological tests in the general population (207, 209), these 
findings corroborate previous documentation of reversible pre-frontal and executive 
difficulties during migraine attacks (60, 96, 98, 100, 102, 109, 159). Several executive 
measurements - such as trail B and Wisconsin(59), alternate finger tapping (210), visual-
spatial SWITCH task(203) and in the Boston Scanning Test and Controlled Oral Word 
Association Test (but not in Trail B) (211) – documented a decline in migraineurs 
compared to controls. The differences were related to length and severity of the 
disease(59), to a reduced middle frontal gyrus GM density(203) but not to the presence 
of white matter lesions on MRI(211), suggesting a reversible cortical involvement during 
migraine without aura attacks. The migraine attack has also been shown to negatively 
influence memory tests, namely in visual memory (60, 96, 97), verbal memory and 
learning (100, 109), that could be related to an increase of baseline hyperexcitability of 
the anterior temporal pole during the migraine attack, as documented by fMRI(152). 
A negative influence on attention tasks, with lower accuracy and speed of 
performance can also occur during tension-type headache attacks, that were irrespective 
of task complexity or task-specific mechanisms and unrelated to pain intensity(208). 
 
 113 
Kuhajda showed that having an headache (migraine or tension-type) during a 
recognition task interferes with its performance while having headache during an 
encoding task does not interfere with performance but with speed of performance, 
suggesting again an attention deficit (99). The effect of experimental pain in healthy 
adults’ attention processes has also been demonstrated, especially in those aspects most 
essential for performance on complex tasks(212). A wide range of chronic pain disorders 
has been studied for evidence of cognitive dysfunction and consistent findings include 
deficits in attention (especially on attention switching and attentional interference), 
slower reaction times, increase impulsivity and difficulties in complex executive tasks, 
impairments that do not seem to follow a disease-specific pattern(89). The cognitive 
impairment associated with pain may have neuroanatomical grounding as structures of 
the “pain matrix”, such as the prefrontal cortex (PFC) and the anterior cingulate cortex 
(ACC), are also crucial cognitive relay stations, especially for executive functioning. There 
are also neurochemical substrates, as several neurotransmitter systems are commonly 
involved in both pain processing and cognition(89).  
In the third part of our study we demonstrated that answers to the Mig-SCog are 
reliable, as scores within the attack reproduced those given while pain free and report 
to the patients’ usual attacks. This implies that even within a given time difference when 
reporting, patients are still able to report impairment occurring during their attack 
accurately. This does not imply that Mig-SCog is a reliable score for real-time subjective 
cognitive symptoms intensity of any given attack, as we did not test this aspect of the 
scale.  
The major limitation of the first part of our study was the population differences 
between the migraine and TTH groups – the migraine group had higher proportion of 
females, were slightly younger (3.5 years) and had a slightly higher literacy (almost 1 
year), age and literacy being known to influence cognitive performance and probably 
awareness of cognitive difficulties. Disease duration was higher in the migraine group 
(by 7 years) and migraine patients were on headache prophylactics more often than 
tension-type headache patients, treatments that can also influence perception of 
cognitive status. Nevertheless regression analysis failed to identify any co-variable that 
had influence on Mig-SCog score difference between diagnoses, including gender, age, 
literacy, and disease duration, presence of other medical conditions, current 
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medication and current prophylactic medication. The use of topiramate was noted in 
18% of migraineurs in this study. Complaints of cognitive dysfunction with topiramate 
in healthy individuals (213) and migraine patients (145) were corroborated by a 
documented decrease in attention, memory and psychomotor speed in previous 
studies. This could be an important bias in our sample, but regression analysis failed to 
relate the use of topiramate to a higher score in Mig-SCog. Possible explanations 
include a coincidental low incidence of cognitive effects in the current sample, a 
dilution of these changes with effects of other treatment with more subtle influence on 
cognition (as other anti-epileptic drugs) or a resistance of this scale to cognitive 
complaints related to topiramate use. This study was not designed nor powered to 
clarify this issue. Due to the inclusion of highly educated individuals, our results cannot 
be extrapolated to lower literacy levels. 
 
The Mig-SCog total score had an AUC of 0.835 for the diagnosis of Migraine, which 
corroborated its specificity for Migraine, when compared to tension-type headache. 
None of the items of the Mig-SCog taken individually had a high power of prediction for 
the diagnosis of migraine. It is important to bear in mind that this instrument was not 
built as a diagnostic tool, so the performance analysis calculated in this study had the 
sole aim of confirming the utility of the Mig-SCog for migraine patients. 
In conclusion, Mig-SCog is a fast, inexpensive and easy to apply instrument that is 
able to quantify subjective cognitive symptoms specific for migraine in a consistent way 
even when reporting attacks occurring in the past, and could be useful as a clinical aid to 
establish attack-related disability assessment, may be of help in migraine diagnosis and 
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OBJECTIVE COGNITIVE DYSFUNCTION DURING MIGRAINE 
ATTACKS 
CHAPTER FOREWORD 
In this chapter the interest is focused on the documentation of objective cognitive 
dysfunction during migraine attacks, to substantiate patients’ perceptions of cognitive 
difficulties.  
 
Neuropsychological tests are clinical and research tools that provide standardized 
measurements of cognitive performance, being widely available and applicable with 
minimum resources. A systematic review of the medical literature was first ensued, 
searching for evidence of attack-related cognitive impairment in migraine, defined as a 
decline in neuropsychological testing during a migraine attack, compared to headache-
free performance. Data obtained had little consistency, probably a result of different 
study methodologies, small sample sizes, different neuropsychological batteries and the 
presence of bias. Nevertheless, most of the studies were positive demonstrating an 
attack-related impairment, probably due to executive dysfunction. 
 
A prospective two-period randomized crossover study was designed trying to improve 
the knowledge gap on this topic. The study design and inclusion criteria had the objective 
of minimizing bias, the battery used was extensive and detailed and the included sample 
size was adequate. Despite having had a high attrition rate that limited the statistical 
power, results were still consistent with the existence of reversible cognitive dysfunction 
during attacks, especially in reading and processing speed, verbal memory and learning.  
 
Having an objective measure of the impact of cognitive dysfunction during attacks is 
relevant for clinical practice and essential in clinical trials of acute attack treatment, yet 
an extensive battery of neuropsychological tests is time consuming and therefore not 
adequate nor practical. A shorter battery was assembled, focusing on executive and 
language domains, to those purposes. The performance on this battery was tested in 
interictal migraine patients and controls and in repeated applications, to identify the 
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predictable score intervals for which a change in test scores in repeated applications 
could be judged clinically meaningful. 
Cognitive performance can also be studied by functional brain imaging, which relies on 
the identification of blood flow changes in certain contexts.  Cortical perfusion changes 
are well documented in the aura phase of migraine with aura attacks, a clinical 
phenomenon though to be related to an intense self-propagating wave of cortical 
(neuronal and glial) depolarization followed by a longer lasting wave of neuronal 
inhibition. The headache phase of migraine often follows the aura yet cortical perfusion 
abnormalities occurring during the headache phase or in migraine without aura are 
inconsistent in the few studies published with different techniques; if present during the 
headache those changes reflecting cortical hypometabolism could relate to cognitive 
symptoms occurrence.  
 
Arterial spin labeling magnetic resonance imaging (ASL-MRI), a non-invasive and 
accurate study of brain perfusion that is sensitive to changes in the capillary level, was 
used for the first time to scan migraine patients during a spontaneous occurring 
untreated migraine without aura attack and again in the headache-free status. Global and 
regional cortical perfusion was found to be identical in both situations reflecting that 
cortical metabolic changes, if present during attacks, fall whitin the range of 
physiological variation. 
 
Nevertheless, brain normal responses could be disrupted by the migraine attack as some 
brain areas (particularly the anterior cingulate and the frontopolar cortex) which are 
effective centers of executive function are recruited and active during migraine 
attacks(29, 53, 153, 214, 215). To test this hypothesis, evoked brain activation using a 
working memory paradigm (the N-Back) was studied using blood-oxygen level 
dependent functional magnetic resonance imaging (BOLD-fMRI) in migraine patients 
during a spontaneous occurring untreated migraine without aura attack and again in the 
headache-free status. In this study, the migraine attack was not associated with any 
difference in brain activation patterns or areas, compared to the headache free status so 
it was not possible to identify the brain processes underlying patients’ symptoms. 
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What is the evidence of cognitive dysfunction occurrence during migraine attacks? 
Assessment of cognitive dysfunction during migraine attacks:  
A systematic review. 
 
Gil-Gouveia R, Oliveira AG, Martins IP. 
 Assessment of cognitive disorders during migraine attacks: A systematic review. 
 Journal of Neurology 2015 Mar;262(3):654-65.   Impact Factor: 3.84 
 
ABSTRACT 
Background: Patients consistently report cognitive impairment during migraine attacks, yet the 
documentation of such dysfunction by neuropsychological evaluation has lacked similar 
consistency. This incongruence may be due discrepant study designs, assessment tools and small 
samples sizes.  
Objective: To search for evidence of decline in cognitive functions during a migraine attack, 
compared to headache-free performance. The secondary objective was to determine if the 
eventual decline had a consistent neuropsychological pattern. 
Methods:  Systematic review of the medical literature using PubMed and Cochrane library 
databases without limitations or restrictions from inception to March 2014, using the search 
terms “migraine”, “cognition”, “neuropsychological”. We included studies in episodic migraine 
that had a neuropsychological evaluation performed during an attack. 
Results:  From 1023 titles screened, a total of 10 articles met criteria for inclusion and were fully 
reviewed. Only five of these studies, comprising a total of 163 individuals, had enough data to 
allow an appraisal of the study question. All five studies were positive in documenting some type 
of reversible cognitive impairment during the migraine attack. The pattern of cognitive 
impairment most often documented was of executive dysfunction, but the presence of bias 
induced by the choice of tests and of small samples prevents this finding from being conclusive. 
Discussion:  This review supports the existence of reversible cognitive dysfunction during the 
migraine attack, corroborating patients’ subjective descriptions. Further work is needed to 
establish the pattern of cognitive dysfunction, their underling pathophysiological mechanisms 





     Cognitive symptoms during migraine attacks were first reported by the roman Aulus 
Cornelius Celsus (25–50 A.D.) as “alienation of the mind” occurring “in addition to 
intolerable pain …. blurred vision, vomiting…”(9). More detailed descriptions of subjective 
cognitive symptoms occurring during migraine attacks are available since 1873, by 
Edward Liveing(11), such as ”...impairment of memory and in confusion and 
incoordination of ideas..”, “.. confusion of thought..”, “…unable to collect his thoughts…”, 
“…feeling silly…”, “…losing their senses…”.  An inventory of such symptoms has been 
detailed in diary studies of migraine premonitory symptoms in clinical samples of 
migraineurs (22-25, 27, 121), although most of these studies failed to evaluate the 
persistence of these symptoms into the headache phase. Subjective cognitive symptoms 
are also included in questionnaires of migraine-related disability assessment or of 
treatment outcomes(95, 133, 136, 156). A specific subjective scale has been developed 
for evaluating and quantifying the presence of subjective cognitive dysfunction during 
the migraine attack(118).  Due to the consistency of these subjective reports, the most 
likely pattern of neuropsychological impairment during migraine attacks would relate to 
the cognitive domains of executive functioning, language and multidomain requiring 
complex tasks (22-25, 27, 118, 121) and it is very likely that these cognitive difficulties 
contribute to migraine related disability (95, 133, 136, 156). Reversible 
neuropsychological impairment could be related to changes in brain function during 
migraine attacks, as ictal changes have been documented in functional neuroimaging 
studies involving the cortical structural such as the cingulated cortex, insula, prefrontal 
cortex and temporal lobe(101).  
      The suspicion of a possible increased risk of long-term or progressive cognitive 
decline in migraine patients was based on these subjective cognitive complaints, taken 
together with the evidence of increased prevalence of silent brain lesions in 
migraine(216). Large reviews of several cross-sectional studies and of large prospective 
epidemiological studies evaluating cognitive performance of migraine patients outside 
attacks failed to document any relevant interictal cognitive dysfunction of otherwise 
healthy migraine patients(105), as well as of any association between migraine and 
progressive cognitive decline(217). 
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      Despite abundant evidence of the occurrence of subjective cognitive difficulties 
during the attack, objective data supporting ictal or attack-related cognitive dysfunction 
is scarce, heterogeneous and difficult to analyze due to small sample sizes and to 
different study designs. 
      In the present study we aimed to perform a systematic literature review with the aim 
of identifying and summarizing existing information on ictal cognitive functioning (i.e., 
during the migraine attack) measured by formal neuropsychological testing. Specifically, 
our questions were: Is there evidence of decrease in any cognitive function during a 
migraine attack, when compared to headache-free performance? If so, is there any 
cognitive domain or neuropsychological pattern that is consistently found, in the context 




      Potentially eligible studies were identified through electronic databases search of 
Medline (through PubMed) and the Cochrane Library from inception to March 2014. We 
did not include any limitations nor restrictions. The search used the free text terms 
“migraine” AND “cognition”, “migraine” AND “neuropsychological”. The thesaurus terms 
used in these searches were "Headache" OR "Headache Disorders" OR "Migraine 
Disorders" OR "Migraine with Aura" AND "Cognition" OR "Cognition Disorders” AND 
“Neuropsychological”. 
Study Selection and Data Collection 
       Titles and abstracts were screened for relevance, studies were included if they 
referred to cognitive evaluation in headache disorders. Studies were then excluded if 
they reported (1) cognitive evaluation on other headache types than episodic migraine  
(including hemiplegic migraine, chronic migraine, medication overuse, post-traumatic 
headache); (2) cognitive effects of treatments used in migraine patients; (3) if they had 
cognitive endpoints unrelated to neuropsychological assessment; (4) if they failed to 
evaluate migraine patients during the pain or post-ictal phase of a migraine attack; (5) if 
the cognitive evaluation was performed during the aura phase of the attack; or if (6) 
reported on individual cases, were letters or comments. References of relevant papers 
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and references of reviews were also screened with the same criteria and selected papers 
were retrieved and evaluated thought the same process. Any disagreements were 
resolved by consensus. 
Data extraction and analysis 
      A table was constructed to summarize relevant results from the studies selected. 
Study designs, objectives and outcome measurements were discrepant and not 
amenable to quantitative analysis. Data was classified and analyzed qualitatively. Ethics 




     The study flow is depicted in figure 1. A total of 10 papers met the eligibility criteria 
for review and their characteristics are depicted in table 1; one of these papers was an 
abstract from a poster presentation(100). One of the included papers had also an 
abstract from a poster presentation with data from the same sample, that was excluded 
due to duplicate data(60, 102).  
 
      The objectives, and therefore designs, of the studies were different – three studies 
analyzed therapeutic interventions and used cognitive evaluation as a therapeutic 
endpoint (96, 97, 102) and all of these were positive in documenting a cognitive decline 
during the migraine attack, when compared to headache-free evaluations, with recovery 
of cognitive performance after the therapeutic intervention (sumatriptan in three 
studies, sumatriptan with naproxen in one study). Two of these studies were 
uncontrolled open label studies (60, 96, 102); the remaining study, by Edwards(97), was 
a double-blind, placebo controlled study that failed to establish differences of the active 










Selected for title review
N=1023






Excluded total = 14
-Neuropsycological evaluation of 
migraine patients in the headache free 
interval, N = 11
- Main outcome not related to 
neuropsychological evaluation = 1 
- Evaluating chronic migraine, N=1
- Duplicate data (abstract), N=1
New titles resulting of search of 
relevant references in all 
screened articles
N = 5
Excluded total = 208
- Other headaches , hemiplegic migraine or aura = 31
-Cognitive changes related to headache treatments =  
21
- Long term cognitive changes related to migraine = 27
- Neuropsycological evaluation of migraine patients in 
the headache free interval = 39
- Non-neuropsychological outcomes = 37
- Comments, Case reports, Descriptive studies = 14 
- Reviews = 17
- Duplicated References = 20
-Not found = 2


















comparison of cognitive 
function of migraine 
patients (N=30) in 
headache-free status with 
onset of migraine, prior to 
treatment and 1 and 2 hours 
after treatment 
(sumatriptan-naproxen) 
Mental Efficiency Workload 
Test (MEWT)  
(computerized test with 4 
subtests): 
(1) simple reaction time 
(SRT); (2) procedural reaction 
time (PRT); (3) matching to 
sample (M2S); (4) pursuit 
tracking (PT) 
. Decline in all tests in 
untreated migraine 
compared to baseline 
. Study drug improved 






study of cognitive 
performance of migraine 
patients (N=16) and 
matched controls (N=18) in 
the first headache morning 
after an attack and 1 and 12 
days after the first 
evaluation. 
Three Computerized Tests:  
(1) Perceptual organization 
(global-local) task; 
(2) Attentional Network Task 
(ANT);  
(3) N-back task 
. No cognitive decline 
in the post-ictal phase  
. Perceptual 
organization of local 
and global visual 
stimuli different in 
migraine and 
controls, in all 
evaluations 





study of headache patients 
(N=80, migraine and 
tension-type headache 
together) performance on a 
cognitive task while in pain 
and pain-free 
A computerized test of 
memory evaluating: 
(1) encoding  
(2) retrieval 
(3) response time 
.Headache during 
encoding had no 
influence on memory 
performance but 
resulted in slower 
response times 







study of cognitive function 
of migraine patients (N=28) 
in headache-free status and 
onset of migraine prior to 
treatment and 15, 45, 75, 







(computerized test with 4 
subtests): 
(1) simple reaction time 
(SRT); (2) continuous 
performance test (CPT); (3) 
matching to sample (M2S); (4) 
mathematical processing (MP) 
. Decline in all tests in 
untreated migraine 
compared to baseline 
. Study drug returned 
all measures to 







study of cognitive function 
of migraine patients (N=10) 
in headache-free status, 
onset of migraine prior to 
treatment and 15, 30 and 45 






(computerized test with 4 
subtests): 
(1) simple reaction time 
(SRT); (2) continuous 
performance test (CPT); (3) 
. Cognitive efficiency 
(number of correct 
answers per minute) 
declined in all tests in 
untreated migraine 
compared to baseline 
. Study drug returned 




matching to sample (M2S); (4) 
mathematical processing (MP) 
Meyer, 
2000(98) 
Observational cohort study 
of cognitive performance of 
migraine (N=65, 17 with 
aura), cluster headache 
(N=7) and chronic daily 
headache (N=5) with 
repeated evaluations in 
intervals of 3 to 12 months 
over a 10-year period, 
sometimes during pain, 




(2) Cognitive Capacity 
Screening Examination (CCSE)  
 








. Findings were 





Open label case-control 
study of cognitive 
performance of migraine 
patients (N=30, 10 with 
aura) and matched controls 
(N=30) in headache free 
status and two evaluations 
30h into two treated 
attacks, one treated with 
NSAID and another with 
sumatriptan 
Neurobehavioural Evaluation 
System (NES2)  (computerized 
test with 4 subtests): 
(1) reasoning; (2) simple 
reaction time (3) switching 
attention; (4) finger-tapping; 
(5) Hand-eye coordination; (6) 
continuous performance 
pictures and letters; (7) color-
word; (8) serial digits; (9) 
symbol-digit substitution; (10) 
horizontal addition; (11) 
visual digit span; (12) pattern 
comparison and memory 
. Headache free 
migraineurs with 
aura in were slower 





color word tests 
. Post-attack 
evaluations failed to 
document differences 
to headache free 





sectional comparative study 
of cognitive performance of 
frequent headache patients 
(N=20) and frequent non-
headache pain (N=20) and 
Mild Traumatic Brain Injury 
patients (MTBI, N=20) 
evaluated once, in a mild 
pain day 
Non-computerized tests: 
(1) Logical Memory; (2) Verbal 
Paired Associates and Visual 
Reproduction (WMS-R)M (3) 
Trail Making test; (4) Stroop 
Test; (5) Block Design (WAIS-
R); (6) Controlled Oral Word 
Association Test; (7) Paced 
Auditory Serial Addition Task 
(PASAT);  Analysis  of  3 neuro-
psychological indexes: 
cognitive efficiency, memory, 
visual-perception ability 
. MTBI groups had 
lower performance on 
memory index 











Observational cohort study 
of cognitive performance of 
migraine (N=30) in 3 
repeated evaluations, two in 
headache free period (office 
and phone-based) and one 
during a migraine attack. 
Non-computerized tests 
evaluating speed of 
processing, immediate and 
sustained attention, verbal 
learning, visuo-constructional 
abilities  










study of cognitive 
performance of migraine 
with aura patients (N=42) 
and matched controls 
(N=20) in headache free 
status and within 24h of a 
migraine with aura attack 
Computerized Posner 
Paradigm, calculating visual 
reaction times (RT) analyzing 
inter-hemispheric differences 
. All RTs increased 
during attack when 
compared to baseline 
. Migraineurs outside 
the attack were 





      The other evaluated studies were all observational. Three were case-control studies 
comparing baseline headache-free cognitive performance to controls (cross-sectional 
evaluation outside the attack) and comparing post-ictal to baseline cognitive 
performance in patients (follow-up study with repeated measures) (103, 159, 218). 
These studies evaluated the post-ictal phase of the migraine attack. Only one had pre-
defined treatment drugs (sumatriptan and NSAIDs) and all subjects had evaluations after 
treating the attacks with both drugs(159).  In these cross-sectional analysis cognitive 
performance in the headache-free period of migraine patients was identical to controls 
in one study(103) and different in two(159, 218). The comparative analysis of repeated 
evaluations in the headache free and post-ictal period of migraine patients was positive 
in one study(103), that documented slower reaction times in the post-ictal compared to 
the headache-free period, and negative in two studies(97, 159).  
      Of the four remaining articles, three were follow-up studies analyzing cognitive 
performance in repeated evaluations by comparison of headache-free status with 
untreated pain(98-100). One of these studies included several headache types (migraine 
with and without aura, cluster and chronic daily headache) and performed a 
comparative analysis of performance at baseline and during pain, between 
diagnosis(98); one other study included migraine and tension-type headache patients 
together in one “headache” group and compared their performance on a cognitive task 
in their headache-free status with the untreated pain status(99). All three studies were 
positive for cognitive dysfunction during the attack compared to headache-free status, 
the study comparing several types of headache found no differences between headache 
diagnosis(98, 100). The last study is a cross-sectional comparative study of migraine 
patients while in mild pain with non-headache pain and mild traumatic brain injury 
patients, that failed to find differences in cognitive performance between headache and 
non-headache pain(219). 
      Most of these studies had small or medium sample sizes, varying from 10 (60, 102) to 
65 (98) migraine subjects evaluated, all together 333 headache patients (mostly 




      Assessment tools were heterogeneous (table 2). Six studies used computerized tests, 
including three batteries: the Mental Efficiency Workload Test (MEWT) (97), that is an 
abbreviated version of another battery also used, the Headache Care Center–Automated 
Neuropsychological Assessment Metrics (HCC-ANAM) (60, 96, 102); both of these 
batteries focused mainly on processing speed, visual-motor abilities and working 
memory. The third battery, the Neurobehavioural Evaluation System (NES2)(159), is 
more extensive but also focus on executive measures (reaction time, motor speed and 
hand-eye coordination, attention and working memory). Other computerized tests used 
included the Posner paradigm(103), other executive tasks (N-back and attentional 
network) tasks(218), a perceptual organization of visual stimuli test(218), and a 
memory test (99). 
      Non-computerized tests were used in 3 studies. One used multidomain screening 
tests (MMSE and CCSE)(98), another used an extensive test battery including memory, 
executive and visual-perception tests(219), and the third (an Abstract from a poster 
presentation) did not specify the tests used(100). 
Table 2 – Neuropsychological tests and Cognitive domains 
Cognitive 
Domain 
Neuropsychological tests Result 
 
Attention 


















Computerized: -  MEWT (97) (procedural reaction time; 
pursuit tracking) 
 
                             - HCC-ANAM(60, 96, 102) (continuous 
performance test) 
 
Conventional:   - Unspecified test (100) 
 
 
2.Comparing  “postdromal migraine” with “headache free”   
Computerized: - NES2 (159) (continuous performance 
pictures and letters; color-word) 
= 
                              - Posner Paradigm (103)  
                              - Attentional Network Task (218) 
 
= 
3.Comparing  “migraine” with “non-headache pain”  
Conventional:    -Stroop test (219) = 
                               -Trail Making test (219) = 




1.Comparing “migraine” with “headache free”  
 Computerized: - MEWT (97) (simple reaction time)  
                              - HCC-ANAM(60, 96, 102) (simple reaction 
time) 
 




2.Comparing  “postdromal migraine” with “headache free”  
Computerized:     - NES2 (159) (simple reaction time; switching 
attention) 
= 
                                 - Posner Paradigm (103) 
 
 
3.Comparing  “migraine” with “non-headache pain”  
Conventional:  -Stroop test (219) = 
                             -Trail Making test (219) = 




1.Comparing “migraine” with “headache free”  
 Computerized:  - MEWT (97) (matching to sample)  




2.Comparing  “postdromal migraine” with “headache free”  
Computerized:     - NES2 (159) (serial digits; symbol-digit 
substitution) 
= 
                                  -  N-back task(218) 
 
= 
3.Comparing  “migraine” with “non-headache pain”  
Conventional:    -Paced Auditory Serial Addition Task(219) = 
Reasoning 
2.Comparing  “postdromal migraine” with “headache free”  





3.Comparing  “migraine” with “non-headache pain”  
Conventional:    -Stroop test (219) = 




1.Comparing “migraine” with “headache free”  
Computerized: - MEWT (97) (pursuit tracking) 
 
 
2.Comparing  “postdromal migraine” with “headache free”  





1.Comparing “migraine” with “headache free”  
Computerized:   - HCC-ANAM(60, 96, 102) (Maths)  
2.Comparing  “postdromal migraine” with “headache free”  
Computerized:   - NES2(159) (horizontal addition) 
 
= 
3.Comparing  “migraine” with “non-headache pain”  
Conventional:     -Paced Auditory Serial Addition Task(219) = 




























2.Comparing  “postdromal migraine” with “headache free”  
Computerized:      - Global-local Task(218); = 
Visual 
Perception 
2.Comparing  “postdromal migraine” with “headache free”  
Computerized:     - NES2 (159) (pattern comparison) 
 
= 
3.Comparing  “migraine” with “non-headache pain”  
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Conventional:  - Visual Reproduction I (Wechsler Memory 
Scale-Revised) (219) 
= 






1.Comparing “migraine” with “headache free”  
Computerized:    - MEWT (97) (simple reaction time)  
                                - HCC-ANAM(60, 96, 102) (simple reaction 
time)  
 
Conventional:      - Unspecified test (100) 
 
 
2.Comparing  “postdromal migraine” with “headache free”  
Computerized:    - NES2 (159) (simple reaction time)  = 
                                 - Posner Paradigm (103) 
 
 
3.Comparing  “migraine” with “non-headache pain”  
Conventional:      -Trail Making test (219) = 











1.Comparing “migraine” with “headache free”  
Computerized:      - MEWT (97) (matching to sample)  




2.Comparing  “postdromal migraine” with “headache free”  
Computerized:    - NES2 (159) (pattern memory) 
 
= 
3.Comparing  “migraine” with “non-headache pain”  





3.Comparing  “migraine” with “non-headache pain” 






1.Comparing “migraine” with “headache free”  
Conventional:      - Unspecified test (100) 
 
 
3.Comparing  “migraine” with “non-headache pain”  
Conventional:  - Verbal Paired Associates (Wechsler Memory 
Scale-Revised)(219) 
= 






1.Comparing “migraine” with “headache free” 
Computerized:     - Memory (encoding/retrieval)(99) 
 
= 





1.Comparing “migraine” with “headache free”  
Conventional:     -Mini-Mental Status Examination (MMSE) (98)  





Legend:  Decreased performance during the “migraine attack” or “postdromal migraine” compared to 
headache free ;  =  Equal performance between “migraine attack”  or “postdromal migraine” and “headache 
free” or “non-headache pain”. 
 
      In some of the studies the authors attempted to control for possible confounding 
factors that could influenced cognitive performance, mostly in their study design. Most 
studies excluded severe medical conditions(97), neurological disorders (ex. epilepsy, 
stroke and traumatic brain injury) and substance abuse (96, 159, 218, 219), some 
precluding frequent headache (96, 218),  complex auras (96) and current headache 
prophylactics (159). In two studies headache prophylactics were allowed (98, 99).  Mood 
disorders were also excluded in some studies (99, 218) and controlled for in one(219) 
and none of the studies mentioned if the migraine attack evaluated had had aura or not, 
with the exception of one study that was specifically designed to evaluate migraine with 
aura(220). The practice effect of repeated neuropsychological testing was not controlled 
for in most of the studies, some studies had the first test presentation while headache 
free, followed by the attack evaluations within an unspecified time frame(60, 96, 97) 
while others did not specify the order or evaluations(98, 220). In one study alternate test 
forms were applied in trying to minimize this bias(100), in two studies the same attempt 
was made by the use of a matched control group who underwent the same 
neuropsychological protocol(159, 218) and in one study the inclusion order was 
randomized(99). 
      The headache status of evaluations also varied between studies – in three studies the 
attack evaluation was exclusively made in the postdromal phase (either after treatment 
or after spontaneous headache resolution) and not during the headache (159, 218, 220). 
In one study there was no baseline (headache free) evaluation(219) and in another study 
the baseline evaluation allowed the presence of mild headache and it also failed to 
discriminate between migraine and tension-type headache patients (99). The majority 
of studies did not contain information about criteria for defining the “headache-free” nor 
the “headache” status (60, 96-98, 100, 219). 
     Taking all the studies globally, 7 documented a decline in the selected 
neuropsychological evaluation during the untreated migraine attack, when compared to 
the baseline headache-free status (60, 96-100, 102, 103). Three were negative, two 
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tested the post-ictal phase of the attack (after successful treatment)(159, 218) and one 
had no baseline evaluation and compared migraine with non-headache pain(219). 
      The pattern of cognitive decline documented was mostly of executive dysfunction 
(96, 97, 99, 100, 102, 103), with decreased performance in attention, processing speed 
and working memory tasks during the untreated attack, but also of memory (visual 
memory (60, 96, 97, 102). and verbal learning(100)). One study only analyzed global 
cognitive functioning, so performance in specific domains was not evaluated(98). 
 
DISCUSSION 
      This review had the purpose of determining if there is evidence of decrease in any 
cognitive function during a migraine attack, when compared to headache-free status. 
Although the search was limited to two databases, we did perform an extensive review 
of bibliographic references of all the articles screened and extended the reference search 
to all review papers on the topic, thus we possibly covered the vast majority of the 
published data available for analysis. 
      There were few studies published whose design allowed to answer to our question 
and all of them had very small sample sizes, so analysis of all studies relies on a total 
sample of around 351 subjects. However, in the study by Kuhajda(99), 80 patients were 
included as one headache group, that included migraine and tension-type headache.  
      Five studies included at least two evaluations, one on a headache-free status and 
another during the painful phase of the untreated migraine attack (96-98, 100, 102). All 
these studies were positive, consistently documenting a decrease in cognitive functions 
while in pain compared to the pain-free period, but relate to a total sample of only 163 
patients. The Kuhajda study also included two evaluations and was also able to identify 
a difference in attention, but due to methodological issues (including migraine and 
tension type headache as one group and allowing mild pain in the headache free 
evaluation) its results were considered unreliable to answer the first study question(99). 
Within these limitations, we can nevertheless conclude that the published evidence is 
consistent with the occurrence of reversible cognitive dysfunction during the painful 
phase of the migraine attack, answering our first study question.  
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       Three of the remaining studies compared the postdromal phase or the treated attack 
with the pain-free status that cannot, in reality, be considered when trying to answer our 
study question. The postdromal phase occurs after the headache phase of the migraine 
attack in 60 to 94% of patients, lasts 18 to 25 hours (<12h in 54% of patients) and 
consists of a constellation of symptoms that may include cognitive disturbances, 
amongst other migraine symptoms (persistent mild nausea, mild pain with head 
movement of physical effort etc)(25, 52).  Two out of three were negative, meaning that 
there was no evidence of changes in cognitive performance when compared to baseline 
headache-free status (159, 218). One of these studies included the use of standard rescue 
medication sequentially with sumatriptan or NSAIDs and tested for differences between 
the two drugs, failing to document any (159). The other negative study did not allow the 
use of medication before evaluation, but this evaluation had to take place on the first 
headache-free morning following the attack(218). It can be argued that studying patients 
after successful headache treatment or following a resolved attack cannot be considered 
a study of the postdromal phase of migraine, but rather a comparison of treated or 
resolved attacks with other headache free days. Neuropsychological cross-sectional 
controlled studies of headache-free migraine patients are consistently negative in 
identifying interictal cognitive dysfunction(105), which is in turn consistent with the 
findings of these studies on treated or resolved attacks.  
      The third study, evaluating patients within 24h of the end of the last migraine with 
aura attack, it was not clear whether acute treatment was allowed(103). This was a 
positive study, documenting an increase of reaction times in the post-attack evaluation. 
Possible explanations include persistence of pain and/or visual impairment of the aura 
at the time of evaluation or the existence of a difference in post-attack brain functions 
between migraine with aura and migraine without aura patients. This is the only study 
included in this review that specifically evaluated migraine with aura; some others 
included aura patients within the migraine group but it was unclear if the evaluated 
attack had had aura (98, 159). The presence of classical aura does not seem to influence 
cognitive performance in migraine patients(105), although some studies of familial 
hemiplegic migraine documented non-progressive mild impairment of memory, 
attention, and some aspects of executive functions in these patients(221).  
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      Another study that was also not able to answer our study question had an evaluation 
during a headache attack but failed to have a headache free evaluation(219). This was a 
controlled study, comparing migraine with non-headache pain, and its findings were 
negative, which might suggest that cognitive dysfunction during migraine is not specific 
to migraine but is a consequence of ongoing pain processing in the brain. Several types 
of chronic pain states have been documented to impair cognitive functions, mainly in the 
domains of attention, speed of processing, executive function, psychomotor and learning 
and memory(89). Nevertheless, a study on tension-type headache reproduced attention 
deficits occurring in experimental non-headache acute pain(208), which suggests that 
headache might have the same ability to influence  cognitive performance in a similar 
way as bodily pain. 
      The second question of our study focused on whether there were any cognitive 
domains or any neuropsychological pattern of dysfunction that could be consistently 
identified, in the context of the acute migraine attack. Excluding one study that did not 
analyze specific cognitive domains(98) and the study that included both migraine and 
tension-type headache patients(99), we were left with 4 studies, with a total sample of 
around 98 patients. The most frequent finding was an attention deficit, which was found 
in all positive studies (60, 96, 97, 100, 102). The remaining impaired domains were 
processing speed and working memory in three studies (60, 96, 97, 102), visual memory 
in two studies (60, 97, 102), visuomotor ability(97) and verbal learning(100) in one 
study each. Although it might be tempting to state, in view of these results, that the main 
deficits are on executive functions (attention, processing speed, working memory), 
serious limitations prevent this generalization, the first being the a priori bias induced 
by the choice of tests to apply during the attack. Neuropsychological evaluation of 
patients while in pain is challenging and should be brief, especially if aiming for repeated, 
serial evaluations as occurred in four out of the remaining five studies (60, 96, 97, 100, 
102). Given this time limitation, it becomes impossible to perform a detailed analysis of 
each neuropsychological domain, and choosing a more detailed evaluation of a specific 
cognitive domain over briefly testing a higher number of cognitive functions was the 
option on most of these studies, which mainly focused their evaluations on executive 
measures (96, 97, 100, 102), including one or other test of learning and visuomotor 
abilities(97, 100). One study was designed to study only one specific aspect of memory, 
evaluating the influence of headache in the encoding and retrieval processes(99). This 
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was considered a positive study, as a difference was found between conditions, but this 
difference was interpreted as unrelated to the memory process but rather due to an 
attention deficit, which corroborates the pattern found in the remaining studies (60, 96, 
97, 100, 102). Although consistent with patients’ subjective symptoms during the 
attacks(118), a similar cognitive pattern of impaired attention is also found in non-
headache chronic pain(89) and tension-type headache(208), so specificity for migraine 
is not warranted. This review had no intention to explore the neurological subtract 
behind the neuropsychological dysfunction nor to compare findings of migraine attacks 
to other headache types or non-headache pain. 
      Other important limitations to the interpretation of these results are the scarce 
control of possible confounding factors that may influenced cognitive performance, such 
as anxiety and mood disorders (222, 223), prophylactic drug treatment for migraine 
(145) or substance abuse (224), the occurrence of aura(103) and the practice effect of 
repeated neuropsychological testing(225). Of the studies considered in answering our 
first study question(96-98, 100, 102), none had information defining the “migraine” nor 
the “headache free” status and none had clear information about the presence of 
migraine aura in the sample; only two had some inclusion restrictions(96, 97) and only 
one had a design that attempted to minimize the practice effect bias(100).   
     From all mentioned limitations and considering the small total sample of patients 
evaluated we conclude that there is not enough data to confirm a specific pattern of 
cognitive impairment of the acute migraine attack. 
      Summarizing, this review provides weak evidence for the occurrence of reversible 
cognitive dysfunction during the headache phase of the migraine attack, which 
subscribes patients’ subjective descriptions and general clinical impression. The pattern 
of dysfunction suggested is mainly of a dysexecutive syndrome but the evidence to 
support this suggestion is frail. Further work is needed to substantiate these findings, 
such as testing specifically other cognitive domains during the attack and controlling for 
migraine related confounding factors, such as treatment effects, affective disorders and 
the presence or aura.  
       This topic has important clinical implications, as migraine attack-related cognitive 
dysfunction may influence patients’ ability to perform in work, school and other 
activities, and therefore be a major contributor to migraine-related disability and 
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burden(15). For this reason, it is essential to better characterize the attack-related 
cognitive dysfunction, in order to be possible to include cognitive-related endpoints in 
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ABSTRACT 
Background: Cognitive difficulties contribute to patients’ disability during migraine attacks and 
have been overlooked in migraine research. Neuropsychological studies performed during 
attacks have produced inconsistent findings due to design differences and limitations.  
Objective: To document changes in cognitive performance of migraine patients during migraine 
attacks with a comprehensive battery of cognitive/behavioral tests, while controlling for 
potential confounders. 
Method: A prospective two-period randomized crossover study compared within-subject 
neuropsychological evaluation in two conditions – during a naturally occurring untreated 
migraine attack and a headache-free period.  
Results: Thirty-nine patients with episodic migraine (37 females, average 38 years-old) were 
included and 24 completed the study. Subjects performed worse during the attack in the majority 
of cognitive tests, compared to the headache-free status, and significantly so in word reading 
speed (p=0.013), verbal learning (p=0.01), short term verbal recall with (p=0.01) and without 
(p=0.013) semantic cueing and delayed recall with (p=0.003) and without (p=0.05) semantic 
cues. Differences found were unrelated to age, gender, literacy, condition order, interval between 
evaluations, anxiety, pain intensity or duration of the attack. 
Discussion: Cognitive performance decreases during migraine attacks, especially in reading and 
processing speed, verbal memory and learning, supporting patients’ subjective complaints. 
These findings suggest the existence of a reversible brain dysfunction during attacks of migraine 
without aura, which can relate specifically to migraine or be a consequence of acute pain 





Migraine is a disabling disease with a significant impact in global health(177). 
Attacks of migraine without aura are complex biological phenomena with distinct 
clinical manifestations that include headache, gastrointestinal symptoms and 
dysfunctional modulation of sensory inputs (light, sound, smell or movement)(226, 
227).  
Additional attack-related symptoms, such as cognitive difficulties (95, 118, 133, 
136, 156) are often reported by patients and probably reflect brain function changes 
during attacks. Cognitive and mental symptoms are significant contributors to patients’ 
disability (95) and may not be relieved by effective abortive medication(158). Difficulties 
most often reported by patients relate to different cognitive domains such as sustained 
and divided attention, concentration, planning, judgment, initiative, processing speed, 
language and memory (98, 118). These may persist beyond the pain phase, up to the 
following day(158), as 80% of patients report mental tiredness, asthenia, depressed 
mood and concentration difficulties(25, 51) after the attack.  
Cognitive dysfunction has probably been overlooked in migraine research, since 
data about its impact on disease-related disability is scarce and it has seldom been 
evaluated as a therapeutic outcome(96, 97).  
Existent data on neuropsychological performance during migraine attacks is 
difficult to summarize due to a paucity of published studies, often based on small 
samples, having different designs and using distinct neuropsychological measures, often 
targeting specific cognitive domains  (60, 96-100, 102, 103, 159, 218, 219). The profile 
of cognitive impairment is inconsistent, varying from dysfunction documented in several 
cognitive domains (attention, processing speed, working memory, calculation, visuo-
motor processing, visual and verbal memory)(96-100, 102, 103) to normal 
performance(159, 218, 219).  In addition, there is lack of control for factors that influence 
cognitive performance in general, such as mood changes (96, 102, 103, 159, 218) 
concomitant drug treatments, substance abuse or the practice effect of repeated 
neuropsychological testing.  Migraine has its own potential confounders that also need 
to be considered, such as the presence of aura (a cortical phenomenon that might 
influence visual processing and speed(103, 159)), photophobia (that might interfere 
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with tasks requiring prolonged staring at a computer screen) and the effects of 
pharmacological agents, either migraine treatments or migraine-triggering drugs. 
 
Our study was designed to evaluate cognitive changes during naturally occurring 
untreated migraine attacks, compared to headache free status. We selected a 
comprehensive battery of cognitive and behavioral tests targeting different cognitive 
domains that have been identified as disturbed on at least one previous study, and we 
controlled for anxiety, depression, pharmacological effects, presence of migraine aura 
and for the practice effect bias. 
 
SUBJECTS and METHODS 
Population  
 Otherwise healthy, episodic migraine patients were recruited consecutively on a 
Headache Outpatient Clinic, both from first and from follow-up visits. Inclusion criteria 
were: a) age between 20 and 65 years; b) ≥ 4 years of formal education; c) diagnosis of 
episodic migraine according to ICDH-II(186); d) ≥ 1 attack/month of migraine without 
aura in the 3 months preceding inclusion; e) living/ working near or at the study center 
(allowing an evaluation within 60 minutes of an established migraine attack); e) written 
informed consent. Exclusion criteria included the co-existence of any other headache 
type, chronic migraine, medication overuse, exclusive or very frequent attacks of 
migraine with aura, history of alcohol or drug abuse, and any medical or psychiatric 
disorder requiring daily treatment. In order to minimize potential cognitive effects of 
pharmacological agents, the only allowed daily medications were oral contraceptives 
and migraine prophylactics. The study protocol was approved by the Hospital and 
Faculty of Medicine Ethics Committee . There was no financial compensation for the 
volunteers. 
Study design 
Study design consisted of a randomized, two-period crossover study requiring 
two evaluations of the same subject in two different conditions : condition 1, during an 
untreated spontaneous attack of migraine without aura (Migraine Attack - M); condition 
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2, during a headache-free period that was not treatment-induced (Baseline - B) with a 
minimum of 72 hours elapsed since the last attack.  Evaluation order was randomized, 
half the patients having the first evaluation while headache-free (B→M), while the other 
half was first evaluated during the attack (M→B). A minimum interval of one month 
between evaluations was required. This design had the purpose to control for the 
practice effect and minimize the need to determine the expected magnitude of 
improvement in neuropsychological testing between such short-term repeated 
evaluations(225, 228) Assessments took place during working hours and within 24 
hours of the onset of the attack. Attacks occurring at night or during weekends, attacks 
with aura and attacks treated with abortive medication in the previous 12 hours were 
not eligible. ICDH-II criteria(186) for migraine without aura and absence of aura in the 
previous 48 hours were re-checked immediately before cognitive assessment in the 
evaluation during an attack. 
Subjects were excluded if they did not have an eligible attack within a two-year 
period after inclusion. At the end of a five years enrolment period, the authors decided 




        Recruitment and inclusion of study subjects were performed by headache 
specialists, who verified study criteria and carried out a standard clinical evaluation, 
including previous medical history and physical examination. After informed consent 
was obtained, data was collected and included verification of the ICDH-II diagnosis, 
gender, age, education years, disease duration, attack frequency, duration and intensity, 
and use of prophylactic treatment and other current treatments. Migraine impact was 
evaluated with the HIT-6(140) and MS-QoL(229) questionnaires. Depressive symptoms 
and anxiety were quantified with the Zung Depression scale(230) and the State-
Trait Anxiety Inventory (STAI)(231) as depression and anxiety are frequent 
comorbidities of migraine(232) and can influence neuropsychological 
performance(139). Attack evaluation included questions about current attack features 
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as well as about pain intensity, which was scored before testing with a 10-point visual 
analogue scale (VAS).  
Neuropsychological testing was applied by licensed neuropsychologists 
following a pre-selected comprehensive neurobehavioral battery (98, 118) which 
included internationally recognized tests applied in clinical practice and validated for 
our population. Tests were applied using paper-and-pencil, and not computerized, based 
on three considerations: (1) the experience of our neuropsychologists in the written 
form of tests; (2) the need to avoid the visual discomfort of a screen display on a 
photophobic patient; and (3) the attempt to minimize the risk of non-compliance, given 
the predicted long (40 to 60 minutes) duration of the evaluation, by introducing an 
interaction with the examiner. Tests were chosen in order to cover the main cognitive 
domains, as depicted in table 1. Test descriptions, reliability and practice effects are 
available in Table 2.  
Table 1 – Neuropsychological Battery 
 



















-Trail Making test A and B 
- Stroop  test 
- Symbol Search 
- Digit Span Forward 
- Verbal Fluency 
Processing speed 
-Trail Making test A and B 
- Finger Tapping 
- Stroop  test 
- Symbol Search 
Mental Flexibility 
-Trail Making test B and B-A  
- Stroop color word test 
- Verbal Fluency 
Inhibitory control and Monitoring 
- Verbal Fluency 
- Stroop color word 
Working Memory 
-Trail Making test A and B 





















Visual Memory - Visual Reproduction 
Declarative Episodic Memory   - Logical Memory 
Verbal Memory and Learning - California Verbal Learning Test 
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Spatial and Visual Perception 
- Symbol Search 
- Famous Faces Test 
Visuo-motor processing 
-Trail Making test A and B 
- Visual Reproduction 














- Snodgrass naming test 
- Famous Faces Test 
Verbal Initiative and fluency - Verbal Fluency 




Table 2 - Test description, reliability and practice effects 
 
Test designation and description Reliability and Practice effects  
FINGER TAPPING TEST (FTT)(233)  
The Finger Tapping test records the total number of 
taps obtained in 10 seconds, using the index finger 
of each hand alternately. Test score is calculated 
averaging the number of taps obtained in three trials 
of each hand. 
Reliability coefficients of the FTT in healthy 
adults vary in different studies, from 0.71 to 
0.94(234, 235); practice effect is small and fades 
after the first repetition(236). 
TRAIL MAKING TEST (TMT)(237)  
The Trail Making Test consists of two parts; in part 
A subjects have to connect numbers in an ascending 
numerical order (from 1 to 25) that are randomly 
spread in a sheet of paper. In part B subjects have to 
connect numbers (from 1 to 13) and letters (from A 
to L) that are randomly spread in a sheet of paper, in 
alternating ascending numerical and alphabetical 
order. Errors are pointed out by the observer and 
must be corrected without interruption of the 
stopwatch. The test scores the time spent to 
correctly complete the task (in seconds) and the 
number of errors made. Subtracting the time of Trail 
A from the time of Trail B is a measure of mental 
flexibility, because it removes bias induced by 
attention, motor speed and visual processing. 
 
Reliability coefficients are always lower for part 
A than for part B of the Trail Making test; part B 
has a reliability of 0.65 or higher(238) and 
presents negligible practice effects (236). 
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STROOP TEST(239)    
The Stroop test includes three tasks; the first is the 
Reading task, in which the individual has to read 
aloud the maximum number of color names (out of 
a list of 100). In the second task, Color Naming, the 
individual has to name the maximum number of 
colors out of a list of 100 Xs printed in different 
colors. In the last task, the Interference Test, a list of 
100 written color names are printed in a color that 
does not correspond to the color print; the 
participant must name the color and ignore the 
written word. Scores of each task are the number of 
items read in a given time (45 seconds) and the 
number of errors made. 
The Stroop test has good reliability (> 0.91) and 
presents  small practice effect in the second 
repetition(236). 
VERBAL FLUENCY (233)  
The verbal fluency tasks accesses the individuals’ 
ability to retrieve specific information in one minute. 
The two subtests used were the Semantic Verbal 
Fluency, in which individuals have to generate 
semantic category exemplars (in this case, animals) 
and Phonemic Verbal Fluency, for generating words 
beginning with a target letter (in this case, the letter 
“P”). The score is the total number of items 
generated per category, excluding repetitions and 
errors. 
The verbal fluency tests have good reliability 
ranging from 0.68 to 0.73(240)  and modest 
(although significant) practice effects(241). 
SYMBOL SEARCH (242)  
The Symbol Search is  a test in which a row with five 
symbols is compared with two targets. Subjects have 
to decide if the targets are repeated in each row. The 
score is the total number of correct answers given in 
120 seconds. 
The Digit Span test is a subtest of the Wechsler 
Adult Intelligence Scale (WAIS) presenting good 
reliability (0.91)(243).  
DIGIT SPAN (242)  
In the Digit Span test  a serial of random sequential 
digits of progressive length is orally presented and 
the participant has to repeat it immediately after its 
presentation, in two subtests – forward (digits have 
to be repeated in the order they were presented) 
and backward (digits have to be repeated in 
backwards order of presentation). Each sub-test 
scores the highest length of digits that is correctly 
repeated (ranging from 2 to 8), final score is the 
average of both sub-test scores. 
The Digit Span test is a subtest of the Wechsler 
Adult Intelligence Scale (WAIS) having negligible 
practice effects and test-retest reliability 
coefficients ranging from 0.66 to 0.89 in normal 
individuals, depending on interval length and 
subject ages(244).  
VISUAL REPRODUCTION (245)  
In the Visual Memory test  three geometric pictures 
of increasing complexity are presented and have to 
be reproduced with as many details as possible 
immediately (short-term) and after 20 minutes 
(long term). The test score is given by adding the 
number of correct details reproduced in each 
drawing. 
The Visual Memory test is a subtest of the 
Wechsler Memory Scale (WMS) that presents 
test-retest stability coefficients over 0.85 in 




LOGICAL MEMORY(245)  
In the Logical Memory test the participant has to 
repeated back two stories with as many details as 
possible immediately (short term) and after 20 
minutes (long term). Each story is scored by adding 
up the number of ideas that are correctly retained 
and final score represents the average of both 
stories. 
The Logical Memory test is a subtest of the 
Wechsler Memory Scale (WMS) in which there is 
a large practice effect and test-retest reliability 
coefficients of 0.62 and 0.68(246). 
CALIFORNIA VERBAL LEARNING TEST (CLVT) (247) 
The California Verbal Learning Test consists in five 
presentations of a list of 16 stimuli (words of four 
semantic categories) and requesting the retrieval of 
these stimuli immediately and after an interference 
list of different stimuli both at short term and after a 
20 minutes delay (long term). Several scores can be 
calculated by counting the number of stimuli that 
the individual is able to recall -  the learning ability 
(the sum of the five repetition trials), short and long 
term (delayed) recall after interference, cued recall 
(obtained by providing the semantic categories) and 
recognition.  
The CVLT has having small to medium practice 
effects and test-retest reliability coefficients for 
total trials range from 0.80 to 0.84 in normal 
adults(248). 
SNODGRASS NAMING TEST (249)  
The Snodgrass & Vanderwart Naming Test has 260 
pictures that are presenting for naming. We used 
only 8 pictures (train, pear, eye, bed, ax, peacock, 
heart and watering can) that were chosen randomly. 
The test scores the number of correct pictures 
named. 
No data available 
FAMOUS FACES TEST(250)    
The Famous Faces Test consists of 71 face 
photographs of famous individuals or personalities 
from different nationalities, time periods and 
professional groups that have to be named by the 
subject. This test is sensitive to cultural differences 
between societies so we used a version that has been 
developed and validated in our country. We used 
only 7 faces (chosen to be representative different 
time periods and professional groups). The test 
score is the number of personalities named 
correctly.  
No data available 
STAI SCALE (231)  
The State-Trait Anxiety Inventory (STAI) is a self-rating 40 questions scale that quantifies anxiety levels 
in two contexts – state reports to anxiety related to an event or moment (20 questions), trait reports on 
usual personal level of anxiety (20 questions). Each question is scored from 1 to 4, higher scores 
representing higher anxiety levels. The scale score is obtained by summing the scores of each item. 
ZUNG DEPRESSION SCALE(251)  
The Zung Depression Scale is a self-rating 20 questions scale that quantifies depressive symptoms; each 






Statistical analysis used SPSS v20. Frequencies and means ± standard deviations were 
used for descriptive statistics. Two-sample t-tests were used to compare baseline patient 
variables between randomization groups. The effect of the exposure to a migraine attack 
on the test scores, controlling for a learning effect, was tested with two-sample Student’s 
t-tests of the difference between groups in the change in test scores from the first to the 
second evaluation (252). A learning effect was tested with standard t-tests of the 
difference between groups in the change in test scores from the evaluation during an 
attack to the baseline evaluation. An exposure-by-period interaction was tested with 
standard t-tests of the difference between groups in the sum of the two evaluations of 
each subject.  Data was tested for normality with the Shapiro-Wilk test and the test 
scores with non-normal distribution were analyzed with the non-parametric Wilcoxon-
Mann-Whitney ranksum test, instead of t-tests. The Hochberg step-up procedure(253)  
was adopted to account for multiple testing and to provide strong control of the type I 
error at the 5% significance level. Reported p-values are adjusted for multiplicity using 
the Bonferroni correction(206). For each test showing a significant difference between 
the two evaluations we used multiple linear regression to evaluate the effect of the 
following variables on the identified difference: gender, age, literacy, time between 
evaluations, anxiety, pain intensity and duration of the attack. The power of this study is 
70% to detect a difference in test scores between evaluations greater than 0.8 standard 




1- Population and Study Flow 
Fifty-eight subjects were randomized, 27 to have their first evaluation while 
headache-free (B→M) and 31 to have the first evaluation during a Migraine attack 
(M→B). There were 34 non-completers (6 withdrawn from the study, 13 did not have an 
eligible attack within 2 years and 15 only performed one of the evaluations). Twenty-




Figure  1 – Study flow and sample 
 
 
The study population consists of 24 patients, all right-handed but one. Table 3 shows 
the baseline characteristics of patients. Four (17%) had migraine with and without aura 
(3 visual, 1 visual and somatosensory). The sample had an average of 38.0±11.6 years of 
age (range 21 to 63), 19.3±12.1 years of education (range 4 to 22) and average disease 
duration of 19.3±12.1 years (range 3 to 57). Average Zung score was 48.7±8.0 (range 35 
to 79) and 8 subjects had scores corresponding to mild depression but none was severely 
depressed.    
 
Table 3 - Patient characteristics 
 
Variable Group BM Group MB Total p 
 n=12 n=12 n=24  





























Females (n, %) 11 9.7 12 100.0 23 95.8 0.99 
Migraine with aura 2 16.7 2 16.7 4 16.7 0.99 
Education years (av, sd) 13.7 5.8 12.2 5.3 12.9 5.5 0.51 
Disease duration years 
(av, sd) 
21.8 13.5 16.6 10.2 19.3 12.1 0.31 
Zung score (av, sd) 48.3 4.4 49.1 10.7 48.7 8.0 0.82 
Positive Zung score (n, %) 4 33.3 4 33.3 8 33.3 0.99 
1-4 attacks monthly (n, %) 5 41.7 6 50.0 11 45.8 0.99 
Attack duration <24 hrs  
(n, %) 
4 33.3 6 50.0 10 41.7 0.68 
Moderate intensity (n, %) 5 41.7 7 58.3 12 50.0 0.68 
Drug prophylaxis (n, %) 3 25.0 4 33.3 7 29.2 0.99 
HIT-6 score (av, sd) 64.5 4.4 62.1 9.4 63.3 7.3 0.43 
MSQoL score (av, sd) 76.4 14.1 74.8 14.6 75.6 14.1 0.79 
Days between evaluations  
(av, sd) 
287 141 124 147 206 164 0.012 
 
On inclusion, the majority of patients (45.8%) had 1-4 attacks monthly, most (42%) 
lasting 4 to 24 hours and of moderate to severe intensity (100%). Seven participants 
(29%) were receiving migraine prophylactics (2 propanolol, 2 propanolol and 
amytriptiline, 2 amytriptiline and 1 topiramate and amytriptiline). Migraine impact was 
moderate to high, with an average HIT-6 score of 63.3±7.3 (range 45 to 76) and an 
MSQoL score of 75.6 ± 14.1 (range 43 to 95).   
Time between evaluations was on average 206±164 days (about 6 months, range 26 
to 568 days).  Patients in group (B→M) had a higher interval between evaluations 
(287±142 days, ≈9 months) than group (M→B) (125±147 days, ≈4 months, p=0.012); no 
other differences were documented between the groups (table 3).  
 
2- Attack and Baseline cognitive performance analysis 
At the time of the studied attack, patients had experienced an average of 3.1±2.5 
(range 0 to 10) attacks in the previous month, lasting an average of 33.2±29.6 hours 
(range 30 minutes to 96 hours). Ninety two percent of the previous attacks were of 
moderate to severe intensity.  
During this attack, 2 patients (8%) experienced vomiting, 15 (62.5%) photophobia 
and mean VAS pain intensity was 5.7±1.6 (range 3 to 9.5). Average duration of symptoms 




Average uncorrected raw test scores are shown in table 4. Two measures were 
removed from the analysis: errors in Trail Making Test (TMT) were too few to be 
compared and the Snodgrass naming test showed a ceiling effect in all evaluations. 
 
Table 4 –Average uncorrected raw scores of neuropsychological tests in each evaluations 
and mean difference of raw scores between evaluations (Baseline-Migraine) 
 











 mean ± sd mean ± sd mean ± SEM    
Executive function tests and measures 
Finger tapping  
(dominant hand) † 
45.9 ± 8.4 
41.8 ± 
10.0 
4.08 ± 1.46 0.009 0.37 0.62 
Finger tapping  
(non-dominant hand) 
40.3 ± 7.6 37.8 ± 8.4 2.47 ± 1.52 0.09 0.10 0.21 
Digit Span Forward 7.0 ± 2.6 6.1 ± 2.6 0.88 ± 0.38 0.03 0.59 0.84 
Digit Span Backwards 5.9 ± 1.7 5.3 ± 2.0 0.58 ± 0.47 0.24 0.86 0.50 
Digit Span Total † 12.8 ± 3.9 11.4 ± 3.7 1.42 ± 0.63 0.03 0.81 0.64 
Stroop words (reading) 
† 
90.6 ± 17.1 
77.6 ± 
21.0 
13.0 ± 3.55 0.0006** 0.02 0.41 
Stroop colors 67.1 ± 13.7 
58.6 ± 
13.9 
8.45 ± 2.55 0.003 0.18 0.03 
Stroop Interference 38.8 ± 10.3 
36.8 ± 
12.7 
2.04 ± 2.08 0.32 0.09 0.35 
Fluency Animals 19.3 ± 4.5 18.3 ± 6.6 1.00 ± 0.87 0.26 0.35 0.50 
Fluency Letter P 11.7 ± 4.9 10.0 ± 5.1 1.71 ± 0.61 0.01 0.74 0.21 
Trail A Time 38.3 ± 14.1 
45.1 ± 
15.5 
-6.75 ± 2.56 0.01 0.26 0.60 
Trail B Time † 91.1 ± 54.0 
102.8 ± 
56.8 
-11.8 ± 8.68 0.08 0.09 0.82 
Trail difference (B-A) † 52.8 ± 46.0 
57.8 ± 
47.1 
-5.00 ± 8.34 0.44 0.51 0.84 
Trail A errors † 0.0 ± 0.2 0.1 ± 0.3 -0.04 ± 0.07 0.58 0.58 0.55 
Trail B errors 0.2 ± 0.4 0.5 ± 0.8 -0.29 ± 0.14 0.04 0.14 0.18 
Symbol Search 31.8 ± 10.9 
29.6 ± 
10.6 
2.17 ± 1.12 0.06 0.10 0.68 
Other tests (memory, language) 
Naming † 7.8 ± 0.5 7.7 ± 0.5 0.04 ± 0.11 0.96 0.31 0.91 
CVLT first immediate 
recall 
7.8 ± 2.4 6.9 ± 2.2 0.88 ± 0.42 0.06 0.92 0.11 
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CVLT total learning 60.2 ± 9.8 
52.5 ± 
12.1 
7.63 ± 1.83 0.0003* 0.91 0.20 
CVLT fifth recall 14.1 ± 2.2 12.5 ± 3.2 1.63 ± 0.60 0.014 0.46 0.32 
CVLT short term free 
recall 
13.0 ± 2.6 11.2 ± 2.8 1.87 ± 0.48 0.0004** 0.07 0.97 
CVLT short term cued 
recall 
13.5 ± 2.6 11.6 ± 2.8 1.88 ± 0.45 0.0003* 0.12 0.84 
CVLT delayed free recall 13.0 ± 2.6 11.6 ± 2.9 1.38 ± 0.38 0.0015** 0.45 0.58 
CVLT cued delayed 
recall 
13.7 ± 2.4 12.0 ± 2.8 1.63 ± 0.34 0.0001* 0.28 0.72 
WMS-III  Logical 
Memory – immediate 
recall 
15.0 ± 5.4 12.9 ± 4.9 2.10 ± 0.90 0.36 0.83 0.96 
WMS-III  Logical 
Memory – delayed recall 
14.7 ± 5.5 11.8 ± 4.9 2.90 ± 0.95 0.008 0.76 0.72 
WMS-III immediate 
visual memory 
11.9 ± 2.9 12.3 ± 2.7 -0.46 ± 0.53 0.41 0.82 0.50 
WMS-III delayed visual 
memory 
11.0 ± 3.1 11.5 ± 3.1 -0.46 ± 0.52 0.38 0.18 0.60 
Famous faces test 5.9 ± 1.5 5.3 ± 1.5 0.58 ± 0.28 0.05 0.57 0.54 
Other measures       
STAI – state 32.2 ± 7.7 
45.5 ± 
11.7 
-13.3 ± 2.64 0.0001* 0.23 0.61 
STAI – Trace 38.9 ± 6.7 38.6 ± 6.7 0.3 ± 4.3 0.81 0.22 0.17 
Legend: sd: standard deviation; SEM: standard error of the mean; †: Wilcoxon-Mann-Whitney ranksum 
test, otherwise Student’s t-test; *: p<0.01 and **: p<0.05 after adjustment for multiple comparisons 
 
 
Significant differences were observed in Stroop word reading (p=0.013), California 
Verbal Learning Test (CVLT) total learning (p=0.01), CVLT short term recall with 
(p=0.01) and without (p=0.013) semantic help, and delayed recall with (p=0.003) and 
without (p=0.05) semantic help (Figure 2). The anxiety state was higher during the 
attack (p=0.003) but trace anxiety showed no difference. There was evidence for a 
learning effect in Stroop word reading (p=0.009) but no evidence that the learning effect 







Figure 2 – Differences in test performance of Baseline versus during a Migraine Attack 
 
Legend:   X axis: Neuropsychological Tests ; Y Axis: Z Scores; White boxes : Baseline Evaluations; Dark boxes: Attack 
evaluations 
   
      The effect of the clinical (independent) variables (gender, age, literacy, time interval 
between evaluations, anxiety, pain intensity and duration of the attack) on the 
differences found between the two evaluations of the Stroop reading, CVLT total 
learning, CVLT short term free and cued recall, CVLT delayed free and cued recall were 
analyzed with multiple linear regression. Pain intensity during the attack was found to 
influence in CVLT short term free recall (p=0.008) but no other variable influenced the 
differences found in the tests (table 5). 
 
Table – Multiple linear regression analysis to evaluate the effect of the clinical 
(independent) variables on the differences between evaluations identified in each test 
(dependent variables). 
 








































p 0.030 p 0.030 






















































































Legend:  B = Unstandardized beta coefficient; p = significance level; * significant at p< 




This study showed that migraine attacks are associated to a nominal performance 
decline in the majority of neuropsychological tests in relation to headache-free periods. 
The only exception were measures with a ceiling effect and those, such as the visual 
reproduction test, that are sensitive to practice(254).The decreased test performance 
during migraine was significant in two tests – the word reading task of the Stroop test 
(measuring processing speed and reading) and the CVLT (measuring learning and 
memory). The observed decline in performance was unrelated to the order of and time 
between evaluations, anxiety state and attack duration; only pain intensity was found to 
influence the short term free recall of the CVLT, a measure related to the retrieval 
process(255).  
This cognitive impairment seems related to the attack itself, giving objective 
support to patient’s subjective complaints(98, 118, 159)  and corroborating previous 
studies that have demonstrated reversible dysfunction in processing speed, working 
memory, visual-spatial processing, alertness/ fatigue (96, 98, 102, 105, 159), immediate 
and sustained attention, verbal learning(100, 105) and inhibition(105). The 
predominant involvement of processing speed, learning and memory could suggest a 
preferential dysfunction of the pre-frontal and temporal cortices and/or frontal 
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subcortical white matter during migraine attacks,  an observation supported by 
functional imaging findings during migraine attacks showing changes in the cingulated 
and pre-frontal cortex(153) insula and the temporal lobe(152) .  
The observed decline in word reading speed of the Stroop test might be related 
to an impaired automatic process of attending to the lexical features of words or reduced 
processing speed.  Visual abilities, such as low contrast sensitivity in older individuals 
has also been linked to slower performance on word reading(238) yet visual factors are 
an unlikely explanation of these finding in our sample of young otherwise healthy 
migraine without aura subjects. The two other subtests of the Stroop test did not show a 
significant decline in performance. This suggests that conscious process of color naming, 
which involves the discrimination and retrieval of names, attention and verbal response 
was maintained, as was selective attention and the ability of suppress an automatic 
response which the interference task and seems to be consistently correlated to 
activation of the anterior cingulated cortex(256).  Additional support of the functional 
integrity of pre-frontal cortical systems was the adequate performance on the remaining 
tests directed to executive functions such as set shifting, divided attention, mental 
flexibility, processing speed and verbal working memory.   
Decline in episodic memory tasks was consistent across the retrieval measures of 
the CVLT test, reflecting a verbal learning and retrieval impairment, tasks supported by 
a large network involving the hippocampus, medial temporal lobe and prefrontal 
(dorsolateral) cortex(257, 258) and connectivity between the thalamus and the putamen 
and striatum (259). The additional memory tests performed, that targeted famous faces 
naming and recognition (semantic memory), logical and visual memory were not 
selectively impaired, which may relate to lower relative sensitivity of these tests (260)in 
which a higher level of contextual information is presented. Another possible 
explanation is a higher resistance of the anterior and dorsal lateral prefrontal cortices 
function during migraine, as those are specifically involved in the context-related 
retrieval process(261).  
Our data therefore favors the involvement of temporal(152) or sub-cortical 
nuclei during the migraine attack, over pre-frontal or the cingulate cortices(153). 
The mechanism by which cognitive impairment occurs during migraine without 
aura attacks is speculative. It may relate to a cortical spreading depression-like 
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phenomena occurring during migraine without aura, shown to decrease cerebral blood 
flow (CBF) in the occipital, temporal and parietal lobes.  
Cognitive dysfunction in migraine can also be secondary to influences of sub-
cortical stuctures, namely the raphe nuclei and its cortical serotoninergic projections (ex. 
orbitofrontal cortex, precentral gyrus, temporal pole, insula and somatosensory area) . 
An alternative subcortical candidate is the thalamus, that is activated during attacks in 
humans(153) and whose activity was shown to control cortical states and influence 
perception, learning and cognition in animal studies(262).  
An important issue that is not answered by this study design is whether these 
findings are specific to migraine or could be simply induced by the cognitive processes 
related to the pain experience. A wide range of neuropsychological and imaging changes 
have been described in chronic pain populations that support an impairment in 
attention, executive and general cognitive function, as a consequence of long-term pain-
related neurochemical and neuroplastic brain changes(89). This data cannot be inferred 
to episodic pain, despite there being some evidence for interictal brain changes in 
migraine (263). Studies on the effects of acute pain in healthy volunteers have 
consistently documented hemodynamic responses in the primary somatosensory (SI) 
cortex (a pain processing area), bilateral insula and second somatoensory (SII) cortices 
(regions involved in somatosensory integration that is influenced by attention), bilateral 
thalamus and brainstem (discriminative and arousal pain responses and descending 
pain modulation) but also other higher cognitive relay areas such as the anterior 
cingulated cortex (involved in the cognitive-attentional response to pain and 
anticipation of pain) and the dorso-lateral prefrontal  (DLPF) and posterior parietal 
cortices (related to cognitive aspects of pain processing)(264). Involvement of these 
areas during pain processing could be the reason for decline in certain 
neuropsychological tests, in particular in tasks requiring attention (265), although this 
is not consistent with the cognitive profile shown in this study.   
A recent fMRI study on migraine was able to demonstrate enhanced functional 
connectivity of the anterior temporal pole with pain related cortical structures involved 
in acute pain processing, which suggests that the pain-processing mechanism of the 
migraine attack may not be entirely identical to experimental acute pain. In particular, 
this study was able to demonstrate hyperexcitability of the anterior temporal pole in the 
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interictal phase of migraine that increased during the attack(152), giving support to our 
observation of pain intensity influencing some measures of the CVLT.   
Another argument against the effect of pain by itself is the fact that cognitive 
subjective symptoms are reported during the prodrome of the migraine attack, before 
pain arises(121). 
The main strengths of this study are its design that dealt with most bias and 
confounders: the migraine population that was free of psychiatric co-morbidities and 
medication overuse, the use of an extensive neuropsychological battery covering the 
main cognitive domains and the control for multiple testing in the analysis. Studies with 
neuropsychological evaluation of migraine patients during attacks imply motivating 
patients to come into office during an untreated attack and keeping them cooperative 
during a one-hour testing. For that reason, as well as because of photophobia, it was 
important that the tests were paper-and-pencil instead of computerized (which may be 
more sensitive to reaction times). Interaction with the examiner was used to improve 
task engagement and to ensure adequate compliance levels throughout the evaluation. 
However, this made blinding impossible and did not allow the use of more accurate tests 
to measure reaction speed. 
The most important limitation of this study was the difficulty to assess patients 
during the attack: 18 subjects were excluded or dropped-out because of not being able 
to be evaluated during an attack; only 12(46%) of the patients first evaluated at baseline 
managed to return during the attack, while only one patient first evaluated during an 
attack did not return for the second, baseline evaluation. The time lapse between 
evaluations in both groups was also quite different; the delay of the group starting with 
the attack evaluation almost doubled the delay of the other group. These facts had 
implications in the interpretation of the results and an impact in final sample size which, 
although in line with the sample sizes from previous studies (96, 98, 100, 103, 159, 218, 
219), was insufficient to ensure adequate statistical power to attain significant statistical 
differences in some tests. Our difficulty in ensuring the actual participation of subjects 
during the attack was perhaps influenced by the lack of financial compensation of 
participants, as evaluations were only possible during working hours. We also 
acknowledge that some cognitive aspects could have been better detailed. In particular, 
a more comprehensive executive testing would be preferable to study frontal lobe 
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dysfunction and the inclusion of measures of crystallized intelligence would help in 
identifying the cognitive profile of dysfunction, such as a dissociation decline between 
fluid and crystallized intelligence, with potential implications in actual cognitive 
performance Poor effort could have influenced neuropsychological scores obtained in 
this study, as we have not included a measure of effort in our battery. Finally, as stated 
earlier, the amplitude of estimated practice effect was not taken into consideration since 
it was minimized by the design of the study that allowed all participants to gain practice 
with the tests at first exposure. 
Our study supports existing literature that reports neuropsychological and 
neurophysiological evidence of reversible brain dysfunction occurring during the 
migraine without aura attack, that probably underlies migraine-related cognitive 
impairment(266). These findings are crucial in supporting patients’ claims of attack-
related cognitive impairment and have clinical implications in relation to working and 
learning abilities during attacks and also on the evaluation of response to acute migraine 
treatment. In the research setting, it may help in the enlightening of the nature of brain 
dysfunction in migraine. More studies are needed to determine if the attack-related 
cognitive impairment is specific of migraine pathopshysiology or is simply related to 











How can we measure attack-related cognitive impairment? 
Sequential evaluation of migraine patients and controls using a short 
neuropsychological battery. 
 
Gil-Gouveia R, Oliveira AG, Martins IP. 
 Sequential evaluation of migraine patients and controls using a short battery of cognitive 
assessment.  
Acta Neurologica Scandinavica 2015 [in press]     
 
ABSTRACT  
Background: Evidence of attack-related cognitive dysfunction in migraine is growing. 
Controversy exists on whether cognitive dysfunction, mainly executive, may persist between 
attacks. Measuring the impact of cognitive function is gaining importance in clinical and research 
settings in Migraine.  
Objective: To compare the performance of interictal migraine patients to controls in an 
assembled neuropsychological battery focused on executive functions and to study the practice 
effect of its repeated applications.    
Method: Assembly of the battery that was then applied twice within 6 weeks to interictal 
migraineurs and matched healthy controls.  
Results: Migraine patients (n=24) and controls (n=24) had similar performance in both 
applications of the battery. There was a slight practice effect between the first and second 
evaluation, significant in Stroop Interference test (p=0.002, multiplicity corrected); a meaningful 
score change was determined for each raw test scores. 
Conclusions: Interictal migraineurs and controls performance is identical in a brief cognitive 
battery focused on executive functions. Repeated applications produced a practice effect that was 
quantified. This short and practical battery may become a tool to measure the cognitive 







Cognitive subjective symptoms are often reported during migraine attacks (95, 
118, 133, 136, 156), contribute to patient disability (95) and may persist after successful 
pain control(158). Dysexecutive (attention, concentration, planning, judgment, 
initiative, speed) and language symptoms are the most frequent spontaneous attack-
related complaints (98, 118). Supporting these subjective complaints, some evidence of 
reversible attack-related cognitive dysfunction exists(108), in processing speed(109), 
working memory, visual-spatial processing, alertness/fatigue(60, 96, 98, 102, 159), 
attention and verbal memory and learning (100, 109). 
Some studies even documented the persistence of these symptoms at long term, 
in subgroups of patients with severe attacks, with aura (59) or in children (267). 
Persisting migraine at old age also seems to influence sustained attention and processing 
speed (268). Large studies performed in community-based cohorts (183-185, 269, 270), 
in twins (271), and longitudinal studies (270, 272) were nevertheless unable to identify 
long-term changes in cognitive profiles of migraineurs.  
Measuring migraine related cognitive dysfunction is increasingly crucial in 
determining migraine impact and migraine related disability. We are unaware of the 
existence of any objective measure of migraine-related cognitive impairment. The major 
problem of producing a measurement of neuropsychological dysfunction related to 
migraine is to determine if it can be useful in both migraine status – during attacks and 
while pain free. Assuming that patients may have different performances in different 
migraine status, the second problem will be that of the bias of the practice or learning 
effect of repeated test applications. Additionally, such a measurement should be 
practical, to be useful both in clinical and research settings. As so, it needs to be brief, 
reliable, provide different cognitive measures and be easily applicable with scarce 
resources. To be promptly available it must include valid routine or well-known tests 
that must evaluate the domains most likely to be affected, both during attacks and while 
pain free – executive functions and language.   
       In this study our aim was to (1) assemble a short battery using routine brief and 
reliable neuropsychological tests focused on executive functions and verbal skills; (2) to 
compare the interictal performance of migraine patients to matched healthy controls; 
(3) to study its practice effects over a short test-retest interval and (4) to identify the 
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predictable score intervals for which a change in test scores in repeated applications 
could be judged clinically meaningful. 
 
SUBJECTS and METHODS 
The study protocol was approved by the Hospital da Luz Ethics Committee. This 
is a prospective longitudinal study with two evaluations with a minimal interval of one 
month in-between, studying migraine patients while headache-free and healthy matched 
controls. Volunteers were recruited among the hospital staff by internal mail and 
intranet advertisement. Inclusion criteria were: a) age between 20 and 45 years; b) at 
least nine years of education; c) cases had either an history of episodic migraine without 
aura, as defined by the ICDH-III(7) , and controls were individuals without headaches 
(less than three headache episodes per year, none fulfilling the ICDH-III criteria for 
migraine or probable migraine); d) written informed consent.  
Exclusion criteria were a) presence of any other headache type including 
migraine with aura, chronic migraine with or without medication overuse or chronic or 
frequent episodic tension-type headache; b) history of past or current alcohol or drug 
dependence or abuse; c) history of past severe medical, neurologic or psychiatric 
disorder; d) current use of any psychoactive medication including migraine 
prophylactics; e) pregnancy or lactation.  
 Three females were included for each male. Recruitment was stratified by three 
age groups (21 to 29, 30 to 37 and 38 to 45 years). Within each age group, one sex-
matched control was included for each migraine case. Recruitment, inclusion and 
evaluation were made by one of the authors (RGG), who verified inclusion and exclusion 
criteria and performed standard clinical evaluation, including medical and neurological 
history and examination.  Volunteers with migraine were only evaluated if they had had 
a free interval of at least 48h since the last attack. After informed consent, protocol data 
was collected, including clinical and ICDH-III diagnosis for volunteers with migraine, 
gender, age, literacy, age at symptom onset, current frequency and duration of attacks, 
and use of prophylactic treatment and/or other current treatments. The presence of 




Neuropsychological Battery – Development and description 
 Tests were included in this battery according to 3 criteria, (1) Tests should be used 
in routine clinical practice and recognized as valid measures of the target functions, (2) 
should be brief and easy to apply, with minimal resources and without the need for 
computerized support and (3) should aim to evaluate the cognitive domains 
corresponding to complaints and to functions reported as impaired during migraine 
attacks. A panel of headache specialists and expert neuropsychologists selected the 
relevant tests based on the aforementioned criteria, as well as on their personal 
experience with the tests and on a literature review. The panel also evaluated the 
duration of each test, the complexity needed for its application and the potential of the 
test to have a marked practice or ceiling effects, as the target population is young and 
literate. The result was a battery with a total application time of around 6 minutes, 
composed by the following tests: Finger Tapping(233) (motor speed), Trail Making 
Test(237) (attention, shift), Stroop Test (interference task)(239) (processing speed , 
inhibitory control), Reverse Digit Span(245) (verbal working memory), phonemic 
(Letter “p”) verbal fluency(275) (verbal initiative, monitoring and semantic memory) 
and naming of 5 compound nouns from the Aachen Aphasia Test(276) (noun retrieval).   
Measures and Scores  
Finger tapping measures motor speed, and its results were averaged for the three 
10 second trials of each hand(233). Trail Making test produces three measures, time in 
seconds to complete part A (attention and processing speed), part B (divided attention) 
and difference B-A(237). Stroop interference measures inhibitory control and was 
scored as the number of colors named in a minute. Digit span backwards is a measure of 
working memory and is scored by the longest sequence of digits correctly repeated. The 
Aachen Aphasia Test includes several naming tasks so we selected the 5 items that 
showed higher difficulty with normal young controls. The answers were scored 
progressively if correct (score of 3) or if having some (score 2) or little (score 1) 
resemblance with the target noun(276). Phonemic verbal fluency evaluates verbal 
initiative and monitoring and produced four scores, the total number of words 
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generated, number of correct words generated (excluding errors and repetitions), 
number and size of clusters (that represented groups of 2 or more words with semantic 
or phonemic similarities - semantic if belonging to the same semantic category or 
phonemic, if having the same initial sound or termination) and switching (that 
represents number of transitions between clusters, including single words, errors and 
repetitions)(277). Analysis and classification of the phonemic verbal fluency task was 
done by two independent observers and cases of conflicting classification were resolved 
by consensus.  
 
Statistical Analysis 
Statistical analysis used SPSS v20. Frequencies and central tendency 
measures were used in descriptive statistics. The Kolmogorov-Smirnov test was used for 
normality testing. Two-sample t-tests were used to compare baseline patient variables. 
Comparison of means between the two study evaluations was performed with the paired 
t-test.  
The Holm-Bonferroni step down procedure(278) was adopted to account for 
multiple testing and to provide strong control of the type I error at the two-sided 5% 
significance level. Reported p-values are adjusted for multiplicity using the Bonferroni 
correction(206). For each test with a significant difference between the two evaluations 
we used multiple linear regression to evaluate the effect of several variables on the 
identified difference.  
For test-retest reliability we computed the Intraclass Correlation Coefficient 
between baseline and follow up scores for each test. The practice, or learning, effect of 
each test was estimated by averaging the difference of the raw test scores between the 
second and the first application of the test in each subject (Individual improvement = 
Score 2nd evaluation – Score 1st Evaluation). The standard error of the difference was 
determined from the standard error of measurement in each test and the 90% 
confidence intervals for the expected retest scores were determined (279). The 90% 
confidence interval of the averaged practice effect was used to determine the expected 







The study population consisted of 48 volunteers (12 males), four left-handed, of 
whom 24 had migraine without aura. The average age (± standard deviation) was 33.3 ± 
7.2 years (range 22 to 45 years) with 13.8± 3.1 years of literacy (range 9 to 20 years). 
The average score on the Beck scale in the first evaluation was 6.1 ± 7.1 (range 0 to 32). 
Although some subjects had scores in the range of depression, none of the volunteers 
were currently being treated with antidepressants, nor had clinical diagnosis of 
depression. Current non-complicated medical illnesses included asthma (2), 
hypertension (1), smoking habits (11), glaucoma (1), hypercolestrolemia (1), and 
diabetes (1).  In the total study population, 22 (56%) individuals were currently on daily 
medication, including 18 (82%) on oral contraception, 2 on asthma treatment, 1 with 
glaucoma topic treatment and 1 with statin treatment.  
The average time between evaluations was 45 ± 13.6 days (range 35 to 108 days).  
In the migraine group, average disease duration was 17.5± 5.9 years (range 10 to 33 
years). Upon inclusion, average attack frequency was 2.5 ± 2.0 per month (range from 
less than 1 to 8) and average attack duration was 22.7 ± 24.5 hours, ranging from 1 to 96 
hours. No patient was currently on migraine prophylactics. 
      Migraineurs and controls were successfully matched in demographic characteristics. 
Groups were similar regarding and dominance, literacy, concomitant diseases, current 
medication use and average Beck score. 
 
2.3 - Cognitive performance analysis – Difference between evaluations 
Table 1 shows the results of the neuropsychological evaluation with the data 
presented as raw scores. The only test in which a statistically significant difference was 
found was the Stroop interference test, having an average increase of 4.9 items (p=0.002) 
and an average decrease of 0.4 errors (p=0.025) from the first to the second evaluation. 




Table 1 – Results of neuropsychological tests in both evaluations and Mean difference 









Finger tapping (dominant hand) 55.9 ± 8.1 57.5 ± 6.5 1.6 ± 5.4 
Finger tapping (non-dominant hand) 51.1 ± 6.8 51.1 ± 6.1 0.0 ± 4.2 
Trail A Time 28.7 ± 8.1 26.3 ± 7.6 -2.4 ± 6.3 
Trail B Time 81.9 ± 32.5 71.4 ± 27.5 -10.5 ± 28.1 
Trail difference (B-A) 53.1 ± 30.1 45.1 ± 25.8 -8.0 ± 28.6 
Trail A errors 0.2 ± 0.4 0.1 ± 0.3 -0.1 ± 0.5 
Trail B errors 0.8 ± 1.2 0.7 ± 1.0 -0.1 ± 1.0 
Digit Span Backwards 4.1 ± 0.9 4.2 ± 1.0 0.1 ± 1.0 
Stroop Interference* 44.3 ± 8.4 49.2 ± 9.0 4.8 ± 3.8 
Stroop Errors† 0.8 ± 0.8 0.4 ± 0.6 -0.4 ± 0.8 
Naming – Total 13.6 ± 3.0 14.1 ± 0.8 0.4 ± 2.9 
Fluency (letter P, total)  12.1 ± 4.0 13.6 ± 4.3 1.4 ± 3.6 
Fluency (number of phonemic 
clusters) 
2.5 ± 1.5 3.3 ± 1.3 0.8 ± 1.8 
Fluency (size of phonemic clusters)‡ 6.0 ± 3.8 8.2 ± 3.4 2.2 ± 4.7 
Fluency (switching of phonemic 
clusters) 
8.1 ± 3.6 8.4 ± 3.4 0.3 ± 4.1 
Fluency (number of semantic 
clusters) 
1.7 ± 1.0 2.2 ± 1.4 0.5 ± 1.4 
Fluency (size of semantic clusters) 4.1 ± 2.7 5.2 ± 3.4 1.1 ± 3.6 
Fluency (switching of semantic 
clusters) 
9.1 ± 3.3 9.5 ± 4.7 
0.4 ± 3.5 
Legend: Paired T-Test was used to compare means; significant differences are: (*) p=0.002, (multiplicity-
adjusted p-value);  (†) p=0.025, (multiplicity-adjusted p-value);  (‡) p=0.048, (multiplicity-adjusted p-
value) 
 
Effects of gender, age, literacy, time lapse between evaluations, Beck Depression 
score and migraine in Stroop performance were analyzed with linear regression and no 





2.2 - Cognitive performance analysis – Migraine patients versus controls 
No statistically significant difference was shown in any neuropsychological test 
performance between individuals with migraine and controls, both in the first and 
second evaluations, as well as in mean differences in test performance between 
evaluations (Table 2).  Improved performance in the Stroop interference test was not 
documented in any of the groups (migraine and controls) individually. 
 
Table 2 – Results of neuropsychological tests in both evaluations between migraine 
patients and controls 
 1st Evaluation 2nd Evaluation 
 Migraine Controls Migraine Controls 
Finger tapping 
(dominant hand) 
55.3 ± 6.8 56.4 ± 9.3 57.0 ± 5.7 57.9 ± 7.4 
Finger tapping 
(non-dominant hand) 
49.9 ± 5.7 52.3 ± 7.6 50.4 ± 4.7 51.9 ± 7.2 
Trail A Time 28.6 ± 8.4 28.9 ± 7.9 26.8 ± 6.4 25.9 ± 8.8 






73.5 ± 32.8 






47.6 ± 30.7 
Trail A errors 0.3 ± 0.5 0.1 ± 0.3 0.1 ± 0.3 0.0 ± 0.2 
Trail B errors 0.6 ± 0.7 1.1 ± 1.5 0.6 ± 0.8 0.8 ± 1.2 
Digit Span Backwards 4.0 ± 0.8 4.2 ± 1.1 4.2 ± 1.1 4.2 ± 0.9 
Stroop Interference 43.8 ± 7.9 44.9 ± 9.1 48.5 ± 8.9 49.9 ± 9.1 
Stroop Errors 0.8 ± 0.8 0.8 ± 0.8 0.4 ± 0.6 0.3 ± 0.7 
Naming – Total 13.3 ± 0.9 14.0 ± 4.2 13.9 ± 0.8 14.2 ± 0.8 
Fluency (letter P, total) 12.2 ± 4.3 12.0 ± 3.8 14.5 ± 4.1 12.6 ± 4.4 
Fluency (number of phonemic 
clusters) 
2.6 ± 1.4 2.3 ± 1.6 3.5 ± 1.4 3.1 ± 1.3 
Fluency 
(size of phonemic clusters) 
6.7 ± 3.8 5.2 ± 3.9 9.2 ± 3.7 7.1 ± 2.8 
Fluency (switching of 
phonemic clusters) 
7.6 ± 3.8 8.5 ± 3.3 8.2 ± 3.7 8.6 ± 3.2 
Fluency (number of semantic 
clusters) 
1.9 ± 1.0 1.5 ± 0.9 2.7 ± 1.3 1.7 ± 1.3 
Fluency 
(size of semantic clusters) 
4.5 ± 2.6 3.7 ± 2.8 6.5 ± 3.2 4.0 ± 3.1 
Fluency (switching of semantic 
clusters) 
8.7 ± 3.5 9.4 ± 3.0 10.2 ± 4.1 8.8 ± 5.2 
Legend: Paired T test was used to compare means; multiplicity-adjusted p-value was 
non-significant in all comparisons 
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2.3 - Cognitive performance analysis – The estimated practice or learning effect 
The average difference between the second and the first applications of each test is 
depicted in table 1, and represents the estimated practice or learning effect of the whole 
population (migraine and controls), as no differences were documented between groups 
in any test. The test-retest reliability and the 90% confidence interval for each averaged 
difference in test scores are presented in table 3 and graphic 1. These values represent 
limits above or below which one can infer a likely change in the status of the patient. 
 
Table 3 – Average Practice or Learning effect and 90% CI of raw scores of the tests 








Finger tapping  
(dominant hand) 
0.712 0.03 - 8.59 to 8.65 
Finger tapping 
(non-dominant hand) 
0.797 1.60 - 5.15 to 8.36 
Trail A Time 0.645 -2.43 - 12.72 to 7.86 
Trail B Time 0.526 -10.48 – 56.14 to 35,19 
Digit Span Backwards 0.769 0.10 -1.45 to 1.66 
Stroop Interference 0.533 4.85 - 1.34 to 11.05 
Naming – Total 0.573 0.85 -0.80 to 2.50 
Fluency (letter P, total) 0.152 1.42 -4.55 to 7.39 
 
Graphic 1 – Expected improvement by practice effect in each test 
 
Legend: Lines represent average raw scores ± 90% CI; FT DH – Finger tapping Dominant Hand; FT NDH – 




Migraine related disability measurement mostly relies on patients’ self-report of 
ictal dysfunction; some instruments already exist that include measurement of interictal 
burden and health-related quality of life related to migraine(131). Part of the migraine-
related disability may be related to cognitive symptoms, either interictally or during 
attacks. Cognitive dysfunction may  contribute to patients’ perception of being only 46% 
effective when working during migraine(92) or to the increased frequency of cognitive 
complaints amongst migraineurs.  
We assembled a short test battery, easily applicable in any clinical setting and 
focused on executive functions and language, in order to obtain a quantitative 
measurement of cognitive dysfunction related to migraine. We then set up to determine 
if migraneurs in their interictal status would perform differently in this battery when 
compared to matched healthy controls.  
Testing this battery produced different measures that may pinpoint different 
aspects of cognitive functioning during the attacks. Executive functions have been 
specifically studied in the interictal period of migraineurs without aura. All the previous 
studies that focused only on executive measures documented a decline in migraineurs 
compared to controls in test such as the trail B and Wisconsin(59), in alternate finger 
tapping (210), in visual-spatial SWITCH task(203) and in the Boston Scanning Test and 
Controlled Oral Word Association Test (but not in Trail B) (211). The differences were 
related to length and severity of the disease(59), and to reduced middle frontal gyrus GM 
density(203) but not to the presence of white matter lesions on MRI(211).  In our study, 
migraine patients’ performance outside attacks was not statistically different to the 
performance of controls in all test scores, including the trail B. This is in accordance with 
Le Pira(211), but in disagreement with Carmarda(59).  Likewise, in our study we have 
found no difference between groups in all composite or derived scores (237, 277) and 
test-retest variance, suggesting that both overall performance but also cognitive 
strategies may not be much different between migraine patients outside an attack and 
controls.  
Most larger studies with broader testing (evaluation of several cognitive domains, 
and including some executive measures) were either negative in documenting interictal 
executive dysfunction in episodic migraine without aura(105, 159, 184, 219, 269, 270, 
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280, 281) or showed very small and trivial changes (105, 282, 283). Our results are 
therefore in line with previous data. Differences to previous studies focusing on interictal 
executive function in migraine without aura may relate to interindividual variations, 
sampling and sample size, co-morbidities (such as vascular risk factors, anxiety and/or 
depression) and concomitant use of migraine prophylactics (59, 105, 203, 210, 211, 
284). Our sample is of otherwise healthy and young migraineurs, with low impact 
disease without migraine prophylactic medication.  
Having determined that this battery will not differentiate migraineurs in the 
interictal status from controls, its potential usefulness would be restricted to the 
identification and quantification of migraine attack-related disability, which implies its’ 
repeated application. Its usefulness in such context would depend on the magnitude of 
its practice effect bias and on the determination of the clinically meaningful change in 
test scores, in repeated applications.  
We tested participants performance in a repeated short term (average 45 days) 
applications and we were able to demonstrate a slight score improvement towards the 
second evaluation, as described in most neuropsychological tests, corresponding to the 
practice effect(279, 285). The magnitude of this effect in our sample was as expected in 
healthy controls.  
Executive tests are slightly less susceptible to practice(285), as their objective is 
to evaluate problem solving strategies, speed and attention. With repeated applications, 
strategies learned can change and attention may be shifted, influencing practice but, on 
the other hand, are more easily influenced by performance variability(286). We need to 
consider this effect in identifying meaningful changes of performance in sequential 
battery applications, to distinguish improvement on test performance (due to practice 
and familiarity) from improvement due to changes in intrinsic cognitive ability. As an 
example, Trail and verbal fluency tests were demonstrated to have scarce learning 
effects over 12 months, but that was not held true for other executive tests(287). In our 
study, the improvement in one particular test– the Stroop test –was found to be 
significant between applications, when considering the total sample, but did not differ 
between groups. This improvement could not be accounted by any of the clinical 
variables considered, including depressive symptoms. The Stroop test differed from 
other tests by showing higher test-retest reliability, thus justifying that small individual 
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changes may have been sufficient to establish a statistical difference between test 
applications, in our small sample. 
We were able to quantify the expected improvement due to the practice effect for 
each test of this battery, using a predefined standard methodology (279), in order to be 
able to correctly interpret individual variation and to identify a meaningful change. 
These calculations were made for each test, using the raw test scores, because variability 
in learning differed between tests.  
In conclusion, we assembled a short and practical battery that was not able to 
identify interictal cognitive performance changes in otherwise healthy migraine patients 
without prophylactic treatment, when compared to age, sex and literacy matched 
controls. We were able to determine the expected practice effect for each of the battery 
tests and to identify the tests more likely to improve. This data can allow further studies 
in which we will be able to correctly interpret variations in sequential short term 
applications of this battery in different migraine status, such as during an attack. We 
recognize this instrument needs to be tested during a migraine attack, in order to 
determine if it is applicable, if it is able to identify cognitive dysfunction and if it 
correlates to other measures of cognitive difficulties, such as subjective ad hoc 
assessment or to the Mig-SCog(118) and to attack related disability. Such an instrument, 
if performing adequately, could be used as an objective end-point in acute treatment 
migraine trials(190), besides simple pain relief and recurrence. Further studies may 
therefore be needed, in larger samples and in more complex migraine populations, such 






Do brain perfusion changes exist during migraine without aura attacks? 
An Arterial Spin Labeling MRI perfusion study of Migraine 
without aura attacks. 
 
Gil-Gouveia R, Pinto JS, Figueiredo P, Vilela PF, Martins IP.  




Background: Studies of brain perfusion during attacks of migraine without aura are scarce and 
have inconsistent results. 
Objective: To study global brain perfusion during a spontaneously occurring untreated migraine 
without aura attack using Arterial Spin Labeling (ASL) MRI. 
Methods:  Prospective study of migraine patients scanned with ASL-MRI during a spontaneous 
untreated attack and in a headache free period. Image analysis used FSL and MATLAB; Group 
analysis used permutation methods in order to identify voxels with statistically significant 
perfusion differences between migraine and migraine-free sessions. 
Results:  Thirteen women were scanned, with an age average of 35.7 years and average disease 
duration of 23 years. The evaluated migraine attack had an average intensity of 6.8 (VAS) and an 
average duration of 16 hours. No global or regional perfusion differences were identified in the 
attack, when compared to the baseline scan. 
Discussion: This is the first study of brain perfusion during attacks of migraine without aura 
using the ASL-MRI technique. Our results substantiate that the painful phase of migraine without 








Brain functional imaging has led to a wider understanding of neuronal processes 
involved in non-structural disorders, such as migraine and other headache syndromes; 
the migraine attack remains the hallmark of migraine and the basis for understanding its 
clinical impact and pathological processes.  
The study of brain perfusion during the migraine attack has yield controversial 
information. Initial perfusion studies measured regional cerebral blood flow (rCBF) with 
133Xe and were the basis of the vascular theory of migraine. In migraine with aura, a 
biphasic pattern with hypoperfusion during the aura phase and hyperperfusion during 
the headache phase(288) was identified with this technique. The studies of the visual 
aura have ever since been associated with a cerebral posterior hypoperfusion wave that 
spreads anteriorly, which is consistently documented in 133Xe, SPECT, PET and perfusion 
perfusion-weighted imaging (PWI) MR(289). 
Over 80% of migraine patients suffer from migraine without aura. These patients 
have been scarcely studied and the results of such studies have been inconsistent(290-
292), with only one PET study being able to identified a reduction in CBF and CBV during 
headache yet without changes in oxygen extraction(293). 
We aimed to evaluate brain perfusion changes during headache in patients with 
migraine without aura, using a non-invasive quantitative MRI perfusion technique, 
Arterial Spin Labelling (ASL-MRI), which presents both high temporal and spatial 
resolutions and is sensitive to the perfusion changes occurring at the capillary level(294, 
295).  In this study we will measure the global and regional brain cerebral blood flow 
twice, once during a spontaneous attack of migraine without aura and later in the same 




Volunteers were recruited among the hospital staff by internal mail and intranet 
advertisement and in the acute care outpatient clinic by screening of the triage nurse. 
 
 171 
We included otherwise healthy adults (20 to 45 years) with episodic migraine without 
aura. The presence of aura, other headaches or headache frequency >15 days per month 
were exclusion criteria, as well as pregnancy, claustrophobia or the presence of 
ferromagnetic foreign bodies or metallic implants or devices. In order to minimize 
potential effects of pharmacological agents, the only allowed daily medication was oral 
contraception. There was no financial compensation for the volunteers. All volunteers 




Prospective longitudinal study with two evaluations of the same individual in two 
conditions, first during a spontaneously occurring migraine without aura attack and 
another in a headache free period, within a minimal interval of 48 hours since the last 
attack.  Acute pain medication was not allowed in the 12 hours before the attack 
evaluation. A minimal headache intensity of 4 on a VAS was required to be eligible for 
the attack evaluation and scanning could be done in any time within the attack, as long 
as pain intensity wasn’t decreasing; attack duration was not a limitation. In the post-hoc 
analysis we compared characteristics of patients scanned early and late during the 
attack, using the frame of the first five hours for the early attack, as it encompasses the 
average duration of the attacks studied in previous series.  
Both evaluations consisted of a brief interview collecting demographic and 
clinical details of headaches and of the evaluated headache, followed by the MRI scan. 
Data collected included ICDH-III diagnosis, gender, age, literacy, disease duration, usual 
frequency, duration and intensity of attacks, use of prophylactic treatment and other 
current treatments and description of the evaluated attack; migraine impact was 
quantified with the HIT-6(140) score and the presence of depressive symptoms with the 
Beck Depression Inventory(274). 
 
Image Acquisition 
Volunteers were studied on 3 Tesla Siemens Verio MRI system (Siemens, 
Erlangen, Germany) using a 12-channel head RF coil. Subject’s motion was restricted 
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with foam padding between the head and the coil. For each subject, a T1-weighted 
structural image (3D T1 MPRAGE, TR=2250m, TE=2.26ms, voxel size of 1x1x1mm3) and 
PASL (Q2TIPS technique; PICORE labeling scheme; 2D echo planar -GE-EPI- readout, 
TR=2500ms, TE= 11ms,  TI1 = 700ms, TIs= 1600ms, TI2= 1800ms, with 9 contiguous 
axial 8mm thickness slices with a voxel resolution of 4 x 4 x 10mm3 were acquired in an 
ascending order baseline images) were obtained during rest. 
 
Image Processing and Analysis 
Image analysis was performed using FSL (http://fsl.fmrib.ox.ac.uk/)(296) and 
MATLAB custom based tools (The MathWorks, Inc., USA). ASL data pre- processing 
included brain extraction(297), motion correction(298), temporal filtering with a 100s 
frequency cutoff and spatial smoothing with a 5mm full width half maximum (FWHM) 
Gaussian kernel. Data were also co-registered to an expanded functional image, to a main 
structural image and to a standard space using the FSL tool FLIRT(298). Subsequently, 
control and labeled images were pairwise subtracted and perfusion weighted maps were 
computed by normalization with the brain equilibrium magnetization estimated from 
the averaged control images. Nine regions of interest (ROI) were identified according to 
the MNI152 atlas (McConnell Brain Imaging Centre, Montreal Neurological Institute, 
McGill University, Montreal, Quebec, Canada) and group averaged CBF values were 
assessed for each ROI and session. 
 
Statistical Analyses 
Statistical analysis of clinical variables was made with SPSS 20.0.  Comparison of 
means between the two study evaluations used the paired t-test; in post-hoc analysis 
comparison of means between groups the independent sample T-test was used. CBF 
variation was calculated by subtracting the total CBF on the baseline session from the 
total CBF of the migraine attack (attack CBF – baseline CBF = ∆CBF) and by averaging the 
∆CBF to the baseline CBF (∆CBF/ baseline CBF = ∆CBF %). Multiple linear regression was 
used to determine in any independent variable, either population related (age, literacy, 
disease duration, HIT-6 and time lapse between evaluations) or attack related (pain 
duration and intensity of pain, nausea, photophobia, phonophobia and aggravation with 
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physical effort) had influence on the ∆CBF (dependent variable). Type I error was set at 




Fourteen right-handed female patients were included yet one patient dropped 
out. The final sample of 13 females had an age average of 35.7 ± 7.4 years. Previous 
medical history was positive for asthma in one patient and 6 were mild smokers (less 
than 10 units per day). Six (46%) used oral contraception; no other medication was 
currently being taken. Average Beck score was 5.0±3.6, all patients scored within normal 
values. 
Average migraine duration was 22.7±10.2 years. The HIT-6 score was 62±4.0, 
representing a high impact disease. Average monthly attack frequency was 2.3±1.6 (1 to 
6) with an average duration of 32.6±25.3 hours and average intensity of 7.4±1.3 on a 0-
10 VAS scale.  Patients described unilateral(54%), predominantly throbbing pain always 
accompanied by photo, phonophobia and nausea, 4(31%) vomited regularly in attacks 
and 11(85%) had pain aggravation by physical effort.  
 
2. Migraine attack evaluation and comparison with baseline 
Details of the evaluated migraine attack are depicted on table 1.   







 MIGRAINE ATTACK 




















1 68 45,0  44,1 7,67 8,0 4,0 3,0 7,0 4,0 
2 64 33,7  27,5 24,17 6,0 2,0 3,0 3,0 2,0 
3 63 42,3  39,1 2,67 6,0 4,0 2,0 2,0 4,0 
4 60 32,5  30,4 69,00 5,0 4,0 4,0 4,0 3,0 
5 65 41,5  35,1 9,67 9,0 6,0 8,0 8,0 9,0 
6 60 46,9  45,6 45,70 8,0 5,0 5,0 0 0 
7 52 45,2  52,1 13,25 6,0 3,0 5,0 5,0 6,0 
8 60 46,0  40,5 6,25 8,0 5,0 7,0 7,0 6,0 
9 59 50,6  57,0 5,00 9,0 5,0 5,0 6,0 6,0 
10 62 42.4  41.7 4,00 5,0 6,5 6,5 8,0 8,0 
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11 65 37,8  40,9 6,67 7,0 5,0 5,0 5,0 5,0 
12 63 36,5  36,8 4,50 6,0 1,0 5,0 5,0 2,0 
13 65 50,8  51,1 12,00 6,0 5,0 5,0 5,0 5,0 






















Legend: HIT-6 – Headache Impact Test (in points); CBF – Cerebral  Blood Flow (in ml/ 100g/ min); 
Duration – Pain duration up to the scan (in hours); Intensity – Pain intensity upon entering the scan (0-10 
VAS); Nausea - Nausea intensity upon entering the scan (0-10 VAS); Photophobia - Photophobia intensity 
upon entering the scan (0-10 VAS); Phonophobia - Phonophobia intensity upon entering the scan (0-10 
VAS); Worse with P. Effort – Intensity of pain aggravation by physical effort upon entering the scan (0-10 
VAS); Av ± sd – average ± standard deviation 
 
The average attack intensity was similar to usual attacks (paired T-Test 0.959, 
p=0.357 n.s.); all patients had nausea and photophobia on the evaluated attack, 2(15%) 
vomited and all but one(92%) had photophobia and pain aggravation with physical 
effort. Average total CBF values during the attack were similar to total CBF values outside 
the attack (41.7±8.8 versus 42.4± 6.2 ml/100g/min, p=0.589, n.s.); Perfusion weighted 
maps across subjects comparing migraine and non-migraine sessions are plotted for 
total CBF (Figure 1).  
 
Figure 1 – CBF maps averaged across subjects during the Migraine Attack and Attack 
free status 
 
Legend – CBF maps averaged across subjects in both conditions (Migraine Attack and Attack free status), 






Figure 2 – CBF of different regions of interest (ROIs) during the attack and attack free 
status 
 
Legend: Group average per session; Bars represent the mean, error bars the standard deviation of the 
mean. No differences were found in any comparison (paired T-test, p n.s.) 
 
CBF analysis in several regions of interest was compared and no differences were 
found in any of the analyzed regions (Figure 2). 
 
3. Post-hoc analysis 
CBF variation (∆CBF %) represented an average -2.25 ± 10.6 % of CBF in the 
attack relative to baseline (ranging from –18.4 to 15.3%). ∆CBF average value was -
0.72±4.46 ml/100gr/min, ranging from -6.40 to 6.90. Multiple linear regression failed to 






Table 2 - Multiple Linear regression to evaluate the effect of clinical (independent) 
variables on ∆ CBF (dependent variable) 
Legend: p = significance level;  
 
Table 3 – Post-Hoc analysis 1 - Comparison of clinical variables of patients scanned 
early (≤ 5h) and late (> 5h) into the attack 
 




 (> 5h) 
N=9 
P 
Mean ± sd Mean ± sd 
Age (years) 33.0 ± 7.6 36.9 ± 7.4 0.402 
Literacy (years) 16.2 ± 3.3 15.1 ± 3.4 0.583 
Disease Duration (years) 22.2 ± 11.1 22.9 ± 10.5 0.923 
HIT-6 score 61.8 ± 1.9 62.1 ± 4.7 0.888 
Pain intensity (VAS) 6.5 ± 1.7 7.0 ± 1.3 0.577 
Nausea Intensity (VAS) 4.1 ± 2.3 4.3 ± 1.2 0.833 
Photophobia Intensity (VAS) 4.6 ± 1.9 5.0 ± 1.6 0.724 
Phonophobia Intensity (VAS) 5.2 ± 2.5 4.9 ± 2.4 0.810 
Worsening with P. Effort (VAS) 5.0 ± 2.6 4.4 ± 2.6 0.729 
Attack total CBF 44.3 ± 11.1 40.8 ± 8.5 0.578 
∆ CBF 1.2 ± 4.8 -1.3 ± 4.4 0.425 
Legend: sd – standard deviation; p = significance level;  
 
 
 ∆ CBF (DEPENDENT VARIABLE) 
INDEPENDENT VARIABLES Unstandardized beta 
coefficient ± Std. 
Error 
p 
1. Population Related Variables 
Age (years) -0.270 ± 0.203 0.232 
Literacy (years) 0.163 ± 0.403 0.701 
Disease Duration (years) 0.255 ± 0.131 0.100 
HIT-6 score -0.708 ± 0.346 0.087 
Time between evaluations (days) 0.023 ± 0.023 0.351 
 
2. Attack related Variables 
Attack duration (hours) -0.027 ± 0.141 0.854 
Pain intensity (VAS) 0.076 ± 2.416 0.976 
Nausea Intensity (VAS) -0.377 ± 2.462 0.884 
Photophobia Intensity (VAS) -0.307 ± 1.662 0.861 
Phonophobia Intensity (VAS) -0.317 ± 1.666 0.857 
Worsening with P. Effort (VAS) 0.490 ± 1.967 0.813 
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Due to the wide variation of scan timing and the range of ∆CBF values, patients 
evaluated early (≤ 5 hours, n=4) and late (>5 hours) into the attack and patients having 
positive (migraine attack>baseline, n=5) and negative ∆CBF (baseline>migraine attack) 
were compared; no significant differences were identified (tables 3 and 4). 
 
Table 4 – Post-Hoc analysis 2 - Comparison of clinical variables of patients with 
negative and positive ∆CBF 
 




∆CBF >  0 




Mean ± sd Mean ± sd 
Age (years) 35.4 ± 6.0 37.8 ± 9.1 0.597 
Literacy (years) 15.3 ± 3.3 15.6 ± 3.9 0.883 
Disease Duration (years) 18.0 ± 8.7 30.0 ± 9.6 0.047 
HIT-6 score 62.0 ± 3.1 60.8 ± 5.5 0.424 
Pain intensity (VAS) 7.1 ± 1.5 6.8 ± 1.3 0.695 
Nausea Intensity (VAS) 4.3 ± 1.2 3.8 ± 1.8 0.590 
Photophobia Intensity (VAS) 4.6 ± 2.2 5.0 ± 0.0 0.629 
Phonophobia Intensity (VAS) 4.4 ± 3.0 5.2 ± 0.4 0.525 
Worsening with P. Effort (VAS) 4.0 ± 2.9 4.8 ± 1.6 0.592 
Baseline total CBF 41.1 ± 5.8 44.2 ± 6.8 0.423 
Attack total CBF 37.5 ± 6.8 47.6 ± 8.4 0.044 
∆CBF -3.6 ± 2.3 3.4 ± 3.2 0.001 
∆CBF % -9.2 ± 6.2 7.5 ± 5.0 0.001 




No significant brain global or regional CBF changes were identified in this study, 
using ASL-MRI to scan 13 migraine without aura attacks, in line with most of existing 
data(290-292, 299). Our findings support that brain perfusion changes are a marker of 
migraine with aura being most likely driven by the a neurogenic CSD-like phenomena, 
which is able to influence the neurovascular unit and decrease regional cerebral blood 
flow(48). These changes do not seem to occur in attacks without aura. 
 
Initial 133Xe perfusion studies in migraine with aura demonstrated 
hyperperfusion during headache, after the initial reduction in blood flow of the aura 
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(288, 300-303). These were supported by SPECT studies, although rCBF increases 
shown after the aura were not clearly timed to pain onset (303, 304). Findings of 133Xe 
studies in attacks without aura are discrepant, some revealing increase in mean CBF 
during headache(305-309) while most showed no differences(292, 299, 310). This 
raised the hypothesis of different pathophysiology of the two types of attacks(311, 312) 
as the visual aura is consistently associated with a progressive postero-anterior 
hypoperfusion wave (CBF variation of –10 to –35%)(291) using different 
techniques(289).  
 
Migraine is a heterogeneous disease and several differences exist between attacks 
with and without aura(311); different clinical manifestations may represent phenotypic 
differences of the same disorder, resulting from genetic and environmental variance, or 
be synonymous of distinct pathophysiology. Although cortical involvement by CSD-like 
phenomenon has been elegantly demonstrated in visual aura with BOLD-fMRI (40, 48), 
other attack-related phenomena independent of aura could also potentially translate 
into brain perfusion changes, such as activation and sensitization of the trigemino-
vascular system and of other cortical and subcortical areas specifically involved in 
migraine pain modulation(48).  
 
Studies of brain perfusion during attacks without aura are scarce; to our best 
knowledge six were published in English literature, comprising 56 patients(290-293, 
299, 313) and using 133Xe(313) CT, Xe-SPET, PET and dynamic susceptibility contrast 
perfusion weighted image (DSC-PWI) MRI. Most of the patients (N=32) were studied 
with Xe-SPECT(290, 292, 299) and only one had a global hyperperfusion during the 
headache. Studies with 133Xe(313) in two patients identified focal oligemia in different 
regions in each (occipitoparietal and parietocentral). PET was used to study 9 patients  
and a slight reductions in CBF (up to 10%) and CBV (up to 5%) during headache were 
identified, although with normal oxygen extraction(293). The most recent study 




These results are not uniform, but the majority of the patients studied had no 
detectable perfusion changes during attacks without aura. The 12 cases in which 
perfusion differences were identified, those were mild and below the range found in 
aura(293) or inconsistent(313). The incongruence of these results could be associated 
with patient selection, timing of the scan, measurement reproducibility and technique 
limitations. Timing of the scan is a particularly important aspect, as a recent PET study 
in migraine without aura has identified brain regional blood flow differences in the 
premonitory phase of a triggered migraine attack (before pain) when compared with the 
painful phase, as well as different patterns of activations with the evolving attack(28).  
 
ASL-MRI allows quantitative measurement of CBF with high temporal and spatial 
resolutions(294) being sensitive to the perfusion changes occurring at the capillary 
level(295), which reflects more closely the changes taking place at the neurovascular 
unit(294). ASL uses an endogenous diffusible tracer (water molecules of the blood) to 
estimate the brain perfusion(294), being non-invasive and showing high reproducibility 
and accuracy for quantitative CBF values, compared to other techniques(314). The major 
drawbacks of ASL perfusion studies are its low signal-to-noise ratio (SNR, 1% of signal 
change), requiring the use of high field MRI units (as was used in the this study) and the 
inadequate CBF quantification in cases of significant delays in the arterial arrival time, 
such as in patients with extracranial atherosclerotic disease (an unlikely problem in our 
population)(315).  
  
There are four patients reports of attacks studied with ASL-MRI, three of auras 
revealing reversible focal hyperperfusion in areas corresponding to the aura 
symptoms(316); one patient without aura was scanned very early (1h into pain) and a 
bilateral thalamic and hypothalamic hypoperfusion was shown, associated with relative 
frontal cortex hyperperfusion; changes reversible 30 minutes after treatment with a 
triptan, correlating with headache “improvement” (317). The ASL findings in this single 
case report are not consistent with our results, maybe resulting from timing of the scan 




Some reports of hypoperfusion changes similar to those observed during auras 
were documented in attacks without aura, in 2 patients with 133Xe(313) and in one with 
PET(318). Visual changes atypical for aura were also associated with brain 
hypoperfusion (using PET and BOLD-fMRI)(319, 320), findings that have led to the 
speculation that CSD-like events could also occur in attacks without aura, although no 
robust scientific evidence supporting these claims exists(48). A most likely explanation 
is probably that aura related neuronal changes and associated hypoperfusion could 
sometimes be clinically silent, as often happens in epilepsy patients that have sub-clinical 
seizures. Some early cases of hypoperfusion waves (133Xe and PWI-MRI studies(291, 
303)) in migraine with aura attacks that persisted into the headache phase after the 
disappearance of the aura are supportive of this view. An alternative hypothesis could 
relate to some minor clinical symptoms occurring in attacks, such as the “visual snow” 
phenomena, could be caused by mild CSD-like changes that did not evolve into full auras 
but are still be a marker of brain metabolism changes related to higher susceptibility of 
having aura(321). 
 
All patients in our sample had migraine without aura and long lasting disease (on 
average 22 years) being therefore unlikely to develop aura-like phenomena in the future. 
The attack studied was representative of their usual attacks, both in pain intensity and 
associated symptoms. We obtained a high impact episodic migraine sample population 
free of preventive treatment with a similar size to the larger published series (n=13) and 
studied an untreated attack, avoiding biases related to the effects of triggering 
substances or treatments. The timing of image acquisition in our sample was 16.2±19.7 
hours (from 2h40 to 69 hours), later than previous studies of spontaneous attacks: 
Bednarczyk scanned patients with PET between 3.8 and 24.5 hours (average 3.3h)(293), 
Sanchez del Rio with PWI-MRI between 1 to 11h (average 4h30 ± 2h50)(291), studies 
with 133Xe SPECT included scans in the first 30 to 60 minutes(299), within about 1 hour 
(292) and from 3h to 20h (average 7h±5h)(299).  We were unable to find changes in the 
subgroup of patients scanned early (<5 hours) and this sub-group was in all aspects 
similar to the group scanned later; although with the inherent limitations of a post-hoc 




We did not impose any limit to the duration of pain in our study, allowing patients 
to come as soon as they felt that they needed treatment in order to reach a moderate 
pain intensity in order to ensure that the scan evaluated a fully symptomatic attack and 
to avoid the late premonitory phase(28), although bearing in mind that variability occurs 
between patients and attacks and that there is no relevant clinical marker that allows the 
identification of attack phases. Nevertheless, available evidence suggests that no 
significant perfusion changes are expected in neither phase of untreated migraine 
without aura attack (292, 299, 310).  
 
Our study has limitations inherent to the used technique, yet it should be 
emphasized that the major limitation (the arterial arrival time differences) should not be 
an issue in the population studied. Relevant aspects include the potential low magnitude 
of perfusion changes occurring during attacks could have falleen in-between the limits 
of the reproducibility of the technique (less than 10% CBF change)(322) and a potential  
bias induced by the expected circadian variation of CBF values(323) could have been 
relevant in this sample, as it was no not possible to scan each patient at the same 
schedule in the two studies. 
Although being one of the largest patient series published, our study still had a small 
sample size. It has been suggested that a cohort of less than 15 patients would be enough 
to obtain valid results(324) however, if we consider that migraine heterogeneity could 
relate to the existence of different subgroups of patients, our patient series may not have 
be sufficient to identify such subgroups. Our post-hoc analysis, separating patients with 
positive and negative ∆CBF was unable to identify meaningful differences to allow 
subgroup characterization. Post-hoc analyses performed in this study imposes further 
limitations of results’ interpretation. Finally, we recognize that the scanning time, 
imposed by our study design, was heterogeneous within the attack, although it did not 
seem to influence results.  
 
In conclusion, our results support previous findings suggesting that no major brain 
perfusion changes occur during the headache phase of the migraine without aura attack, 









Are there neuronal network abnormalities underlying the attack-related executive 
symptoms in migraine? 
Executive function in migraine without aura attacks.  
An fMRI study using the N-Back paradigm. 
 
Gil-Gouveia R, Pinto JS, Figueiredo P, Vilela PF, Martins IP.  
Executive function in migraine without aura attacks. An fMRI study using the N-Back 
paradigm. [in preparation] 
 
ABSTRACT  
Background: Migraine attack-related reversible cognitive dysfunction is characterized by an 
attention and working memory impairment and slower processing speed. The neuronal subtract 
underling this changes is unknown but involvement of the anterior cingulate and the fronto-
polar cortex in possible, as both structures are active in pain processing and during migraine 
attacks. 
Objective:  To explore cortical activation in response to a working memory task (N-Back) in 
migraine patients in and outside migraine attacks.  
Methods: A BOLD-fMRI study and a brief neuropsychological evaluation focused on executive 
functions were conducted in episodic migraine patients during an untreated spontaneously 
occurring migraine without aura attack and repeated in a headache-free period. Brain activation 
patterns and neuropsychological performance were compared between the two situations. 
Results: Thirteen female migraine volunteers were studied, with an age average of 35.7 years. 
The evaluated migraine attack had an average intensity of 6.8 (VAS) and an average duration of 
16 hours. No changes in neuropsychological performance nor relevant disruption of cortical 
oxygen consumption while performing the working memory task were identified in the attack, 
when compared to the baseline scan.  
Discussion: This study was not able to demonstrate a group difference neither in 
neuropsychological performance, brain activation patterns or areas between the migraine attack 
and the headache-free status thus failing to provide an explanation to attack-related cognitive 






Migraine patients describe reversible subjective cognitive changes during 
migraine without aura attacks that contribute to migraine attack-related disability.  
Neuropsychological evaluation supports an attack-related reversible performance 
decline when compared to baseline performance, although the pattern of dysfunction 
has been inconsistent across studies (108, 109). 
The most often described spontaneous symptoms are attention difficulties, 
diminished cognitive efficiency and processing speed impairment, which are nicely 
correlated to evidence of an attack-related attention and  working memory deficit and of 
impaired processing speed obtained in studies focusing on neuropsychological executive 
measures (60, 96, 97, 100, 102, 108).  
Attention can be defined as the ability to focus on a task relevant stimulus and is 
believed to be mediated by anterior cingulate cortex (ACC) function(325); working 
memory represents the ability to temporarily store task relevant information and has 
been associated with fronto-polar cortex (FPC) activity(326). Processing speed is not a 
cognitive function that can be attributed to a specific brain area, it depends on functional 
and effective interactions among distant brain regions involved in the execution of 
different cognitive functions(327). 
Involvement of the cingulated and prefrontal(29, 53, 153, 214, 215) cortices (as 
well as other cortical and subcortical structures) has been consistently documented by 
PET during migraine without aura attacks being generally attributed to modulation of 
pain sensory input and in the cognitive processing of pain perception(153).  
An increased ACC activation in episodic migraine patients responding to 
trigeminal noxious stimulation has been interpreted as analgesic compensatory 
reorganization of pain-processing regions(328); in fact, migraine chronicity (as well as 
other chronic pain conditions) has been related to a decrease in ACC grey matter(172), 
a probably adaptive phenomenon that is partially reversible with effective pain 
treatment(329-331).  
Structural abnormalities have also been documented in interictal episodic 
migraine without aura patients, such as reduced middle frontal gyrus and inferior 
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parietal lobe grey matter density(203) and reduced connectivity of the fronto-
parietal(executive) network (FPN)(170), supporting the involvement of the executive 
system in migraine. 
All these findings are probably related to involvement of the general pain 
processing brain network in migraine yet the evidence of functional implication of these 
brain changes in actual cognitive performance is scarce(170, 203). In particular, no 
evidence of relation to attack-related cognitive dysfunction exists. 
Our objective was to study the cortical activation pattern using fMRI and 
executive neuropsychological performance in response to an executive challenge during 
and attack of episodic migraine without aura and to compare it to the headache-free 
status.  The fMRI paradigm chosen was the verbal N-Back, a working memory task that 
also involves attention and processing speed, and is able to activate the prefrontal, 
premotor, dorsal cingulate and posterior parietal cortices(332), some of the areas 




Volunteers were recruited among the hospital staff by internal mail and intranet 
advertisement and in the acute care outpatient clinic by screening of the triage nurse. 
We included otherwise healthy adults (from 20 to 45 years) with episodic migraine 
without aura (ICDH-III(7)). Exclusion criteria were the presence of aura, other 
headaches types, headache frequency >15 days per month, pregnancy, claustrophobia 
or the presence of ferromagnetic foreign bodies or metallic implants or devices. The only 
allowed daily medication was oral contraception. There was no financial compensation 
for the volunteers. All volunteers signed a written informed consent. The study protocol 
was approved by the Hospital Ethics Committee. 
Study design 
This was a prospective longitudinal study with two evaluations of the same 
individual in two conditions, first during a spontaneously occurring migraine without 
aura attack and another in a headache free period, within a minimal headache-free 
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interval of 48 hours. Eligibility for the attack evaluation implied a minimal headache 
intensity of 4 on a 0-10 VAS and the absence of acute pain medication in the previous 12 
hours.  
Both evaluations consisted of a clinical interview including detailed headache 
history followed by the application of a short neuropsychological battery and the MRI 
scan, which included structural high resolution T1-weighted 3 Tesla MRI and the fMRI 
N-Back paradigm(333). 
Tests included in the neuropsychological battery were Finger Tapping (233) 
(motor speed), Trail Making Test(237) (attention, shift), Stroop Test (interference 
task)(239) (processing speed, inhibitory control), Reverse Digit Span(245) (verbal 
working memory), phonemic (Letter “p”) verbal fluency(275) (verbal initiative, 
monitoring and semantic memory) and naming of 5 compound nouns from the Aachen 
Aphasia Test(276) (noun retrieval). Migraine impact was quantified with the HIT-6(140) 
score and the presence of depressive symptoms with the Beck Depression Inventory 
(273, 274). The Mig-SCog was used to evaluate the impact of cognitive symptoms during 
the migraine attack(118). 
In the N-Back paradigm we used the 2-Back task, in which a sequence of letters is 
displayed one at a time and subjects are asked to determine if the current letter was the 
same as that presented 2 letters previously. The control condition was the search for a 
pre-specified target (ex. “find the letter “A”). Each block had 21 letters presented in a 
pseudorandom sequence for 1 second each and an interstimulus interval of 1 second 
(total duration of 42 seconds); the ratio of target stimuli to distracter stimuli was 1:4 Five 
blocks of task/control were presented so the total task had a duration of 420 seconds (7 
minutes). 
Monitoring of N-Back performance included scoring correct, false positive and 
false negative answers. The attack evaluation also included scoring of migraine related 
symptoms (pain, nausea, photophobia, phonophobia, aggravation by physical effort and 






Volunteers were studied on 3 Tesla Siemens Verio MRI system (Siemens, 
Erlangen, Germany) using a 12-channel head RF coil. The participants were made 
familiar with the scanner and the NBack task was explained and trained before the scan. 
Subject’s motion was restricted with foam padding between the head and the coil. For 
each subject, a T1-weighted structural image (3D T1 MPRAGE, TR=2250m, TE=2.26ms, 
voxel size of 1x1x1mm3). BOLD images were obtained during the execution of an N-Back 
task, using a gradient-echo EPI sequence (TR=2000ms/TE=30ms). 22 slices were 
acquired with voxel size of 4x4x3 mm3.  
Image Processing and Analysis 
Image analysis was performed using FSL (http://fsl.fmrib.ox.ac.uk/)(296, 334) 
and MATLAB custom based tools (The MathWorks, Inc., USA).  BOLD data pre- 
processing included brain extraction, motion correction, temporal filtering with a 100s 
frequency cutoff and spatial smoothing with a 5mm FWHM Gaussian kernel. Data were 
also co-registered to a main structural image (MPRAGE) and to a standard space (MNI 
2mm). BOLD responses were modeled by a block design with specific timings of the 
NBack task convolved with a double gamma HRF and entered into a General Linear 
Model (GLM). Standard motion parameters, temporal derivatives and temporal filtering 
of the regressor were also added to each individual GLM. Voxelwise parameters were 
obtained from the GLM coefficients over the cluster-thresholded (p<0.05 and Z>2.3) 
mask, for each subject.  
Group analysis was performed on the individual contrasts of parameters using 
mixed effects, in order to identify voxels exhibiting statistically significant N-back-
related BOLD signal changes. Group analysis was also performed in order to identify 
voxels exhibiting statistically significant BOLD differences between migraine and non-
migraine sessions across subjects. Only voxels exhibiting statistically significant N-back-
related BOLD signal changes were considered for the session comparison. 
Effects of individual measures such as age, education, age of migraine onset, 
attack average duration, and migraine average frequency were added as additional 
explanatory variables. These where masked with the main contrast (mean). Voxelwise 
parameters were obtained from the GLM coefficients over the cluster-thresholded 
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(p<0.05 and Z>2.3) mask, for each of the mean sessions, whereas effects of individual 
measures were obtained using uncorrected p<0.05 thresholding. 
Group analysis was also performed in order to identify voxels exhibiting 
statistically significant BOLD differences between migraine and non-migraine sessions 
across subjects. Additional effects of physiological tests performed previously to the 
scanning (Stroop Test, Trail Test, Finger tapping with dominant hand and Finger tapping 
with the non-dominant hand) were also added as explanatory variables and these were 
contrast masked with the main contrast (difference between sessions). 
 
Statistical Analyses 
Statistical analysis of clinical variables was made using SPSS 20.0. Descriptive 
data included frequencies and central tendency measures; comparison of means 
between the two study evaluations was performed using the paired t-test. The Holm-
Bonferroni step down procedure(278) was adopted to account for multiple testing and 
to provide strong control of the type I error at the two-sided 5% significance level. 
Reported p-values are adjusted for multiplicity using the Holm-Bonferroni 
correction(206). Multiple linear regression was used to determine in any independent 
variable, either population related (age, literacy, disease duration, HIT-6 and time lapse 
between evaluations) or attack related (Mig-SCOg, pain duration and intensity, intensity 
of nausea, photophobia, phonophobia, aggravation with physical effort and cognitive 
impairment) had influence on the tests that showed significant difference between 
evaluations (dependent variables). 
 
RESULTS  
Fourteen right-handed female patients were included yet one patient dropped 
out before completing the study. The final sample of 13 females had an age average of 
35.7 ± 7.4 years. Previous medical history was positive for asthma in one patient and 6 
were mild smokers (less than 10 units per day). Six (46%) used oral contraception; no 
other medication was currently being taken. Average Beck score was 5.0 ± 3.6, all 
patients scores were within normal values. 
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Average migraine disease duration was 22.7 ± 10.2 years. The HIT-6 score was 
62±4.0, representing a high impact disease. Average monthly attack frequency of our 
sample was 2.3 ± 1.6 (range 1 to 6) with an average duration of 32.6±25.3 hours, having 
an average intensity of 7.4 ± 1.3 on a 0-10 VAS.  Patients described unilateral(54%) 
predominantly throbbing pain always accompanied by photophobia, phonophobia and 
nausea; 11(85%) had pain aggravation by physical effort, 4 (31%) vomited regularly and 
4 reported osmophobia regularly.  
The studied migraine attack had an average pain duration of 16.2±20 hours 
(range: 2.6 to 69 hours) and an average pain intensity of 6.8±1.4 on a 0-10 VAS, similar 
to usual attacks (paired T-Test 0.959, p 0.357 n.s.).  All patients had nausea and 
photophobia on the evaluated attack; 2 (15%) patients vomited, although the average 
nausea intensity was 4.7±1.5 and of photophobia 4.9±1.7, on a 0-10 VAS. All but one 
patient (92%) had phonophobia and pain aggravation with physical effort, with an 
average intensity of 5.0±2.3 and 4.6±2.5 respectively. Attack-related decrease in 
cognitive efficiency plotted on a 0-10 VAS was 5.3±2.6 on average and the Mig-SCog 
average score was 5.1±2.5 (range 2 to 11). 
The average time between evaluations was 74.4 ± 61.6 days (range 36 to 275 
days). Average raw scores and differences of neuropsychological tests performed in both 
evaluations are depicted in table 1.  
 
Table 1 – Results of neuropsychological tests in both evaluations and mean difference 












(dominant hand)  
49.6 ± 8.6 55.1 ± 5.0 5.6 ± 7.4 p 0,19* 
Finger tapping 
(non-dominant hand) 
43.9 ± 6.5 47.5 ± 4.4 3.6 ± 4.6 p 0,015* 
Trail A Time  25.1 ± 4.3 22.5 ± 5.4 -2.6 ± 5.4 p 0,981 





45.6 ± 17.6 38.0 ± 16.0 -7.5 ± 15.6 p >0.99 
Trail A errors  0.4 ± 0.6 0.2 ± 0.4 -0.2 ± 0.8 p >0.99 
Trail B errors  0.3 ± 0.6 0.8 ± 0.9 -0.5 ± 1.1 p >0.99 
Digit Span 
Backwards  
4.6 ± 1.2 4.5 ± 1.5 -0.1 ± 1.0 p 0,794 
Stroop Interference 55.4 ± 13.0 64.5 ± 11.0 11.1 ± 10.9 p 0,039* 
Stroop Errors  0.8 ± 0.8 0.5 ± 0.5 -0.2 ± 1.0 p >0.99 
Fluency (letter P, 
total)  
14.8 ± 4.6 15.3 ± 5.0 0.5 ± 4.8 p >0.99 
Naming – Total 13.3 ± 1.3 13.5 ± 1.0 0.0 ± 0.1 p >0.99 
 
    
fMRI NBack –  
Correct answers   
21.6 ± 2.4 23.5 ± 2.2 1.4 ± 2.7 p >0.99 
fMRI NBack – 
Wrong answers  
4.3 ± 2.8 3.2 ± 2.9 -1.1 ± 3.1 p >0.99 
Legend: Av ± sd – average ± standard deviation; Paired T-Test was used to compare means; †p multiplicity-
adjusted p-value; (*) p<0.050 was considered significant 
 
 
Two tests showed an increase in performance from the attack to the baseline 
evaluation, the finger tapping (dominant hand 5.6 ± 7.4 score increase, p=0.019 and non-
dominant hand 3.6 ± 4.6 score increase, p=0.015) and the stroop interference task (11.1 
± 10.9 score increase, p=0.039). The practice effect bias of short term repeated 
application of this battery was quantified in a previous study. For the Stroop interference 
task, the average expected score improvement is 4.85 (90% CI -1.34 to 11.05) so our 
observed value falls in the upper end of the 90% CI. For the finger tapping task, the 
average expected score improvement was 0.03 (90% CI -8.59 to 8.65) and 1.60 (90% CI 
-5.15 to 8.26) for the dominant and non-dominant hand respectively, so our observed 
values are within expected improvement. Linear regression failed to identify any 
influence of any of the studied disease or attack related variables to the performance 
improvement in the finger tapping and stroop tasks. 
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Three subjects were removed from further analysis due to motion (R9, R12 and 
R14). N-Back task showed an increased BOLD signal in both conditions in bilateral 
dorsolateral and ventrolateral prefrontal cortex and frontal poles, frontal lateral and 
medial premotor cortex, lateral and medial posterior parietal cortex and bilateral 
thalamus. (Figure 1)  
  
Figure 1 – N-Back activation patterns outside and during the Migraine Attack 
Headache Free                                                Migraine Attack 
 
Legend: Activation maps for the N-Back task (versus control task) in migraine patients while headache-
free and during a migraine attack. Regions of activation are color coded, cluster corrected (Z>2.3, cluster 
p<0.05). Areas activated in both situations include bilateral dorsolateral and ventrolateral prefrontal 
cortex and frontal poles, frontal lateral and medial premotor cortex, lateral and medial posterior parietal 
cortex and bilateral thalamus. 
 
No significant differences were found between N-Back pattern activation in migraineurs 
during the migraine attack when compared to themselves while headache free, as 





Figure 2 – N-Back subtraction images 
 
Headache Free > Migraine Attack            Migraine Attack > Headache Free 
 
Legend: Subtraction maps for the N-Back task activations between headache status: Headache free > 
Migraine attack and Migraine attack > headache free. Regions with differences of activation between 
conditions are color coded (uncorrected, p<0.05). 
 
Age, literacy, disease duration, attack frequency and performance on the stroop, 
trail and finger-tapping tasks had no effect on BOLD activation patterns.  
 
DISCUSSION  
This study was not able to demonstrate disruption of cerebral activity associated 
with the execution of a working memory task during a migraine without aura attack.  
We were able to study spontaneous occurring migraine attacks of moderate to 
high pain intensity and in which patients subjectively rated their attack-related cognitive 
efficiency in 5.3 (out of 10) and obtained robust activations of our areas of interest, the 
anterior cingulate and fronto-polar cortex, in both conditions with the N-Back paradigm, 
as expected(332). Our assumption was that the involvement of the cingulated and 
prefrontal cortex in migraine without aura attacks (29, 53, 153, 214, 215) could act as an 
internal interference disrupting the working memory construct therefore changing the 
pattern of brain activation in response to the N-Back paradigm and impairing task 
performance(335). An alternative hypothesis was that the increased workload imposed 
to this system by the competing stimulus (migraine attack and N-back task) would 
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induce an increase in fMRI signal in these areas(88, 336) regardless of task performance. 
We therefore hoped to investigate the neuronal subtract underling the attack-related 
migraine executive dysfunction(108) yet we were unsuccessful in demonstrating a 
group difference neither in activation patterns nor areas between the migraine attack 
and the headache-free status. Existent evidence supports the existence of attack-related 
cognitive dysfunction in migraine, with a fairly consistent pattern of executive functions 
impairment (108, 109, 284). In addition, involvement of executive brain structures is 
found in experimental pain studies(264) and chronic pain conditions are able induce 
brain neurochemical and neoplastic reorganization in cognitive related systems(87, 89). 
Our target structures, the ACC and FPC seem to exert top-down control to primary 
sensory processing areas in order to modulate information coming from several sensory 
stimuli(325, 326), including pain(264). In healthy volunteers cognitive engagement has 
been shown to reduce pain-related activity but cognitive-related activity was not altered 
by simultaneous pain stimuli although it increased the brain areas involved in the 
cognitive activity(88). 
Our data supports that migraine attack-related cognitive dysfunction is not 
associated with relevant disruption of cortical oxygen consumption; migraine associated 
cortical metabolic changes in cognitive related brain areas probably falls into the range 
of physiological variability of cortical function.  If true, the study of functional 
connectivity would have been more appropriate to identify a system imbalance in this 
experimental setting. 
However, a number of limitations exist that may interfere with interpretations of 
these findings, the most important is probably the data analysis. Our option was to try to 
identify a group difference, assuming that topographic consistency of activation across 
subjects would be high, in order to make small VOIs meaningful with a small sample size; 
by doing so, we might have missed individual activity pattern variations. Also, we 
scanned attacks of heterogeneous durations (from 2.6 hours up to almost 3 days) and so 
brain activation patterns could be obscured in grouping different phases of the 
attack(28). A final issue relates to test-retest reliability, as this study used two sequential 
scans; repeatability of the selected N-back task seems to be fairly consistent in terms of 
pattern of activations (qualitatively) yet quantitative analysis (mean activation 
amplitudes and number of activated voxels) is not as reliable(337). 
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We additionally screened these patients for executive performance using a short 
neuropsychological battery (encompassed the domains of attention, processing speed, 
mental flexibility, monitoring and inhibitory control, working memory and verbal 
initiative and fluency) and monitoring N-Back response accuracy, although it correlates 
weakly with brain activation(337). Patients performed equally in the majority of tests 
both within a migraine attack and while headache-free. A performance improvement 
from attack to headache free was identified on the finger tapping and stroop interference 
tasks that were within the range of the expected practice effect for this tests. Executive 
dysfunction has been documented during migraine attacks in task of attention, 
processing speed, working memory and visuo-motor processing on computerized tests 
(60, 96, 97, 102). The conventional stroop and trail(219) as well as the other executive 
tests included in this battery have not been able to demonstrate performance decline 
neither during migraine attacks(109)  nor in headache-free migraine patients compared 
to matched controls.  Demonstrating executive dysfunction can be difficult, as there is 
almost no specific task to a given executive function nor there is a specific mapping to 
each brain function. Nevertheless patients consistently describe cognitive symptoms 
during attacks and in their subjective experience feel cognitively impaired, despite weak 
evidence of actual objective impairment. 
Despite having mostly negative findings, this study has some strengths – it adds 
to the scarce fMRI data available about spontaneous occurring migraine attacks. Testing 
during attacks is difficult as migraine episodes are unpredictable while planning an fMRI 
is complex and time consuming(338). Because the attack scan is difficult to obtain, we 
always scanned the attack first, in order to minimize attrition. This induced a practice 
effect bias of repeated testing(225, 228) that we had to control for. 
Another strength was the ability to include a homogeneous sample of otherwise 
healthy episodic migraine without aura patients with a long standing high impact disease 
but nevertheless without important confounders of cognitive function such as chronic 
medication (including headache prophylaxis) or depression, a sample that mirrors high 
impact community dwelling patients. As all the patients included were females, we 
cannot generalize to male patients nor to chronic headache patients.  
In conclusion, our data supports that brain activation during performance of a 
working memory task is not disturbed by the neuronal processes associated with an 
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acute migraine without aura attack. Further work needs to be ensued to identify brain 







































The final chapter relates to the potential persistence or long term effects of migraine 
related cognitive (executive(59)) dysfunction, in analogy to other chronic or recurrent 
pain conditions. 
 
To study the effects of persisting headache and migraine in older adults (over 50) a cross 
sectional survey using an extensive neuropsychological battery was conducted in a large 
sample of community dwelling individuals and their performance was compared 
between headache diagnoses, finding slight differences in some of the applied measures 
of executive function both in migraine and in non-migraine headache patients, compared 
to controls. These findings argue for an interictal effect of recurrent pain (either migraine 
or non-migraine headache) on executive functions. 
 
To explore if these differences could relate to an increased risk of cognitive decline, a 
follow up study with neuropsychological revaluation of the same sample was 
undertaken after 5 years. Rate of cognitive decline was not found to differ between 
migraine, non-migraine headache and control patients supporting that older adults with 
persisting headaches and migraine do not have an increased risk of cognitive 
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ABSTRACT 
Objectives and Background: The possible effects of migraine on executive abilities remain 
controversial, hence we studied inter-ictal cognitive performance of individuals with migraine 
and non migraine headaches (NMH) compared to headache free controls. 
Design and Method:  In a cross sectional observational study, taking place in primary care, 
adults aged 50 or above were evaluated by a neurobehavioral battery including several executive 
measures. Present history of headache was sought and migraine was diagnosed by the ID-
Migraine questionnaire. Effect of headache type on cognitive measures was analysed with 
multiple regression with adjustment by diagnosis, age, gender, education and depressive 
symptoms. 
Results:  Among 478 participants 23.2% reported current headache of whom 50 NMH and 61 
migraine. No group differences were found in the majority of cognitive measures. Compared to 
controls, migraine subjects performed worse on a test of attention, while NMH participants 
presented more intrusions and worse discriminability in memory recognition plus a lower 
performance on semantic memory tests. 
Conclusion: The presence of headaches in late adulthood was related to a worse performance 
on few measures of executive functioning, suggesting that cognitive impact is not specific to 





Introduction   
 
Migraine is a highly prevalent brain disorder characterized by recurrent attacks of 
severe headache associated with nausea or vomiting. During attacks, patients are 
sensitive to all sensory stimuli and experience cognitive symptoms, often beginning 
before the headache itself (40, 157). They feel distracted, unable to concentrate or reason 
at their usual speed, and have difficulty performing mental tasks and retrieving names 
(115, 283, 339), symptoms that might suggest a dis-executive disorder. These 
manifestations  may contribute to the impairment associated to the attacks and influence 
patients quality of life (340). Moreover, there is some controversy regarding their inter-
critical and long term persistence. 
The study of inter-ictal cognitive abilities in migraine has produced inconsistent 
results. While some authors found disturbances involving the executive functions(60)  
either in migraine patients in general, or in specific migraine subgroups, such as those 
with severe attacks, patients with aura (59) and children (267), others were unable to 
find any difference between subjects with and without migraine (183, 184, 272, 281, 
341).  
The consistency of executive-like symptoms reported during attacks and deficits 
observed between the attacks could indicate a disturbance of the frontal lobes, 
exacerbated and becoming symptomatic during the attacks. That hypothesis received 
support from the finding of decreased grey matter density in the frontal and parietal 
lobes in 25 migraine patients compared to matched controls (203). The presence of 
subcortical white matter lesions, that are more common in migraine and headache 
sufferers than controls (341) could also be a possible explanation for the executive 
deficits but has been ruled out, at least in two studies. One study that excluded 
participants with such findings (203) and another (281) that controlled age related 
cognitive decline for that specific variable, did not find a negative effect of white matter 
lesions on cognition. 
An alternative explanation for migraine-associated cognitive impairment is pain 
itself. The experience of chronic, or chronic recurrent pain, could interfere in the activity 
of some frontal networks that are shared by the pain matrix. Although most clinical and 
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brain imaging data (36, 40, 303, 318, 342) point to the participation of the occipital 
cortex in migraine rather than the fronto-subcortical networks subserving executive 
functions, several regions of the frontal cortex participate either in the pain matrix or in 
pain modulation (343). The orbitofrontal cortex, for instance, participates in inhibition 
and habituation to pain and has been shown to be dysfunctional in migraine, particularly 
in those with long duration of disease (344). According to this hypothesis, the executive 
dysfunction should not be exclusive to migraine but also apply to other conditions of 
chronic pain.  
Due to the high prevalence of migraine in the general population(16)  this 
question may be particularly relevant. Normal ageing is related to some decline in 
executive abilities (345) and a functional re-organization of the frontal lobes (346). Thus, 
migraine and other primary chronic headaches might be studied as contributing to, or 
risk factors of, long term age-related cognitive changes. Although a recent study 
comparing cognitive performance of migraine and headache patients with controls 
found no differences in visual perception and  memory, it failed to explore most 
measures of executive functioning, apart from  processing speed (281).      
To disentangle these two hypotheses, i.e. that executive changes are specific to 
migraine or due headache pain, we compared the inter-ictal cognitive performance 
between adult and elderly individuals with or without headaches and migraine, focusing 
on different measures of executive functioning included on a comprehensive battery of 




The present study is part of an ongoing larger project dedicated to the effect of 
ageing in cognition. Baseline data of this project was analysed in a cross sectional 
observational design. Participants are adult individuals, with a minimum age of 50 years 
attending eleven primary health care centres of the National Health Service. Inclusion 
was made on a volunteer basis and participants were first screened and invited to 
participate by their GPs. Subjects were excluded if they had any known present or past 
history of a central nervous system disorder, namely stroke, brain injury, epilepsy, 
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dementia (known or suspected), psychosis, or a severe medical disorder like 
uncontrolled cancer, HIV infection, renal or hepatic failure or if their score on the Mini 
Mental State Evaluation (MMSE) (347) was below literacy-adjusted cut off point (348). 
Before being enrolled in the study, patients were required to give their informed consent. 




Patients were invited to participate during their regular medical appointments. 
After informed consent, participants undertook the MMSE and GP’s filled a checklist of 
vascular risk factors (hypertension, diabetes and dyslipidemia).  
 Neuropsychological evaluation was then scheduled so that participants could be 
in their best conditions, not under time pressure and without headache. The 
neurobehavioral battery included the following tests: California verbal Learning Test - 9 
item version (349), Wechsler Memory Scale III version (WMS-III) Visual Reproduction 
and Faces I subtests (245), Trail Making Test (29), semantic (Foods and Animals) and 
phonemic (Letter “p”) verbal fluency, Stroop Test  (237, 239), Digit Span (245), Symbol 
Search (242), Wechsler Abbreviated Scale of Intelligence (WASI) Vocabulary and Matrix 
Reasoning subtests (350), Information (351, 352) and a Famous Faces Test(250) . The 
battery also included scales of depression (Geriatric Depression Scale) (353) and 
Subjective Memory Complaints (SMQ) (354). A more detailed description of the battery 
and targeted domains has been reported elsewhere (355). 
Although the cognitive measures collected in this project covered different 
cognitive domains, in this study we focused mostly on measures of executive functioning. 
Therefore, in addition to executive tests primarily directed to executive functions, we 
computed measures from the memory tests that are known to be sensitive to frontal lobe 
dysfunction. Such measures were the following: mental flexibility as assessed by TMT B 
and B-A, the latter being considered a more pure measure of set shifting (237), inhibitory 
control (Stroop test interference task), working memory (digit span backwards), 
processing speed (TMT A and Symbol Search),  abstract reasoning (WASI Matrix 
Reasoning subtest) and speed of word retrieval and monitoring (evaluated by two 
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semantic fluency tasks and one phonological fluency task, known to be more sensible to 
frontal lobe dysfunction(233) . Episodic memory and learning were also evaluated 
(CVLT immediate first recall, total learning over 5 trials, short delay recall after 
interference, 20-minute delayed recall and WMS-III delayed visual memory). Particular 
emphasis was given to measures of episodic memory with executive contribution: CVLT-
9 resistance to proactive interference (List B recall), intrusions (false positives) in 
recognition, discriminability index, and response bias (356).  
During the interview participants were asked whether they were currently 
suffering from headaches. Whenever the answer was positive, subjects undertook the 
ID-Migraine (357), a brief and effective questionnaire for the diagnosis of migraine in 
primary care(358) that has been translated and validated to Portuguese with  0.94 
sensitivity and 0.60 specificity(359) , compared to the ICHD-II criteria(186). It consists 
of three questions regarding headaches experienced in the past 3 months: the first 
concerns pain intensity (“Do your headaches limit your ability to work, study, or do what 
you needed to do for at least 1 day?”), the second screens photophobia (“Does light 
bother you a lot more than when you don’t have headaches?”) and the third is directed 
to nausea (“Do you feel nauseated or sick to your stomach when you have a headache?”). 
Subjects were classified as suffering from migraine headaches whenever there was a 
positive answer to two or three of those questions. Participants who did not complain of 
headaches were considered headache-free controls, those that complained of headaches 
and did not filled any or just one of the three ID-Migraine questions were classified as 
non migraine headache (NMH) sufferers(358).  
 
Statistical Analysis 
Statistical analysis was performed with the SPSS package 19.0. The chi-square 
test was used to compare the distribution by gender and vascular risk factors (presence 
or absence of hypertension, diabetes and serum cholesterol above normal range) among 
the three study groups (participants with migraine, NMH and headache free controls). 
Differences between these groups in age, literacy and scales scores were tested with 
oneway ANOVA with post-hoc Tukey tests.  
The impact of migraine or NMH on cognitive performance, controlling for the 
possible confounders (355), was evaluated by multiple linear regression analysis (MRA). 
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Scores obtained on cognitive measures under study were the dependent variables. Since 
the three subgroups were different in their demographic features (age, gender, literacy 
and depressive symptoms) it was not possible to compare directly their mean cognitive 
raw scores. Therefore, to analyze the influence of migraine and NMH on cognitive 
measures, controlling for possible confounders, repeated MRAs were performed on 
which the dependent variable was each cognitive measure and the independent 
variables were subjects’ age, gender, literacy (divided in two groups, low education if 
equal or inferior to 4 years and basic to high education if equal or above five years), 
depressive symptoms (considered significant if equal or above 4 points in the GDS, and 
non significant if under that value). 
Due to the multiplicity of analyses performed, in order to avoiding type I errors, 
the statistical significance level was adjusted to p<0.01. The distribution of the 
dependent variables involved in the model was tested and whenever normality was 
excluded the variables were dichotomized.  
 
Results 
The study population consisted of 479 volunteers; one patient was excluded due 
to incomplete fulfilling of the headache questionnaire. Of the 478 individuals included, 
306 (64.0 %) were females and the age average was 66.44 + 8.95 years (range: 50 to 
95 years). The majority, 367 (76.8%) individuals, did not complain of headaches while 
111 (23.2 %) were headache sufferers. Sixty-one participants (12.8 % of total sample) 
fulfilled the operational diagnostic criteria of migraine (MH). Twenty eight subjects 
reported two symptoms of the ID migraine and 33 all symptoms of this headache 
questionnaire. Fifty participants (10.5%) were classified as having NMH. 
The frequency of headaches changed significantly by decade of age (Table 1) (Chi-
Square = 21.65 (6), p<0.001). The frequency of migraine decreased between the 6th and 
the 8th decades of life while the frequency of non migraine headaches increased and the 










% (total number) 
Non migraine headaches 
(N=50) 
% (total number) 
Migraine 
(N=61) 
% (total number) 
50-59 years 73.4% (80) 4.6% (5) 22.0% (24) 
60-69 years 75.1% (148) 10.7% (21) 14.2% (28) 
70-79 years 81.4% (105) 14.0% (18) 4.7% (6) 
>80 years 79.1% (34) 14.0% (6) 7.0% (3) 
As depicted in Table 2, headache patients were more often female than 
individuals without headache (Chi-Square=24.52 (1), p<0.0001). Migraine subjects, 
when compared to participants without headache and to those with NMH, were 
significantly younger (5 and 7 years younger, respectively), had a higher scores on the 
depression scale (GDS)(p<0.0001) and more subjective memory complaints (SMQ) 
(p<0.0001). There were no significant differences on these variables between 
headache-free individuals and those with NMH (Tukey HSD post-hoc test). There was 
a moderate correlation between GDS and SMQ score (Pearson r=0.475, p<0.0001). The 
three groups had different levels of literacy and participants with migraine had lower 
education than those without headache. There were no differences, among the three 
groups on the proportion of individuals with any of the vascular risk factors sought, 
either hypertension (X2= 2.88 (2), p= n.s.), diabetes (X2= .50 (2), p= n.s.) or high levels 
of total serum cholesterol (X2= 4.89 (2), p= n.s.) nor in the number of risk factors (X2= 
7.11 (6), p=n.s.).  
Table 2 – Population characteristics by diagnosis 




Migraine Chi–Square / 
ANOVA 
N 367 50 61  
Gender (F: M) 213:154 37:13 56:5 P < 0.0001 
Age (mean+sd) 66.8 + 9.0 69.3 + 7.9 61.9 + 7.6 P < 0.0001 
Literacy(mean+sd) 7.4 + 4.3 6.3 + 4.4 5.8 + 3.9 P = 0.007 
GDS(mean+sd) 3.1 + 3.3 4.0 + 3.1 5.4 + 3.2 P < 0.0001 
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SMC(mean+sd) 5.7 +3.5 5.9 +3.1  8.7+ 3.3 P < 0.0001 
Legend to table 2: F= females, M= males; GDS= geriatric depression scale; SMC=subjective memory 
complaints; numbers in bold identify the group that is significantly different from others in the pos hoc 
test. 
 
Table 3 – Multiple regression analysis  





  Difference to controls (means) 
Executive function tests and measures 
Stroop Interference .304 -2.913 -1.135 
Digit Span Backwards .184 -.047 -.173 
Trail A Time .352 11.310 12.459 
Trail B Time .386 25.670 21.095 
Trail difference (B-A) .238 14.055 15.217 
Fluency Animals .216 -.099 -.172 
Fluency Food .141 -1.033 .340 
Fluency Letter P .204 .259 .160 
Symbol Search .397 -2.438* -1.104 
Matrix reasoning .252 -1.346 -1.113 
Mazes (time) .187 -.147 1.932 
CVLT intrusions in recognition .124 -.128 1.139** 
CVLT recognition discriminability index .136 .636 -3.531** 
CVLT resistence to proactive 
interference (List B recall) 
.130 .288 .504 
CVLT response bias .012 .008 .094 
Other tests and measures 
CVLT first immediate recall 1.00 .204 .317 
CVLT total learning  (sum 1 to 5 trials) .174 .531 .452 
CVLT short term free recall .166 -.020 -.108 
CVLT delayed recall .158 .303 -.295 
CVLT recognition correct responses .033 .082 -.026 
WMS-III delayed visual memory .259 .998 -4.086 
WMS-III memory for faces .163 -1.055 -.126 
WASI Vocabulary .386 -1.209 -6.192** 
Information Subtest .345 -.170 -1.488 ** 
Famous faces test .193 -.294 -.689 
Legend to table 3: Multiple regression analysis. Independent variables included in each regression were: 
migraine, non-migraine headache, gender, age, literacy (low or medium to high), depressive symptoms 
(significant or nonsignificant score in GDS).  Adjusted R Square represents the proportion of variance on 




Multiple regression analysis results are presented in Table 3. Few cognitive 
measures showed a significant association with the diagnosis of headache. Concerning 
executive functions, individuals with migraine had a lower score in Symbol search 
compared to controls. NMH participants, on the other hand, produced more intrusions 
in word list recognition (in CVLT-9) and had a worse recognition discriminability 
compared to controls. Mean scores obtained by participants with MH, NMH and 
controls in tests that showed significant differences were, respectively: intrusions in 
recognition (0.66 ± 1.10 in migraine patients,  2.32 ± 2.84 in participants with NMH and 
1.11 ± 1.76 in controls, Anova F 12.36, p<0.0001); Symbol Search (15.33 ± 7.46 in 
migraine patients, 15.50 ± 7.64 in those with NMH and 18.31 ± 7.39 in controls, Anova 
F 6.44, p=.002) and CVLT recognition discriminability index (96.8 ± 4.35 in MH, 91.15 
± 8.85 in NMH and 94.8 ± 6.55 in participants without headache, Anova F 10.3, 
p<.0001). It is worth noticing that the mean scores presented above are raw scores, not 
adjusted for age, gender and literacy and therefore the differences presented here are 
less evident than those found on the regression analysis. 
Neither migraine nor NMH had any impact on the performance of other 
cognitive tests and measures except for the language/semantic memory tests 
(Information and Vocabulary) where NMH subjects had lower performance compared 
to other groups. Their scores were respectively: Information (16.4 ± 2.87 in MH, 15.68 
± 3.45 in NMH and 17.79 ± 2.51 in participants without headache, Anova F 18,453, 
p<.0001) and Vocabulary (48,07 +14,38 in MH, 45,33+14,65 NMH,53,73+13,43 
controls, Anova F 11,237, p<.0001).  
Besides, there was an effect of subject’s age in all measures, an effect of 
education in the majority of tests and measures and of gender in verbal memory (CVLT, 
reverse digit span) and food fluency. Severity of depressive symptoms had an effect in 
tests of attention (Trail A and B, but not B-A) and visual memory. 
 
Discussion  
The present study, aimed to detect the long term impact of migraine and other 
headaches on executive functioning and other cognitive abilities, produced mainly 
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negative results, which is reassuring for the large number of subjects that suffer from 
headaches most of their lives.  
Indeed, this study showed that the presence of migraine or NMH in middle to 
late adult life did not modify significantly the vast majority of cognitive functions 
evaluated. Namely, it did not affect several tests of executive functions such as the 
verbal fluency tasks, working memory (digit span backwards) or inhibitory control 
(Stroop test). It also had no effect on measures of learning or correct recall in episodic 
memory (verbal or visual). These results are in agreement with studies performed in 
community-based cohorts of adult individuals (183-185, 269, 270), including a large 
study in twins (271), as well as with three longitudinal studies of adults, one of them 
including patients with aura (270, 272) that showed no decline over time on MMSE, 
memory visuo-perceptive and attention tests.  
In the present study only a few tests were negatively influenced by the presence 
of headache. Migraine sufferers were slower in a task of sustained attention and 
processing speed (Symbol search test) a function related to the activation and integrity 
of the prefrontal cortex (360) and that correlates with cerebral health markers in the 
frontal lobes, as quantified by neuro-imaging. On the other hand, few tests were 
negatively influenced by NMH. These were related to semantic memory (Information 
and vocabulary) and executive functioning (recognition discriminability and the number 
of intrusions on memory recognition, both derived from the CVLT). Concerning the latter 
two tests, there is evidence that subjects with frontal-executive dysfunction are more 
likely to produce false positives or “intrusions” in memory recognition and to have a 
difficulty in discriminating targets from distractors. Those are measures of faulty 
retrieval strategies, poor source memory and are associated to a tendency to confabulate 
(361-364). Subjects with frontal lobe dysfunction tend to endorse semantically related 
distracters, which highlights their defective ability to inhibit irrelevant activations to 
select relevant activations(365). Although response bias has also been linked to frontal 
lobe lesions leading to a more liberal response set, i.e., tendency to answer “yes” (366), 
this was not affected in our sample of participants with headache, suggesting that there 
might be subtle differences among those measures.  
However the performance in other tests of frontal-executive functioning was not 
significantly worse in migraine or NMH, namely the Trail Making Test-B possibly the test 
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most consistently found to be disturbed in individuals with migraine compared to 
controls (59, 280, 367). 
Thus, the present results show that suffering from headache in late adult life 
may be associated with a worse performance in some executive tests, though not 
consistently among all measures, nor between different headache types. These changes 
do not seem specific to migraine.  
Although these results are exploratory and their interpretation can only be 
tentative they raise the question of the possible role of headache or pain in cognition. 
Chronic or chronic recurrent pain causes disability and behavioural changes. Patients 
often withdraw from social, family, physical and professional activities, leading 
eventually to less cognitive stimulation, mental distress, learned helplessness, 
depression, sleep disturbances, analgesics or anti-inflammatory intake, just to mention 
a few. Thus, these different factors might influence cognitive functioning through 
different mechanisms (368) and may eventually lead to morphometric changes in the 
brain. Studies of individuals with other types of chronic pain, like chronic back pain, 
fibromyalgia, tension type headache and phantom limb pain have shown a decreased 
of frontal grey matter density (369-372).  
It is difficult to explain the lower performance in test of semantic memory in 
subjects with NMH, particularly because these might be a heterogeneous group 
regarding headache diagnosis and duration. One may just speculate that hypothetical 
avoidance of social interaction due to headache might lead to less acquired knowledge, 
but this needs to be investigated in homogeneous groups of patients. 
Pain is a multidimensional experience that involves somatic, visceral, cognitive 
and emotional domains. We do not assume that the frontal component of this matrix is 
directly related to pain intensity or localization, but rather that it is involved in the 
general pain experience. More research is necessary, in particular in other types of 
chronic pain and distress situations (e.g., psychosocial stress, mood disorders), to 
understand what may be the contribution of these different domains to executive 
functions. 
Changes found in cognition and brain morphometry (373) in headache sufferers 
could also result from a functional adaptive strategy, or neural reorganization, 
developed to overcome repeated episodes of pain in a kind of scaffolding mechanism 
similar to that described in ageing (374). These grey matter changes in pain matrix 
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structures are probably cross-sectional to all chronic or recurrent pain syndromes 
(263)  At least two studies have found a relationship between cognitive abilities and 
the severity or frequency of migraine attacks (219, 280, 373), and others found a 
relationship between the duration of migraine and grey matter density, reinforcing the 
idea that disease activity implies structural changes (263).  
 The observed cognitive changes could, alternatively, result from subcortical 
white matter hyperintensities that have been described in migraine (373, 375) and 
other chronic headache (341), but this has been dismissed in other studies (281). 
Besides in there were no differences in vascular risk factors between the groups that 
could explain a higher risk for subclinical ischaemic lesions in either group.  
Finally, one can also hypothesize that primary headache can be a marker of the 
failure of the normal anti-nociceptive mechanisms, which require the participation of 
the frontal lobes, and both pain and cognition can be a consequence of that dysfunction. 
The finding of an orbito frontal dysfunction in migraine with aura, related to the 
duration of migraine, supports this hypothesis (344).   
Another interesting finding of this study was that participants with migraine 
had a worse subjective perception of their cognitive abilities, presenting significantly 
higher scores on a questionnaire of subjective memory complaints, in spite of being 
significantly younger than other groups and not differing from controls on the majority 
of cognitive tests (namely in all memory measures). This was found in studies of 
chronic pain (376). The subjective complaints score correlated with depressive 
symptoms. This information is useful to give patients an explanation for their 
complaints and to decide upon pharmacological interventions that can be useful for 
both migraine and depression. 
We acknowledge some limitations of this study. Firstly, the present results can 
only be applied to the presence of  headaches above 50 years of age. Secondly, it only 
takes into account the present history of headaches, not its past history, severity and type 
(migraine with or without aura or other diagnosis). The presence of headache was 
inquired by a subjective question. This method does not guarantee that “without 
headache patients” are headache free; these subjects can have infrequent headaches 
that, eventually, might be migraine headaches. NMH were not characterized in detail and 
may constitute a heterogeneous group. Moreover migraine is known to change with age 
and to lose some of its typical associated features (377). Therefore it is possible that 
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among the NMH group there are also patients with age-modified migraine. Yet, so far 
there are neither specific criteria for migraine in advanced age, nor evidence supporting 
the use of another criteria (186) and at this point, we must consider that NMH 
participants have other headaches than migraine. Indeed, the demographic features of 
the migraine group were quite typical with a female predominance, younger age and 
associated depression (378-380) and the prevalence of headache and migraine by age 
reproduced the existing epidemiological data in the adult population (16, 381). This can 
be viewed as a measure of external validity of the ID migraine questionnaire used in the 
diagnosis of headache. The method used also does not differentiate between migraine 
patients with and without aura and excludes subjects with acephalgic migraine, although 
the latter is relatively rare compared to other migraine variants. 
Thirdly, we also acknowledge that the battery used does not cover all domains 
of executive functioning and more studies are necessary to provide a fine grain analysis 
of those abilities in headache patients. 
 Yet, this study includes a large sample of subjects from primary care that was not 
selected because of headache, who were evaluated by an extensive battery of cognitive 
and behavioural tests and controlled for the presence and severity of co-morbidities and 
factors that might affect cognitive performance. The majority of studies demonstrating 
migraine-associated cognitive impairment were performed in small samples of subjects 
from migraine clinics or through community advertisement (59, 159, 219, 282, 283), 
which may produce a selection bias towards patients with the most severe or 
complicated forms of this disorder. In addition, this represents one of the few studies 
comparing migraine with other headaches, controlling for the effect of head pain. One 
study contrasted migraine with post-traumatic headache(219)  and found differences in 
the latter, which can be expected following traumatic brain injury. Burker (382) 
compared migraine with NMH in a community setting yet recruited only young women, 
finding no differences in cognitive performance, Meyer (98) found reversible changes 
during attacks in migraine, cluster and chronic daily headache and Rist found no 
differences in age related cognitive decline in a period of 4 years(281) between headache 
patients and controls.  
Conclusion. Age-associated changes of cognitive function, a major concern among 
persons that are expected to live beyond the eight decade, are overall not significantly 
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affected by the late presence of migraine or headache. Yet, the presence of headaches in 
late adulthood , and not just migraine, may have some impact on speed of information 
processing and few measures of executive function. More studies are required to 
understand if these findings are reproduced on longitudinal studies with a more 
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Objectives and Background: Cognitive performance of older adults and elderlies with 
persisting headaches and migraine has been shown to differ from control individuals in some 
aspects of executive functioning yet the influence of persisting migraine and non-migraine 
headache on cognitive decline is controversial. 
Design and Method:  Older (>50 years) adults with migraine, non-migraine headache and healthy 
controls had an extensive neuropsychological evaluation at baseline and after 5 years, to screen 
for cognitive decline in memory and/or executive functions.  
Results: From the original 478 individuals, 275 (57.5%) were evaluated, with an age average 
of 70.40+8.34 years, 64% being females. Cognitive decline occurred in 14.9% of the sample, 
yet neither migraine nor non-migraine headache influenced the odds of decline. In migraine 
patients, decline was not consistently associated with any migraine characteristic. 
Conclusion: Persisting migraine and non-migraine headache at old age is not associated with 
an increase in probability of cognitive decline. Although chronic pain and aging are able to 
influence cognitive function, pain-related changes are probably due to pain adaptation 




Introduction   
The interaction between migraine and cognition is complex and dynamic. One its’ 
most consistent aspect is the existence of attack-related cognitive symptoms(95, 118) 
which are substantiated by findings of reversible neuropsychological impairment in 
executive functions, memory and learning during attacks (108, 109)  although the brain 
processes underling this phenomena still remain speculative.  
Some patients also complain of cognitive changes outside attacks – cross-
sectional controlled inter-ictal studies identify a negligible to small effect of migraine on 
visuomotor processing speed, attention, verbal learning and recall, working memory and 
sustained attention, sometimes more expressive in patients’ subgroups, such as 
migraine with aura or severe migraine(104, 105). Inter-ictal brain perfusion changes on 
migraineurs have also been documented (280, 383) supporting the hypothesis that 
migraine associated white matter abnormalities and brain lesions(216, 384) could 
increase the risk of late-life cognitive impairment or dementia.  However, evidence 
obtained from longitudinal studies, some with large samples and population-based, does 
not associate migraine to and increased risk of cognitive decline (185, 217, 270, 281) nor 
to the progression of such white matter abnormalities or infarct-like lesions(385). 
Furthermore, it is debatable if cognitive changes identified in migraine patients, 
regardless of the setting, are specific to migraine and/or headache or relate only to the 
experience of recurrent pain, in which executive and cognitive impairment has also been 
documented(89).  
In a previous study we compared the inter-ictal cognitive performance of older 
adults and elderlies with or without headaches and migraine concluding that the vast 
majority of cognitive functions evaluated were uninfluenced by the presence of migraine 
or non-migraine headache at late adult life. However, a few tests were influenced by 
headache – both migraine and non-migraine headache patients performed worse in 
some of the executive tests, suggesting an effect of persistent recurrent pain in executive 
functioning(268). Executive abilities also show some decline with normal ageing (345) 
associated with functional re-organization of the frontal lobes(346).  
In the current study we aimed to determine if persisting migraine and non-
migraine headache has influence in cognitive decline, specifically in executive 
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functioning and/ or memory, by performing a 5 years follow-up revaluation if our initial 
patient cohort.  
 
Methods  
The present study is part of an ongoing larger project dedicated to the effect of 
ageing in cognition(386). Baseline data of this project was analysed in a cross sectional 
observational design; this follow-up study includes revaluation of the original sample 
after an average period of 5 years. Participants are adult individuals who gave their 
written informed consent, with a minimum age of 50 years at inclusion, attending eleven 
primary health care centres of the National Health Service. Participants were screened 
and invited to participate by their GPs; exclusion criteria included history of any 
neurologic or psychiatric disease (ex. stroke, brain injury, epilepsy, dementia or 
psychosis), any severe medical disorder with potential influence on neurological 
function (ex. metastatic cancer, HIV infection, renal or hepatic failure) or a Mini Mental 
State Evaluation (MMSE)(347) score below their literacy-adjusted cut-off value(348). 




Baseline cross sectional data retrieved upon inclusion was (1) medical history 
(MMSE, checklist of vascular risk factors, medication); (2) current headache status 
(without headache/ with headache) then further characterized into migraine(MH) or 
non-migraine headache(NMH), as defined by a positive or negative ID-Migraine(357) 
and (3) Complete neuropsychological evaluation along with scales of depression 
(Geriatric Depression Scale)(353) and Subjective Memory Complaints (SMQ)(354). 
Further details about this study have been reported elsewhere(268). 
In the present study, the participants were submitted to complete 
neuropsychological revaluation, in order to screen for significant cognitive decline in the 
5 years follow up. Test results were computed into Z-Scores using normative data 
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matched to gender, age and literacy. Cognitive decline was defined as a decrease superior 
to 1.5 standard deviations in the average Z-Scores of tests of memory and/or executive 
functions. Memory score was calculated by averaging the Z-scores of 2 memory tests 
(California verbal Learning Test 9-item version(349) and Wechsler Memory Scale III 
version (WMS-III)(245)); executive score was calculated by averaging the Z-scores of 5 
executive tests (Trail Making Test a and B(29), semantic (Foods and Animals) and 
phonemic (Letter “p”) verbal fluency). Scales of depression (Geriatric Depression 
Scale)(353) and Subjective Memory Complaints (SMQ) (354) were again included.  
Patients with migraine headache (MH) at baseline were additionally contacted by 
telephone and systematically assessed for the current occurrence of headaches and 
details of headache history (disease duration, presence of aura, frequency and duration 
of attacks and headache impact, measured with HIT-6(140)).  
 
Statistical Analysis 
Statistical analysis was performed with the SPSS package 21.0. Descriptive 
statistics are presented as absolute and frequencies or mean ± standard deviation. Data 
was compared between the study groups (MH, NMH and headache free controls) with 
oneway ANOVA and post-hoc Tukey tests (for continuous variables) and chi-square 
tests for categorical variables. 
In migraine patients the chi-square and independent sample T-test were used 
to compare patient variables as appropriate; the relation between the HIT-6 score and 
executive and memory scores was explored using the Pearson correlation coefficient. 
The statistical significance level was adjusted to p<0.01.  
 
Results  
The baseline study population included 478 individuals, 306 (64.0 %) females 
with an age average of 66.44+8.95 years (range: 50 to 95 years). As baseline, 367 
(76.8%) patients were without headache (WH), 61 (12.8 %) had migraine (MH) and 50 
(10.5%) non-migraine headache (NMH). 
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Two-hundred and three individuals(42.5%) were lost at follow-up – 109(23%) 
refused further participation,  53(11%) could not be reached or had moved, 3 had 
terminal illnesses and 15(3%) had died. Average follow up time was 58.9+7.2 months 
(~4.9 years), ranging from 40 to 70 months. 
The follow-up study population included 275 individuals, 176 (64.0 %) females 
with an age average of 70.40+8.34 years (range 55 to 98 years). The headache 
diagnosis retained at follow-up included 216 (78.5%) subjects without headache (WH), 
35 (12.7 %) with migraine (MH) and 24 (8.7%) with non-migraine headache (NMH). 
Retention rates were 58.9% in the group without headache, 57.4% in the migraine 
group and 48% in the non-migraine headache group. Demographic differences 
between groups are depicted in table 1. 
Table 1 – Population characteristics by diagnosis 










N 214 24 35  
Gender (F(%):M) 126(60%):90 17(70%):7 33(94%):2 
217.430 (df2) 
p < 0.0001 
Age Baseline 
(Mean+Sd) 
65.8 + 8.4 68.4 + 6.8 61.1 + 7.4 
F 6.741 
p = 0.001 
Age (Mean+Sd) 70.8 + 8.5 73.0 + 6.6 66.1 + 7.3 
F 6.246  
p = 0.002 
Literacy(Mean+Sd) 7.8 + 4.2 6.5 + 4.4 6.1 + 4.2 
F 3.040 
p = 0.049 
GDS† (Mean+Sd) 3.6 + 3.2 5.2 + 3.8 5.9 + 3.1 
F 8.619 
p < 0.0001 
SMC(Mean+Sd) 6.2 + 3.7 6.3 + 4.1  8.3 + 3.9 
F 4.584  
p = 0.010 
Vascular risk 
factors 
0 : 1 : 2 : ≥ 3 
 
 
17: 48: 89: 57 
 
 
1 : 4 : 10 : 9 
 
 
4 : 6 : 19 : 4 
 
26.976 (df6) 
p = 0.323 
     
Cognitive Decline 
(Yes(%):No) 
33(15.3%):183 4(16.7%):20 4(11.4%):31 
20.416 (df2) 
p = 0.812 
Executive Score 
(Mean+Sd) 
0.086 ± 1.17 -0.226 ± 1.22 -0.049± 1.48 
F 0.816  
p = 0.443 
Memory Score 
(Mean+Sd) 
-0.090 ± 0.99 -0.136 ± 1.02 0.259 ± 1.08 
F 1.914  
p = 0.150 
Legend: F= females, M= males; GDS= geriatric depression scale; SMC=subjective memory complaints; 
p≤0.010 was considered significant; numbers in bold identify the group(s) that is significantly different 
from others in the post hoc test; †GDS scores of migraine were different from those of patients without 
headache; non-migraine patients had no differences from migraine or without headache patients. 
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Similarly to the initial base line data, MH patients were more often females, were 
younger than NMH (by 6.7 years) and WH (by 4.7 years) and had more subjective 
memory complaints (SMQ) (p=0.011). The depression scale (GDS) scores differed 
between MH and WH (p<0.0001) while NMH patients had no differences from either of 
the other groups. The three groups had similar literacy. There were no differences, 
among the three groups on the proportion of individuals of the number of risk factors 
(table 1). 
Cognitive decline was documented in 41(14.9%) of the revaluated sample, yet 
having migraine (2= 0.383 (df1), p=0.536, n.s.) or non-migraine headaches (2= 0.064 
(df1), p=0.800, n.s.) had no influence on the decline rate when compared to the 
remaining sample. Headache or migraine also had no impact on the memory and 
executive scores (table 1).  
From the 35 migraine patients (MH) included at baseline, 29(83%) were 
successfully interviewed about their headaches after the neuropsychological 
revaluation; 5 did not answer their phones and one died.  
Nine patients (31%) reported having had aura with their headaches, although 
only one patient reported that all the attacks had aura. Eleven patients had had 
migraine for less than 20 years, 7 had had it from 21 to 50 years and 5 from 51 to 70 
years; average HIT-6 score of this sample was 54.3 ± 11.1 (range 36 to 76). 
Twenty patients had had migraine attacks in the last year, although in most, 
their frequency was scarce - 13(65%) patients only had up to one attack per monthly. 
Five (25%) patients had more than 15 monthly days with headache (chronic migraine), 
2 of which had daily headache. Average attack duration was 17.9 ± 22.0 hours, ranging 
from 45 minutes to 3 days; one of the daily headache patients had continuous 
headache. Some patients changed their migraine characteristics at follow up, as 
11(55%) ceased to have nausea with their attacks, 6(30%) ceased to be disturbed with 
photophobia and 7(35%) individuals were now able to work and function during their 
migraine attacks.  
In patients with Migraine, having aura had no influence in cognitive decline (2= 
1.688 (df1), p=0.194, n.s.) nor on the executive (T= 0.639, p=0.529, n.s.) or memory 
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scores (T= -1.139, p=0.266, n.s.). The disease duration (2= 7.256 (df6), p=0.298, n.s.), 
attack frequency (T= 1.291, p=0.213, n.s.), attack duration (T= 0.989, p=0.336, n.s.) and 
the presence of vascular risk factors (2= 1.856 (df3), p=0.603, n.s.) had no association 
with decline in migraine patients.  
Migraine patients showing a decline in cognitive functions were more likely to 
have a high HIT-6 score than those who remained cognitively normal (63.3±2.3 versus 
53.1± 2.2, T=3.874, p=0.001) although the HIT-6 score did not correlate to the 
executive (Pearson -0.254, p 0.183) or memory scores (Pearson -0.032, p 0.867). These 
patients had lower literacy (4.0±0.0 versus 6.35± 4.6, T=-2.882, p=0.007) and were 




Our data supports that persisting migraine and non-migraine headache in older 
adults does not increase the risk of cognitive decline and does not influence 
performance in memory and executive tests.  
All population-based longitudinal studies on the association of migraine with 
cognitive decline were also negative (185, 217, 270, 281, 385). The effect of non-
migraine headache on cognition has only been studied in the Epidemiology of Vascular 
Aging (EVA) study(281, 341) that, similarly to our results and of findings in migraine, 
was also negative. It seems reasonable to assume that persisting headache and/or 
migraine at old age does not increase the risk of cognitive decline. 
Cross sectional controlled studies in migraine(104, 105) have suggested  the 
existence of migraine associated cognitive impairment yet the majority of these studies 
used small samples of clinic-based patients, biased for young age and higher severity of 
disease and did not control for comorbidities and treatment effects(105). 
Nevertheless, findings of an increased incidence of white matter abnormalities 
and brain lesions associated with migraine has raised the clinical suspicion that migraine 
patients could have a greater risk of cognitive decline(216, 384). Longitudinal imaging 
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data failed to show that an association of migraine with progression of such brain 
lesions; the deep white matter hyperintensities observed more frequently in migraneurs 
were also not associated with poorer cognitive performance at long-term(385). 
Likewise, chronic bodily pain patients have worse cognitive functioning than 
matched controls in some cross-sectional studies (89, 284) but not in others(387), 
suggesting the influence of study limitations such as sample sizes, selection bias or 
psychiatric comorbidity. Evidence of longitudinal changes in long term population 
studies of other chronic or recurrent pain conditions is lacking, therefore the 
discussion about the  ability of chronic or recurrent to induce neurochemical and/or 
neoplastic brain changes that potentially could negatively influence cognitive 
processing is speculative(89). Pain, in general, has not been recognized as a risk factor 
for dementia(85-87).  
Chronic pain and highly recurrent episodic pain of any origin seem to have the 
ability to influence cognitive performance and to induce a decrease in cortical grey 
matter volume in areas the central nociceptive system, in particular in areas  with 
relevance for cognitive processing, such as the cingulate cortex, the orbitofrontal 
cortex and the insula(263). These morphometric changes have no clear correlation to 
any neurochemical nor anatomical functional abnormalities and may reflect only 
neuroplastic brain re-organization in response to chronic pain; reversibility of some of 
these changes has been attained with effective pain treatment(329, 330, 388) 
supporting the dynamic aspect of pain adaptive brain processes and the findings that 
all these abnormalities do not seem to have long-term influence on cognitive decline.  
This interpretation may not be that simple in older adults, as age is a consistent 
risk factor for cognitive decline and dementia(85). Even normal heathy older 
individuals present some age-related decline in cognitive functions (with high 
interpersonal variability) that is not uniform amongst brain functions – frontal lobe 
systems show earlier signs of change than do temporal lobe systems(81). Age has been 
proposed to have a moderating role on in the relationship between chronic pain and 
associated cognitive changes in one study where a decrease in one task of executive 
performance was associated with higher pain ratings in younger individuals and to 
lower pain ratings in older otherwise healthy individuals, with similar chronic pain 
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duration and analgesic use(389). Another contributing factors are the disability and 
behavioural changes associated with chronic pain that impair physical capabilities, 
psychological and social well-being, with negative influence on the healthy aging 
process (390). Curiously, The effect of age was studied in three longitudinal studies of 
migraine and only in one an decreased risk of decline was found in older (> 50 years) 
migraine with aura patients(185), while the others failed to find any differences(217, 
281). Age has also an impact on the prevalence of migraine, that decreases after the age 
of 45(391), increasing the complexity of the association between cognitive decline, 
aging and persisting migraine. 
       Migraine aura did not seem to influence cognitive decline in our sample nor in 
other longitudinal studies (185, 217); cross-sectional studies present conflicting 
findings, some finding evidence of a different cognitive profile between patients with 
and without aura(211, 282), while other fail to do so(104). Again, methodological 
differences are proposed to underlie these findings. In our sample, migraine patients 
progressing to cognitive decline were younger and more likely to have a higher impact 
disease than those who remained cognitively normal despite no influence was 
documented regarding attack frequency; the impact of the disease measured in attack 
frequency has been often associated with impairment in processing speed, attention 
and memory in some large clinic-based studies but not in larger populational 
studies(104). Nevertheless, in our sample the total number of migraine patients with 
cognitive decline was small (4 in total) and these patients had lower literacy, a fact that 
has clear influence on cognitive performance(77) and therefore limits speculation 
about the effect of migraine impact found. 
       An interesting observation in this study is that the in older migraine patients 
migraine characteristics change over a 5 years timespan; in our sample 31% of the 
revaluated migraine patients had no attacks in the previous year and those with 
persistent attacks, the overwhelming majority (65%) has less than one monthly attack. 
In 55% of patients their attacks ceased to accompanied by nausea, in 30% the 
photophobia was no longer present and 35% had milder attack impact, being now able 
to work and function during attacks. These changes in migraine characteristics with 
aging are documented (17, 377) but clearly influence our ability to diagnose migraine 
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and to distinguish it from non-migraine headache, being a recognized limitation of our 
study.  
        Another study limitations include the high attrition (around 42%) when compared 
to similar length studies that had retention rates of 80% at 3 years(217), 98% at 5(281) 
and 75% at 6 years(270) follow up. Possible explanations may include lack of financial 
compensation for participation and lower population education levels. Migraine 
patients in or sample were younger, more often females and had higher depression 
rates and subjective memory complaints, nevertheless their cognitive performance 
was uninfluenced by these factors(268). The lack of imaging data in our study also 
limits interpretation of cognitive decline etiology; however vascular risk factors were 
similar between groups, which argues against the odds of a higher risk for subclinical 
ischaemic lesions in either group. 
       In conclusion, persisting migraine and non-headache pain at older age may 
influence some aspects of cognitive executive performance but is not associated with 
an increase probability of cognitive decline, supporting that these changes are related 
to pain adaptation mechanisms and not to pain-associated degenerative processes. 
These findings suggest that pain control may influence improvement of cognitive 






























SUMMARY OF FINDINGS  
Research question #1 - Are cognitive symptoms included in clinical series of migraine 
patients describing the migraine attack phenomenology? 
 
A systematic literature review retrieved 28 studies (including 8392 patients) in which cognitive 
symptoms were described to occur during the migraine attack. This observation supports that 
cognitive symptomatology is a part of the subjective experience of a migraine attack and is 
consistent with early historical descriptions of migraine and with everyday clinical experience. 
The type and pattern of cognitive symptoms differed in each phase of the attack, being more 
consistently described in the prodromal and posdromal phases than during the headache and 
affecting executive functions predominantly. Cognitive symptomatology of the aura included 
complex neuropsychological phenomena probably associated with focal cortical depression.  
 
Research question #2 - What attack-related cognitive symptoms do migraine patients 
report? Is there a pattern? 
 
The overwhelming majority of episodic migraine patients (87.3%) reports having on average 2.5 
different cognitive symptoms during the headache phase of migraine attacks, when asked. The 
frequency of these symptoms occurrence is identical to that the occurrence of migraine defining 
symptoms (nausea, photophobia, phonophobia and worsening with physical effort) in clinical 
series of migraine. None of the clinical or demographic variables influences the reporting of 
cognitive symptomatology. 
Some specific symptoms were described very consistently using similar phraseology - lower 
ability to concentrate (14.7% of symptoms, reported by 37% of patients); difficulty in reasoning 
(9.8% of symptoms, 25% patients) and  being “less able” to think (9.1% of symptoms, 23% 
patients). Two-thirds of spontaneous described symptoms during attacks can be attributed to 
executive dysfunction and include attention deficits and decreased cognitive processing 
efficiency and processing speed. 
 
Research question #3 - Are attack-related cognitive symptoms relevant to migraine-




Patients subjectively rate pain as the most relevant symptoms of the migraine attack, both in 
terms of intensity and disability. Intensity and disability attributed to attack-related cognitive 
symptoms are rated secondly, being higher than photophobia, nausea and all other migraine 
defining symptoms.  The intensity and disability of attack-related cognitive symptoms correlates 
to intensity and disability attributed to the attack itself, supporting the relevance of these 
symptoms in migraine impact.  
 
Research question #4 - Can we identify and quantify attack-related cognitive symptoms 
in migraine? 
 
A fast, inexpensive and universal way to systematically identify and quantify symptomatology is 
through the use of a questionnaire. A multiple choice 9-item self-administered questionnaire– 
the Mig-SCog – was developed for that purpose and validated, showing good construct validity, 
internal consistency, temporal stability and external validity. The questionnaire covers the 
domains of executive functions (attention, processing speed, orientation, planning) and language 
(naming, verbal comprehension and sentence production). 
 
Research question #5 - Are cognitive complaints identified with the Mig-SCog specific for 
migraine? How reliable is the Mig-SCog?  
  
Mig-SCog scores are consistently higher in migraine than in tension-type headache, particularly 
in items related to cognitive functions. Obtaining a high score on the Mig-SCog has a high 
specificity for the diagnosis of migraine. In migraine patients, the scoring of the Mig-SCog in 
consistently higher when it relates to migraine than to non-headache pain or being headache 
free, reflecting again its specificity for the migraine diagnosis. Mig-SCog also showed negligible 
recall bias when comparing scores obtained by memory of usual attacks to within attacks.  
 
Research question #6 - What is the evidence of cognitive dysfunction occurrence during 
migraine attacks? 
  
A systematic review of medical databases retrieved 10 articles (including 351 patients) with 
relevance to the study question. Five of these articles had enough data to be analyzed and all 
were positive in documenting reversible cognitive dysfunction measures by neuropsychological 
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testing during migraine attacks. The pattern of cognitive dysfunction most often evoked in 
attacks was dysexecutive however most of the studies were biased towards including more 
executive function tests. This review disclosed the existence of important study limitations not 
accounted for in most of the data available, such as controlling for the practice of learning effect 
bias, for treatment effects, concurrent mood disorders and the occurrence of aura during studied 
attacks. 
 
Research question #7 - Do migraine patients have reversible cognitive impairment 
during attacks? 
 
Extensive neuropsychological testing within a spontaneously occurring migraine without aura 
attack revealed a decline in most of the tests performed, although the high attrition prevented 
most of these changes to attain statistical significance. A significant decrease was observed only 
in tests of reading and processing speed, verbal memory and learning. 
 
Research question #8 - How can we measure attack-related cognitive impairment?   
 
It was possible to obtain a short battery of executive and language tests and to apply it in 
interictal migraine patients and controls in repeated short-term (6 weeks) applications. The 
battery was fast and easy to apply with minimal resources. Patients’ interictal performance on 
this battery was identical to that of matched controls and a clinically meaningful predictable 
score change of repeated applications was identified for each test, therefore fulfilling the basic 
requirements to test this battery usefulness in determining attack-related cognitive dysfunction.  
 
Research question #9 - Do brain perfusion changes exist during migraine without aura 
attacks? 
 
The existing information about brain perfusion changes during migraine without aura attacks 
was scarce, inconsistent and used different techniques, some of them updated. Cerebral global 
and regional brain perfusion evaluated with ASL- MRI was not able to identify perfusion 




Research question #10 - Are there neuronal network abnormalities underlying the 
attack-related executive symptoms in migraine? 
 
The involvement of certain brain areas (such the anterior cingulate and the frontopolar cortex) 
both during migraine attack and in executive tasks lead to the assumption that evoking cognitive 
activity in this areas during attack would result either in internal interference or an increase in 
workload of these areas, that could potentially changes the expected activation pattern or areas 
in response to the task. Testing this hypothesis with a BOLD-fMRI study using the N-Back 
working memory paradigm yielded negative results, both in activation patterns but also in 
concurrent neuropsychological performance evaluation.   
 
Research question #11 - Is ongoing migraine related to worse cognitive performance 
late in life? 
 
Comparing neuropsychological performance of a population-based sample of older adults (aged 
50 or over) with persisting migraine, non-migraine headache and headache-free individuals 
revealed a worse performance of migraine and non-migraine headache individuals in some 
measures of executive functioning, while most of the tests were comparable to headache-free 
controls. In particular, migraine subjects performed worse in a test of attention and processing 
speed while non-migraine headache subjects had lower sematic memory performance and faulty 
retrieval strategies. 
 
Research question #12 - Is migraine associated with an increased risk of cognitive 
decline later in life, compared to other headaches or being headache-free? 
 
The repeated neuropsychological evaluation of a population based study of older adults (aged 50 
or over) in a five years period was ensued to identify cognitive decline in memory and/or 
executive functions. Having migraine or non-migraine headache did not increase the frequency 
of cognitive decline (in neither of the domains) when compared to headache-free controls. In 
patients with migraine who did decline none of the migraine characteristics was associated with 





Migraine attacks are complex and variable phenomena (inter-individual and intra-
individual variability) that are disabling, recurrent and with clinical expression on 3 
symptomatic axis - (1) Head pain; (2) Gastrointestinal symptoms; (3) Intolerance to 
sensorial stimulation(7). Based on shared clinical experience and daily exposure to 
patients descriptions of “not being able to function”, “feeling distracted” or “unable to 
think” during attacks it was our clinical impression that, based on the frequency and 
severity of these symptoms, they should be considered as the fourth symptomatic axis 
of the attacks, and probably as one relevant contributor to attack-related disability(392).  
 
There is, in our opinion, a clinical need to improve knowledge on this topic, to value such 
symptoms and to improve their control with acute attack treatments; adjusting 
treatment strategies will improve disease control and decrease migraine-related 
disability. Additionally, the study of these symptoms represent a window of opportunity 
to learn about the neuronal mechanisms that are subjacent to them will improve current 
knowledge on migraine pathophysiology.  
 
Motivation for this studies was patient-driven; our research plan was designed to try to 
understand the frequency, quality and clinical relevance of these symptoms, and to some 
extent to explore the neuronal subtract of some attack related changes and the possible 
long term effects that persisting migraine could have on cognitive performance at later 
ages.  
 
We screened the literature for studies including cognitive symptoms in the clinical 
description of migraine attacks, which we have found to be relatively scarce (considering 
that the first written description we found dated from the first century, by one of 
Hippocrates disciples, Aretaeus of Cappadocia(8)), yet consistent. From the existing data, 
the most often described cognitive symptoms included concentration problems, 
impaired thinking, intellectual disturbances and language difficulties (speech, reading 
and writing) and were present in all phases of migraine attacks, although less frequently 
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during the aura phase. We conducted a prospective study screening for the occurrence 
of cognitive symptoms during attacks that disclosed a very high frequency (87%) of such 
symptoms and many had very consistent inter-individual descriptions, despite their 
natural subjectivity. Very frequent complaints included a lower ability to concentrate, 
difficulty in reasoning and being less able to think, which corroborated nicely data 
previously obtained from the literature. More importantly, these symptoms descriptions 
were consistent with the dysexecutive pattern of reversible cognitive dysfunction 
supported by a literature review on studies including neuropsychological testing during 
migraine attacks(108). This seemed to support that tasks requiring attention(265) were 
preferentially involved in the migraine associated brain process, and led to the suspicion 
that migraine related cognitive dysfunction could be associated with neuronal 
recruitment of areas involved both in pain processing and attention, such as the anterior 
cingulated and the dorso-lateral prefrontal  (DLPF) cortices (264).  
 
This dysexecutive pattern was not reproduced in our study of neuropsychological 
performance during attacks, that despite having had a high attrition rate that resulted in 
a small final sample and therefore less optimal statistical power, it was able to control 
for the most common bias of previous existing data(108, 109). Nevertheless, our data 
supported a nominal performance decline in the majority of neuropsychological tests 
during attacks, when compared to headache-free periods, but most expressively in 
complex episodic memory tasks, suggesting either temporal(152) or sub-cortical nuclei 
involvement during the migraine attack (153), both structures found to be activated in 
functional studies of migraine attacks (152, 153) .  
 
Further supporting the absence of cingulated and prefrontal cortex dysfunction during 
migraine attacks came from our fMRI- BOLD study, in which the execution of a working 
memory task during a migraine without aura attack had no influence on the cerebral 
activity pattern, when compared to the headache-free status. Arguing against significant 
cortical dysfunction, as demonstrated during auras, we were also unable to identify brain 





Regardless of what the neuronal subtract of attack-related cognitive symptoms in 
migraine might be, their occurrence is very consistent and relevant to patients and they 
were found to correlate to attack-related disability(392). As the description of cognitive 
difficulties can be subjective, it is important in clinical practice and the research settings 
that they can be identified and graded in a consistent and standardized manner. We 
developed an adequate tool to identify and quantify specifically migraine attack related 
subjective cognitive symptoms, the Mig-SCog(118), that we hope will contribute to due 
valorization of these symptoms. 
 
In our studies we assumed that cognitive performance differed between brain states 
(attack and pain-free) in migraine patients, in line with patients’ complaints, so the pain-
free status was used as a control situation to try to identify attack-related dysfunction. 
Some cross-sectional studies on clinical-based samples of migraine patients suggested 
that their interictal cognitive performance could be inferior to controls in some 
neuropsychological tests, suggesting a small effect of migraine in processing speed, 
attention, working memory, sustained attention, inhibition, verbal memory and verbal 
skills(105).  
 
We assembled a short neuropsychological battery including executive and language tests 
and applied it in a small sample of young and healthy episodic migraine patients having 
a low-impact disease (no prophylactic treatments, low comorbidities) in their interictal 
(pain-free) status and to matched controls and we were unable to reproduce these 
findings. Our data is in line with data from population or community-based studies, both 
cross-sectional and longitudinal, that have been consistently negative in trying to 
identify cognitive differences of performance or cognitive decline rates of migraine 
patients compared to controls; in general, these studies have larger samples but shorter 
and less sensitive neuropsychological evaluations(104, 105).   
 
We additionally studied a large sample of older adults in primary care setting, comparing 
those with migraine and non-migraine headaches after the age of 50, to non-headache. 
An extended neuropsychological battery was used in this study that was able to pick up 
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some minor differences between groups – migraineurs were slightly worse in an 
attention task while non-migraine headache individuals had more intrusions and worse 
discriminability in a memory recognition task and lower performance on a semantic 
memory test. Although there were no differences in the vast majority of tests, these 
findings suggest the existence of mild dysexecutive dysfunction associated with 
persisting headache at older ages, either migraine or non-migraine headache(268). We 
then conducted a 5-years follow-up study of the same sample to screen for cognitive 
decline and we were unable to document any influence of migraine or non-migraine 
headache in the risk of decline or dementia, again supporting data from population-











Cognitive and behavioral symptoms are a part of the migraine attack that often precede 
and exceed the painful more disturbing phase. Headache doctors listen to patients’ 
descriptions everyday yet no true appreciation of the importance and impact of such 
symptoms exists, neither in clinicians nor in researchers. As a small example, the ability 
to predict attacks and to start treatment early can be of exceeding help in acute pain 
control and increase cost-effectiveness of treatment (167, 168). Lack of physician 
awareness prevents adequate treatment strategies, either pharmacological or coaching 
or life-style adaptations. It also concurs to lack of empathy, and therefor to an increased 
burden of disease.  
 
Although some work has been done to increase awareness about these symptoms and 
an instrument was developed that allows their identification and quantification, there is 
still the need of testing the usefulness of this instrument in measuring outcomes of 
therapeutic trials or in helping to quantify migraine impact and/or attack-related 
disability. The potential use of this outcome measure could help to improve acute attack 
control strategies or to the development of drugs targeting cognitive dysfunction 
specifically.    
 
Another useful tool would be the identification or development of a brief and practical 
neuropsychological test to allow repeated short term applications in order to be possible 
to test migraine patients’ executive performance in any given moment. Although a brief 
neuropsychological battery was assembled and tested to that purpose, it failed to 
disclose relevant impairment during attacks. Further work should focus on developing 
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and testing a task designed to disclose the most consistently identified attack-related 
impairment, in attention and processing speed.  
 
The brain processes underlying attack-related cognitive symptoms in migraine are still 
elusive, although potentially relevant for understanding migraine without aura 
pathophysiology and new potential treatment targets that would promptly restore 
cognitive function aside with pain control. Comparing migraine data to other episodic 
recurrent or chronic pain conditions will help to clarify some of the mechanisms that 
could be involved in these processes. 
 
It is possible that our view of the attack related phenomena will change, in line with our 
current understanding of migraine pathophysiology(28). Migraine could then be 
understood as a brain state, in a given susceptible individual, that sequentially oscillates 
between syndromic manifestations with a variable frequency or rhythmicity. Extremely 
relevant issues are the study of the brain processes triggering attack onset and 
resolution; such knowledge could potentially help inducing a long lasting migraine free 
state.   
 
The absence of brain perfusion abnormalities in migraine without aura episodes seems 
to be consistent in most of the published series and was documented with different 
techniques, so further studies of brain perfusion in migraine patients do not seem 
advantageous, at least with the technology currently available. On the other hand, studies 
of brain function in clinical samples seem promising in further elucidating brain changes 
underlying cognitive dysfunction during attacks with particular relevance to the study 
of patterns of functional connectivity and of evoked subcortical neuronal function during 
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attacks. Clinical research of cognitive function during attacks can expand into other 
techniques that were not explored in the current research project, such as other brain 
functional studies, neurophysiological studies or the combination of both.   
 
Al evidence supports that migraine related cognitive impairment occurs mostly during 
attacks. However, repeated persistent or chronic pain is associated with brain changes 
that seem reversible with effective pain treatment, therefore not contributing to late-life 
cognitive impairment. As migraine prevalence declines after the forth to fifth decades of 
life, having migraine does not seem likely to be a significant contribute to cognitive 
impairment. Nevertheless, data analysis of this problem is complex, as both migraine 
prevalence, migraine frequency and its clinical expression (in which we base our 
diagnosis in) change with aging and, on the contrary, age is the most relevant factor 
associated with cognitive dysfunction and decline. Further studies on this topic should 
take into consideration all this factors and still be able to evaluate neuropsychological 
function thoroughly and use large community-based samples. Other important line of 
future research includes the study of the effect of chronic headache and pain control in 
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